SLMT 6-K 2025 - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025.

Commission File Number 001-41606

BRERA HOLDINGS PLC

(Translation of registrant’s name into English)

Connaught House, 5th Floor

One Burlington Road

Dublin 4

D04 C5Y6

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

PIPE Transaction

As previously disclosed, on September 18, 2025, Brera Holdings PLC (the “Company”) entered into several securities purchase agreements (the “Securities Purchase Agreements”) with certain accredited investors (the “PIPE Investors”) pursuant to which the Company agreed to sell and issue to the PIPE Investors in a private placement offering (the “PIPE Offering”) an aggregate of (i) a combination of 61,505,516 shares of the Company’s Class B Ordinary Shares, with a nominal value of $0.05 per share (the “Class B Ordinary Shares”), and Class B Ordinary Share purchase warrants (the “PIPE Common Warrants”) to purchase 61,505,516 Class B Ordinary Shares, at a combined offering price of $4.50 per Class B Ordinary Share and PIPE Common Warrant to purchase one Class B Ordinary Share and (ii) a combination of pre-funded warrants (the “PIPE Pre-Funded Warrants”) to purchase 5,161,152 Class B Ordinary Shares and PIPE Common Warrants to purchase 5,161,152 Class B Ordinary Shares, at a combined offering price of $4.45 per PIPE Pre-Funded Warrant to purchase one Class B Ordinary Share and PIPE Common Warrant to purchase one Class B Ordinary Share.

The PIPE Common Warrants are immediately exercisable for 36 months at an exercise price of $6.75 per share. The PIPE Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the PIPE Pre-Funded Warrants issued in the PIPE Offering are exercised in full at an exercise price of $0.05 per share. Each PIPE Investor’s ability to exercise its PIPE Pre-Funded Warrants and PIPE Common Warrants, as applicable, in exchange for Class B Ordinary Shares is subject to certain beneficial ownership limitations set forth therein.

The aggregate gross proceeds for the PIPE Offering is approximately $300 million, which amount was paid in cash, USD Coin, Tether, or SOL, the native cryptocurrency of Solana, a blockchain ecosystem, or a combination thereof.

Cantor Fitzgerald & Co. acted as exclusive financial advisor and sole placement agent in connection with the PIPE Offering.

The Company intends to direct a portion of the funds secured into revenue-generating crypto infrastructure projects in the UAE, the first of which will be bare metal servers in Abu Dhabi configured to outperform typical DAT validator strategies.

In connection with the PIPE Offering, the Company entered into certain agreements and certain actions occurred as described below.

Strategic AdvisorAgreement

On September 18, 2025 (the “Effective Date”), the Company entered into a Strategic Advisor Agreement (the “Strategic Advisor Agreement”) with certain strategic advisors (the “Strategic Advisors”), pursuant to which the Strategic Advisors will provide the Company with strategic advice and guidance relating to the Company’s business, operations and growth initiatives, and industry trends in the crypto technology sector (the “Services”). In return for their Services, the Strategic Advisors will receive the following from the Company.

(i)	cash compensation equal to 1% per annum of the<br>amount of the Company’s SOL Assets Under Management (“SOL AUM”) (as determined in accordance with the provisions of<br>the Strategic Advisor Agreement) as of the anniversary date of the Effective Date of the applicable year, up to $1,000,000,000 of SOL<br>AUM, and 0.5% per annum of the amount by which the Company’s SOL AUM as of the anniversary date of the Effective Date of the applicable<br>year exceeds $1,000,000,000;
(ii)	pre-funded warrants (the “Strategic Advisor<br>Pre-Funded Warrants”) to purchase a number of Class B Ordinary Shares equal to 10.0% of the aggregate number of Class B Ordinary<br>Shares and pre-funded warrants issued pursuant to the Securities Purchase Agreements (the “Strategic Advisor Pre-Funded Warrant<br>Shares”);
---	---
(iii)	warrants (the “Strategic Advisor Common Warrants 1”)<br>to purchase an amount of Class B Ordinary Shares equal to, in the aggregate, 50.0% of the aggregate number of Strategic Advisor Pre-Funded<br>Warrant Shares; and
---	---
(iv)	warrants (the “Strategic Advisor Common Warrants 2”,<br>and together with the Strategic Advisor Pre-Funded Warrants and the Strategic Advisor Common Warrants 1, the “Strategic Advisor<br>Warrants”) to purchase, in the aggregate, an amount of Class B Ordinary Shares equal to 9.0% of the aggregate number of Class B<br>Ordinary Shares and pre-funded warrants issued pursuant to the Securities Purchase Agreements.
---	---

The exercise price per share of the Strategic Advisor Pre-Funded Warrants shall be set at a price equal to $0.05. The exercise price per share of the Strategic Advisor Common Warrants 1 shall be set at a price equal to $6.75. Half of the Strategic Advisor Pre-Funded Warrants are exercisable immediately upon issuance, in whole or in part, at any time and from time to time, until all of such Strategic Advisor Pre-Funded Warrants are exercised in full. The remaining half of the Strategic Advisor Pre-Funded Warrants are exercisable, in whole or in part, at any time and from time to time, beginning on the third anniversary of the closing of the PIPE Offering and until all of such Strategic Advisor Pre-Funded Warrants are exercised in full. Half of the Strategic Advisor Common Warrants 1 are exercisable immediately upon issuance, in whole or in part, at any time and from time to time, until the five (5) year anniversary of the issuance thereof. The remaining half of the Strategic Advisor Common Warrants 1 shall be exercisable, in whole or in part, at any time and from time to time, beginning on the third anniversary of the closing of the PIPE Offering and until the five year anniversary of the issuance thereof. The Strategic Advisor Common Warrants 2 shall be exercisable pursuant to the following performance based metrics: (i) one-third of the purchase rights represented by the Strategic Advisor Common Warrants 2 shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than $6.75 per share; (ii) one-third of the purchase rights represented by the Strategic Advisor Common Warrants 2 shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than $9.00 per share; and (iii) one-third of the purchase rights represented by the Strategic Advisor Common Warrants 2 shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than $11.25 per share (each, a “Performance Metric”). The exercise price per share of the Strategic Advisor Common Warrants 2 shall be equal to the closing market price of the Class B Ordinary Shares on the trading day on which the applicable Performance Metric is achieved. The Strategic Advisor Common Warrants 2 each have a term of five years from the date of issuance thereof.

The Company will also reimburse reasonable expenses reasonably and necessarily incurred by each of the Strategic Advisors in the course of providing the Services, including airfare, lodging and meals, subject to the Company’s receipt of documentation for such expenses reasonably satisfactory to the Company.

The Strategic Advisor Agreement has a term of ten (10) years; provided however, (i) the Company and any individual Strategic Advisor may terminate the Strategic Advisor Agreement upon mutual written consent executed by the Company and such Strategic Advisor, solely as it pertains to the engagement of such Strategic Advisor or (ii) the Company or any individual Strategic Advisor, solely with respect to itself, may terminate the Strategic Advisor Agreement at any time, effective immediately upon notice, if it has good cause for termination as set forth under the Strategic Advisor Agreement.

The foregoing summaries of the Strategic Advisor Pre-Funded Warrants, the Strategic Advisor Common Warrants 1, the Strategic Advisor Common Warrants 2 and the Strategic Advisor Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text of those documents, which are attached hereto as Exhibits 4.3, 4.4, 4.5 and 10.4, respectively, to this Report on Form 6-K and are hereby incorporated by reference.

Concurrent Securities Issuances

In connection with entering into the Securities Purchase Agreements, the Company entered into a Registration Rights Agreement (the “DM Registration Rights Agreement 2”) with certain entities owned and controlled by Daniel J. McClory (the “DM Entities”), our Executive Chairman, pursuant to which the Company agreed to file a registration statement with the U.S. Securities and Exchange Commission, within 30 days of the closing of the PIPE Offering registering the resale of the Class B Ordinary Shares held by the DM Entities.

In connection with entering into the Securities Purchase Agreements, the Company entered into a Warrant Purchase Agreement (the “Investor Warrant Purchase Agreement”) with five investors (the “WPA Investors”), pursuant to which the Company will offer and sell a Class B Ordinary Share purchase warrant to purchase an aggregate of 622,080 Class B Ordinary Shares to the WPA Investors (the “WPA Investor Warrant”) for $6,221 (the “WPA Investor Purchase”). The closing of the WPA Investor Purchase is conditioned upon the occurrence of and will occur simultaneously with the closing of the PIPE Offering.

In connection with entering into the Investor Warrant Purchase Agreement, on September 23, 2025, the Company and WPA Investors entered into a Registration Rights Agreement (the “WPA Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement with the U.S. Securities and Exchange Commission, within 30 days of the closing of the WPA Investor Purchase registering the resale of the Class B Ordinary Shares underlying the WPA Investor Warrant.

In connection with entering into the Securities Purchase Agreements, the Company entered into a Warrant Purchase Agreement (the “DM Warrant Purchase Agreement”) with an entity (the “DM Purchaser”) owned and controlled by Daniel J. McClory, the current Executive Chairman of the Company, pursuant to which the Company will offer and sell a Class B Ordinary Share purchase warrant to purchase 200,000 Class B Ordinary Shares to the DM Purchaser (the “DM Warrant”) for $2,000 (the “DM Warrant Purchase”). The closing of the DM Warrant Purchase is conditioned upon the occurrence of and will occur simultaneously with the closing of the PIPE Offering.

In connection with entering into the DM Warrant Purchase Agreement, on September 23, 2025, the Company and the DM Purchaser entered into a Registration Rights Agreement (the “DM Registration Rights Agreement 1”), pursuant to which the Company agreed to file a registration statement with the U.S. Securities and Exchange Commission, within 30 days of the closing of the DM Warrant Purchase registering the resale of the Class B Ordinary Shares underlying the DM Warrant.

The foregoing summaries of the Investor Warrant Purchase Agreement, the WPA Registration Rights Agreement, the DM Warrant Purchase Agreement, the DM Registration Rights Agreement 1, and the DM Registration Rights Agreement 2 do not purport to be complete and are qualified in their entirety by reference to the complete text of those documents, which are attached hereto as Exhibits 10.5, 10.6, 10.7, 10.8 and 10.10, respectively, to this Report on Form 6-K and are hereby incorporated by reference.

Resignations and Appointments of CertainDirectors and Officers.

Resignations

Effective September 23, 2025, Dr. Fabio Scacciavillani resigned from the Company’s Board of Directors (the “Board”) and as Chief Executive Officer of the Company. Dr. Scacciavillani will continue in his role as Chief Financial Officer.

Additionally, on September 23, 2025, Abhishek Matthews, Christopher Gardner, Giuseppe Pirola and Goran Pandev resigned as members of the Board. Neither Mr. Matthew’s, Mr. Gardner’s, Mr. Pirola’s or Mr. Pandev’s resignation was a result of any disagreement relating to the Company’s operations, policies or practices.

Appointments

Appointment of Dr. Arthur Laffer as a Director

On September 23, 2025, the Company appointed Dr. Arthur Laffer as a member of the Board.

There are no other arrangements or understandings between Dr. Laffer and any other person pursuant to which Dr. Laffer was appointed as a Director of the Company. There are also no family relationships between Dr. Laffer and any director or executive officer of the Company, and Dr. Laffer has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Appointment of Victor Fischer as a Director

On September 23, 2025, the Company appointed Victor Fischer as a member of the Board.

There are no other arrangements or understandings between Mr. Fischer and any other person pursuant to which Mr. Fischer was appointed as a Director of the Company. There are also no family relationships between Mr. Fischer and any director or executive officer of the Company, and Mr. Fischer has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Appointment of Keren Maimon as a Director

On September 23, 2025, the Company appointed Keren Maimon as a member of the Board.

There are no other arrangements or understandings between Ms. Maimon and any other person pursuant to which Ms. Maimon was appointed as a Director of the Company. There are also no family relationships between Ms. Maimon and any director or executive officer of the Company, and Ms. Maimon has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Appointment of Ron Sade as a Director

On September 23, 2025, the Company appointed Ron Sade as a member of the Board.

There are no other arrangements or understandings between Mr. Sade and any other person pursuant to which Mr. Sade was appointed as a Director of the Company. There are also no family relationships between Mr. Sade and any director or executive officer of the Company, and Mr. Sade has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Appointment of Alyazi Almheiri as a Director

On September 23, 2025, the Company appointed Alvazi Almheiri as a member of the Board.

There are no other arrangements or understandings between Ms. Almheiri and any other person pursuant to which Ms. Almheiri was appointed as a Director of the Company. There are also no family relationships between Ms. Almheiri and any director or executive officer of the Company, and Ms. Almheiri has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Appointment of Tarek Alnuaimi as a Director

On September 23, 2025, the Company appointed Tarek Alnuaimi as a member of the Board.

There are no other arrangements or understandings between Mr. Alnuaimi and any other person pursuant to which Mr. Alnuaimi was appointed as a Director of the Company. There are also no family relationships between Mr. Alnuaimi and any director or executive officer of the Company, and Mr. Alnuaimi has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Employment Agreement with Chief ExecutiveOfficer and Director

On September 23, 2025, the Company entered into a formal employment agreement (the “Agreement”) with Marco Santori to become the Company’s Chief Executive Officer and Director.

Mr. Santori’s term as the Company’s Chief Executive Officer and Director will begin on September 23, 2025, and continue until terminated by either party, subject to the terms of the Agreement (the “Term”). For his services, Mr. Santori will be paid $650,000 per year. Additionally, Mr. Santori will be granted a signing bonus of $1,000,000 and an equity grant of $15,000,000 in Restricted Stock Units which are subject to time and performance based vesting. During the course of the Term, Mr. Santori will be eligible for (i) performance bonuses to be granted at the discretion of the Company’s Compensation Committee, (ii) an AUM-based bonus, determined each calendar year based on the Company’s SOL AUM as of December 31 of such year, equal to (a) 0.1429% of SOL AUM up to $1,000,000,000, and (ii) 0.0714% of any SOL AUM in excess of $1,000,000,000, and (iii) to participate in the Company’s 2025 Equity Incentive Plan. The Agreement contains a perpetual confidentiality covenant as well as non-competition and employee and customer non-solicitation covenants that apply during the Term and for a period of one year following Mr. Santori’s termination.

There are no other arrangements or understandings between Mr. Santori and any other person pursuant to which Mr. Santori was appointed Chief Executive Officer and a Director of the Company. There are also no family relationships between Mr. Santori and any director or executive officer of the Company, and Mr. Santori has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The newly appointed officers and directors of the Company will enter into standard indemnification agreements with the Company (the “Indemnification Agreements”) whereby the Company will agree to indemnify such new officers directors for losses related to the fact that they are officers and directors of the Company.

The foregoing summaries of the Agreement and the form of Indemnification Agreements do not purport to be complete and are qualified in their entirety by reference to the complete text of those documents, which are attached hereto as Exhibits 10.3 and 10.9, respectively, to this Report on Form 6-K and are hereby incorporated by reference.

Press Releaseon Closing the Offering

On September 23, 2025, the Company issued a press release announcing the closing of the PIPE Offering. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference.

Corporate Presentation

In connection with the PIPE Offering, the Company delivered an investor presentation to potential investors on a confidential basis, a copy of which is furnished as Exhibit 99.2 to this Report on Form 6-K.

Updated Risk Factors

In connection with the PIPE Offering, the Company is supplementing the risk factors previously disclosed in its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and as supplemented by the Company’s subsequent periodic filings. A copy of the additional risk factors is included as Exhibit 99.3 hereto and is incorporated herein by reference.

Forward-Looking Statements

This Report on Form 6-K contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This Report on Form 6-K also includes express and implied forward-looking statements regarding the Company’s current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as “believes,” “expects,” “endeavors,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “should” and “objective” and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that the Company will achieve or is likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the failure to realize the anticipated benefits of the PIPE Offering and related transactions, including the proposed digital asset treasury strategy, economic conditions, fluctuations in the market price of SOL, the impact on the Company’s business of the evolving regulatory environment, the ability of the Company to execute on its digital asset treasury strategy, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally as well as those risks and uncertainties identified under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and other information the Company has or may file with the U.S. Securities and Exchange Commission, including Exhibit 99.3 attached hereto. Forward-looking statements contained in this Report on Form 6-K are made as of the date of this Report on Form 6-K, and the Company undertakes no duty to update such information except as required under applicable law.

This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(a) Exhibits

Number	Description
3.1	Constitution of the Registrant
4.1	Form of PIPE Pre-Funded Warrant (Incorporated by reference to Exhibit 4.1 filed on Form 6-K September 18, 2025)
4.2	Form of PIPE Common Warrant (Incorporated by reference to Exhibit 4.2 filed on Form 6-K September 18, 2025)
4.3	Form of Strategic Advisor Pre-Funded Warrant
4.4	Form of Strategic Advisor Common Warrant 1
4.5	Form of Strategic Advisor Common Warrant 2
10.1	Form of Securities Purchase Agreement, dated as of September 18, 2025, between Brera Holdings PLC and each Purchaser (as defined therein) (Incorporated by reference to Exhibit 10.1 filed on Form 6-K September 18, 2025)
10.2	Form of Registration Rights Agreement, dated as of September 18, 2025, between Brera Holdings PLC and each Holder (as defined therein) (Incorporated by reference to Exhibit 10.2 filed on Form 6-K September 18, 2025
10.3	Employment Agreement with Marco Santori, effective September 23, 2025
10.4	Strategic Advisor Agreement, dated September 18, 2025
10.5	Investor Warrant Purchase Agreement, dated September 23, 2025
10.6	Investor Registration Rights Agreement, dated September 23, 2025
10.7	DM Warrant Purchase Agreement, dated September 23, 2025
10.8	DM<br> Registration Rights Agreement 1, dated September 23, 2025
10.9	Form of Indemnification Agreement
10.10	DM Registration Rights Agreement 2, dated September 23, 2025
99.1	Press Release, dated September 23, 2025
99.2	Corporate Presentation, dated September 2025 (Incorporated by reference to Exhibit 99.2 filed on Form 6-K September 18, 2025).
99.3	Risk Factors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 25, 2025	BRERA HOLDINGS PLC
	By:	/s/ Dr. Fabio Scacciavillani
		Dr. Fabio Scacciavillani
		Chief Financial Officer

Exhibit 3.1

COMPANIES ACT, 2014

PUBLIC COMPANY LIMITED BY SHARES

CONSTITUTION

BRERA HOLDINGS PUBLIC LIMITED COMPANY

Incorporated on 30 June 2022

COMPANIES ACT, 2014

PUBLIC COMPANY LIMITED BY SHARES

MEMORANDUM OF ASSOCIATION

BRERA HOLDINGS PUBLIC LIMITED COMPANY

1.	Company Name

The name of the Company is Brera Holdings Public Limited Company

2.	Company Type

The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014.

3.	The objects for which the Company is established are:
3.1	To promote the practice and play of football and other athletic sports, games and exercise of every description,<br>and other sports, recreation, amusements or entertainments, and to buy, sell, exchange or hire, all articles, implements, fixtures, furniture,<br>apparatus and things used in the playing or practice of such games or pursuits, and any other implements or things used or required therefor,<br>or for the promotion of the objects of the Company, including prizes to be given in any competition or competitions promoted by the Company,<br>and for that purpose to establish, engage, and maintain, teams of football and other players whether composed of amateur or professional<br>players, or partly of one and partly of the other.
---	---
3.2	To acquire and take over as a going concern the assets contracts and liabilities of football clubs including<br>but not limited to Brera FC.
---	---
3.3	To carry on the business of a holding company and to co–ordinate the administration, finances and<br>activities of any subsidiary companies or associated companies, to do all lawful acts and things whatever that are necessary or convenient<br>in carrying on the business of such a holding company and in particular to carry on in all its branches the business of a management services<br>company, to act as managers and to direct or coordinate the management of other companies or of the business, property and estates of<br>any company or person and to undertake and carry out all such services in connection therewith as may be deemed expedient by the Company’s<br>board of directors and to exercise its powers as a member or shareholder of other companies.
---	---
3.4	To arrange, conduct, promote, organise, stage, advertise and publicise football matches, tournaments,<br>exhibitions and meetings of all kinds, and join in and promote competitions for challenge cups or other similar competitions for the purposes<br>of the Company or for the benefit of charities or other like objects.
---	---
3.5	To acquire and hold controlling and other interests in the share or loan capital of any company or companies<br>and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts<br>and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry<br>on, in all its branches, the business of a management services company, to act as managers and to direct or coordinate the management<br>and operation of other companies or of the business, property and estates of any company or person and to undertake and carry out all<br>such services in connection therewith as may be deemed necessary or appropriate by the Company’s board of directors.
---	---

A-1

3.6	To carry on any other business, except the issuing of policies of insurance, which may seem to the Company<br>capable of being conveniently carried on in connection with the above, or calculated directly or indirectly to enhance the value of or<br>render profitable any of the Company's property or rights.
3.7	To invest any monies of the Company in such investments and in such manner as may from time to time be<br>determined, and to hold, sell or deal with such investments and generally to purchase, take on lease or in exchange or otherwise acquire<br>any real and personal property and rights or privileges.
---	---
3.8	To subscribe for, take, purchase or otherwise acquire and hold shares or other interests in, or securities<br>of any other company having objects altogether or in part similar to those of the Company or carrying on any business capable of being<br>carried on so as, directly or indirectly, to benefit the Company.
---	---
3.9	To develop and turn to account any land acquired by the Company or in which it is interested and in particular<br>by laying out and preparing the same for building purposes, constructing, altering, pulling down, decorating, maintaining, fitting up<br>and improving buildings and conveniences, and by planting, paving, draining, farming, cultivating, letting on building lease or building<br>agreement and by advancing money to and entering into contracts and arrangements of all kinds with builders, tenants and others.
---	---
3.10	To acquire and undertake the whole or any part of the business, property, goodwill and assets of any person,<br>firm or company carrying on or proposing to carry on any of the businesses which the Company is authorised to carry on, or which can be<br>conveniently carried on in connection with the same, or may seem calculated directly or indirectly to benefit the Company.
---	---
3.11	To employ the funds of the Company in the development and expansion of the business of the Company and<br>all or any of its subsidiary or associated companies and in any other company whether now existing or hereafter to be formed and engaged<br>in any like business of the Company or any of its subsidiary or associated companies or of any other industry ancillary thereto or which<br>can conveniently be carried on in connection therewith.
---	---
3.12	To lend money to such persons or companies either with or without security and upon such terms as may<br>seem expedient.
---	---
3.13	To borrow or otherwise raise money or carry out any other means of financing, whether or not by the issue<br>of stock or other securities, and to enter into or issue interest and currency hedging and swap agreements, forward rate agreements, interest<br>and currency futures or options and other forms of financial instruments, and to purchase, redeem or pay off any of the foregoing.
---	---
3.14	To secure the payment of money or other performance of financial obligations in such manner as the Company<br>shall think fit, whether or not by the issue of debentures or debenture stock, perpetual or otherwise, charged upon all or any of the<br>Company's property, present or future, including its uncalled capital.
---	---
3.15	To adopt such means of making known the Company and its products and services as may seem expedient.
---	---
3.16	To sell, improve, manage, develop, exchange, lease, mortgage, enfranchise, dispose of, turn to account<br>or otherwise deal with all or any part of the property, undertaking, rights or assets of the Company and for such consideration as the<br>Company might think fit. Generally to purchase, take on lease or in exchange or otherwise acquire any real and personal property and rights<br>or privileges.
---	---

A-2

3.17	To acquire and carry on any business carried on by a subsidiary or a holding Company of the Company or<br>another subsidiary of a holding company of the Company.
3.18	To provide services of any kind including the carrying on of advisory, consultancy, brokerage and agency<br>business of any kind.
---	---
3.19	To guarantee, grant indemnities in respect of, support or secure, whether by personal covenant or by mortgaging<br>or charging all or any part of the undertaking, property and assets (present and future) and uncalled capital of the Company, or by both<br>such methods, the performance of the contracts or obligations of and the repayment or payment of the principal amounts of and premiums,<br>interest and dividends on any securities of any person, firm or company, including (without prejudice to the generality of the foregoing)<br>any company which is for the time being the Company's holding company as defined by section 8 of the Companies Act 2014, or another subsidiary<br>as defined by section 7 of the Companies Act 2014 of the Company's holding company or otherwise associated with the Company in business<br>notwithstanding the fact that the Company may not receive any consideration, advantage or benefit, direct or indirect from entering into<br>such guarantee or other arrangement or transaction contemplated herein.
---	---
3.20	To amalgamate with any other company.
---	---
3.21	To apply for, purchase, hold, exploit, deal in, dispose or otherwise acquire any patents, brevets d'invention,<br>licences, trade marks, copyright, franchise, technology, intellectual property right and knowhow and the like, whether by means of licensing,<br>sub-licensing, distribution, research and development or similar arrangement or agreement, conferring any exclusive or non-exclusive or<br>limited right to use or any secret or other information as to any invention or technology which may seem capable of being used, for any<br>of the purposes of the Company or the acquisition of which may seem calculated directly or indirectly to benefit the Company, and to use,<br>exercise, develop or grant licences in respect of or otherwise turn to account the property rights or information so acquired.
---	---
3.22	To enter into partnership or into any arrangement for sharing profits, union of interests, co-operation,<br>joint venture or otherwise with any person or company or engage in any business or transaction capable of being conducted so as directly<br>or indirectly to benefit the Company.
---	---
3.23	To grant pensions or gratuities (to include death benefits) to any officers or employees or ex-officers<br>or ex-employees of the Company, or its predecessors in business or the relations, families or dependants of any such persons, and to establish<br>or support any non- contributory or contributory pension or superannuation funds, any associations, institutions, clubs, buildings and<br>housing schemes, funds and trusts which may be considered calculated to benefit any such persons or otherwise advance the interests of<br>the Company or of its members.
---	---
3.24	To promote any company or companies for the purpose of acquiring all or any of the property and liabilities<br>of the Company or for any other purpose which may seem directly or indirectly calculated to benefit the Company.
---	---
3.25	To remunerate any person or company for services rendered or to be rendered in placing or assisting to<br>place or guaranteeing the placing of any of the shares in the Company's capital or any debentures, debenture stock or other securities<br>of the Company, or in or about the formation or promotion of the Company or the conduct of its business.
---	---

A-3

3.26	To draw, make, accept, endorse, discount, execute and issue promissory notes, bills of exchange, bills<br>of lading, warrants, debentures, letters of credit and other negotiable or transferable instruments.
3.27	To undertake and execute any trusts the undertaking whereof may seem desirable, whether gratuitously or<br>otherwise.
---	---
3.28	To procure the Company to be registered or recognised in any country or place.
---	---
3.29	To promote freedom of contract and to counteract and discourage interference therewith, to join any trade<br>or business federation, union or association, with a view to promoting the Company's business and safeguarding the same.
---	---
3.30	To do all or any of the above things in any part of the world as principal, agent, contractor, trustee<br>or otherwise, and by or through trustees, agents or otherwise and either alone or in conjunction with others.
---	---
3.31	To distribute any of the property of the Company in specie among the members.
---	---
3.32	To do all such other things as the Company may think incidental or conducive to the attainment of the<br>above objects or any of them.
---	---

NOTE A: The objects specified in each paragraph of this clause shall, except where otherwise expressed in such paragraph, be in no way limited or restricted by reference to, or inference from, the terms of any other paragraph.

NOTE B: It is hereby declared that the word "company" in this clause (except where it refers to this Company) will be deemed to include any partnership or other body of persons, whether or not incorporated and whether formed in Ireland or elsewhere.

4.	Liability of Members

The liability of the members is limited.

5.	Share Capital

The authorised share capital of the Company is $501,750,000 divided into 5,000,000 class A ordinary shares with a nominal value of $0.05 each, 10,025,000,000 class B ordinary shares with a nominal value of $0.05 each, 50,000,000 preferred shares with a nominal value of $0.005 each.

A-4

COMPANIES ACT2014

PUBLIC COMPANYLIMITED BY SHARES

ARTICLES OF ASSOCIATION

BRERA HOLDINGSPUBLIC LIMITED COMPANY

PRELIMINARY

1.	The provisions of the Act which are stated therein to apply to a public limited company will apply to<br>the Company subject to the alterations contained in these Articles, and will, so far as not inconsistent with these Articles, bind the<br>Company and its members.
2.	In these Articles the following expressions shall have the following meanings:
---	---

Act means the Companies Act 2014;

Acts means the Act and all statutes and statutory instruments which are to be read as one with, or construed or read together with or are one with the Act and every statutory modification and re-enactment thereof for the time in force;

A Shares means the class A ordinary shares of nominal value $0.05 each in the capital of the Company;

A Share(s) Transfer means any sale, assignment, transfer, conveyance, hypothecation or other transfer or disposition of such share or any legal or beneficial interest in an A Share, whether or not for value and whether voluntary or involuntary or by operation of law. An A Share Transfer shall also include, without limitation, a transfer of an A Share to a broker or other nominee (regardless of whether or not there is a corresponding change in beneficial ownership), or the transfer of, or entering into a binding agreement with respect to, Voting Control over an A Share by proxy or otherwise; provided, however, that the following shall not be considered an A Share Transfer:

a)	the granting of a proxy to officers or directors of the Company at the request or approval of the Board<br>in connection with actions to be taken at an annual or special meeting of members or by written consent of members;
b)	the transfer of one or more A Shares by (i) gift or pursuant to a domestic relations order from a holder<br>of an A Share to such holder’s Privileged Relation or (ii) to a trust or trusts for the exclusive benefit of such holder or his<br>Privileged Relation for no consideration;
---	---
c)	the transfer of one or more A Shares effected pursuant to the holder’s will or the laws of intestate<br>succession;
---	---
d)	as to any holder that is a trust established for the exclusive benefit of a prior holder of such A Shares<br>or such prior holder’s Privileged Relation, the transfer of one or more A Shares to the prior holder or such prior holder’s<br>Privileged Relation for no consideration;
---	---
e)	the granting of a repurchase right to the Company pursuant to an agreement wherein the Company has the<br>right or option to purchase or to repurchase A Shares provided, however, that the Company's purchase or repurchase of such A Shares pursuant<br>to the exercise of such right or option shall constitute an A Share Transfer; or
---	---

A-5

f)	upon the request of the transferor, any transfer approved by a majority of the disinterested members of<br>the Board, even though the disinterested directors may be less than a quorum, or if there are not any disinterested members on the Board,<br>the entire Board;

Automatic ConversionEvent means an event wherein one or more A Shares automatically convert into five or more B Shares pursuant to Article 3;

B Shares means the class B ordinary shares of nominal value $0.05 each in the capital of the Company;

Board means the board of directors for the time being of the Company;

Clear Days means in relation to the period of notice, means that period excluding the day when the notice is given or deemed to be given and the day for which it is given or on which it is to take effect;

Committee means a committee established by the directors which may consist in whole or in part of members of the Board;

Company means Brera Holdings Public Limited Company;

Control means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract, or otherwise;

Director means a director for the time being of the Company or a director present at a meeting of the Board and includes any person occupying the position of director by whatever name called, and directors means all of such persons;

electronic communicationhas the meaning given to such expression in section 2 of the Electronic Commerce Act, 2000;

Holder means in relation to any Share, the member whose name is entered in the Register as the holder of the Share;

intermediary has the meaning given to that term in Section 1110A of the Act;

Ireland means Ireland excluding Northern Ireland;

Preferred Shares means the preferred shares of nominal value $0.005 each in the capital of the Company;

Privileged Relationmeans in relation to an individual, such person’s spouse or Spousal Equivalent, the lineal descendant or antecedent, brother, sister, nephew or niece, of such person or such person’s spouse or Spousal Equivalent, or the spouse or Spousal Equivalent of any lineal descendant or antecedent, brother, sister, nephew or niece of such person, or his or her spouse or Spousal Equivalent, whether or not any of the above are adopted;

the registermeans the register of members to be kept as required by the Act and registered address means the address of a member as entered in the register;

A-6

Spousal Equivalentmeans any two natural persons if the relevant person and the related party are registered as “domestic partners” or the equivalent thereof under the laws of their state of residence or any other law having similar effect or provided the following circumstances are true: (a) irrespective of whether or not the relevant person and the Spousal Equivalent are the same sex, they are the sole spousal equivalent of the other for the last twelve (12) months, (b) they intend to remain so indefinitely, (c) neither are married to anyone else, (d) both are at least eighteen (18) years of age and mentally competent to consent to contract, (e) they are not related by blood to a degree of closeness that which would prohibit legal marriage in the state in which they legally reside, (f) they are jointly responsible for each other’s common welfare and financial obligations, and (g) they reside together in the same residence for the last twelve (12) months and intend to do so indefinitely;

the seal means the common seal of the Company; and

Voting Control means the power (whether exclusive or shared) to vote or direct the voting of A Shares by proxy, voting agreement or otherwise.

2.1.	Unless the contrary is clearly stated, references to the Act or to any other enactment (including any<br>subordinate legislation) or any section or provision thereof shall mean the Act or such enactment, subordinate legislation, section or<br>provision (as the case may be), as the same may be consolidated, amended, extended, modified, supplemented or re-enacted (whether before<br>or after the date hereof) from time to time and may be for the time being in force.
2.2.	Unless specifically defined in this Constitution or the context otherwise requires, words or expressions<br>contained in this Constitution and not specifically defined herein shall bear the same meanings as in the Act, but excluding any statutory<br>modification thereof not in force when this Constitution became binding on the Company and the members.
---	---
2.3.	Reference to any document includes that document as amended or supplemented from time to time.
---	---
2.4.	Unless the context otherwise requires, expressions in this Constitution referring to writing shall be<br>construed, unless the contrary intention appears, as including references to printing, lithography, photography and to writing in electronic<br>form and any other modes of representing or reproducing words in a visible form, and expressions in this Constitution referring to execution<br>of any document shall include any mode of execution whether under seal or under hand.
---	---
2.5.	Unless the context otherwise requires, words importing the singular include the plural and vice versa,<br>words importing the masculine include the feminine, and words importing persons include corporations.
---	---
2.6.	Headings are inserted for convenience only and do not affect the construction or interpretation of this<br>Constitution.
---	---

Unless the context otherwise requires, reference to Articles and to paragraphs in these Articles are to the Articles, and paragraphs of the Articles, of this Constitution.

A-7

SHARE CAPITALAND VARIATION OF RIGHTS

3.	Share Capital, Variation of Rights And Migration;

3.1.	Rights attaching to A Shares
3.1.1.	The A Shares shall rank pari passu with each other in all respects and shall, subject to the right of<br>the Company to set record dates for the purposes of determining the identity of members entitled to notice of and/or to vote at a general<br>meeting and the authority of the Board and chairperson of the meeting to maintain order and security, (i) include the right to attend<br>any general meeting of the Company and to vote on the basis set out in Article 3.1.2 below; (ii) include the right to participate<br>pro rata in all dividends declared by the Company; and (iii) include the right, in the event of the Company’s winding up, to<br>participate pro rata in the total assets of the Company.
---	---
3.1.2.	Each holder of A Shares shall be entitled to ten (10) votes for each A Share held as of the applicable<br>date on any matter that is submitted to a vote or for the consent of members of the Company.
---	---
3.1.3.	Each A Share shall be convertible, at the option of the holder thereof, at any time after the date of<br>issuance of such share, at the office of the Company, and without the payment of additional consideration by the holder thereof, into<br>five (5) fully paid B Shares. In the event that a holder of A Shares elects to convert such shares into B Shares, the conversion shall<br>be deemed to have been made immediately prior to the close of business on the date of the surrender of the A Shares to be converted.
---	---
3.1.4.	On the occurrence of an A Share Transfer, each A Share the subject of such transfer shall automatically,<br>without any further action, convert into five (5) fully paid and non-assessable B Shares; provided, however, that if a holder of<br>A Shares transfers any A Shares to another holder of A Shares, then such A Share Transfer will not constitute an Automatic Conversion<br>Event. In the event of an Automatic Conversion Event, such conversion shall be deemed to have been made at the time that the Transfer<br>of such shares occurred.
---	---
3.1.5.	The rights attaching to the A Shares may be subject to the terms of issue of any series or class of Preferred<br>Shares allotted by the Directors from time to time in accordance with Article 6.7.
---	---
3.2.	Conversion Mechanism for A Shares
---	---
3.2.1.	Before any holder of A Shares shall be entitled to convert A Shares into B Shares, the holder shall either<br>(1) surrender the certificate or certificates therefor, duly endorsed, at the office of the Company; (2) notify the Company that<br>such certificates have been lost, stolen or destroyed and execute an agreement satisfactory to the Company to indemnify the Company from<br>any loss incurred by it in connection with such certificates, and shall give written notice to the Company at its registered office, of<br>the election to convert the same and shall state therein the name or names in which the certificate or certificates for B Shares are to<br>be issued; provided, however, that on the date of an Automatic Conversion Event, the outstanding A Shares subject to such Automatic<br>Conversion Event shall be converted automatically without any further action by the holder of such shares and whether or not the certificates<br>representing such shares are surrendered to the Company; provided further, however, that the Company shall not be obligated to issue<br>certificates evidencing the B Shares issuable upon such Automatic Conversion Event unless either the certificates evidencing such A Shares<br>are delivered to the Company as provided above, or the holder notifies the Company that such certificates have been lost, stolen or destroyed<br>and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such certificates.
---	---

A-8

3.2.2.	On the date of a conversion pursuant to this Article 3.2, all rights of the holder of the A Shares shall<br>cease and the holder or holders in whose name the certificate or certificates representing the B Shares are to be issued shall be treated<br>for all purposes as having become the record holder of such B Shares, notwithstanding that the certificates representing such A Shares<br>shall not have been surrendered at the registered office of the Company, that notice from the Company shall not have been received by<br>any holder of record of A Shares, or that the certificates evidencing such B Shares shall not then be actually delivered to such holder.
3.2.3.	In the event of a conversion pursuant to, and in accordance with the terms of, this Article 3.2, the Company<br>shall, as soon as practicable thereafter, issue and deliver at such office to such holder of A Shares, or to the nominee of such holder,<br>a certificate for the number of B Shares to which such holder shall be entitled.
---	---
3.2.4.	The Company may, from time to time, establish such policies and procedures relating to the conversion<br>of A Shares to B Shares, including the issuance of share certificates with respect thereto, as it may deem necessary or advisable, and<br>may request that holders of A Shares furnish affidavits or other proof to the Company as it deems necessary to verify the ownership of<br>A Shares and to confirm that a conversion to B Shares has not occurred, provided, however, that such policies and procedures shall not<br>inhibit the ability of a holder to convert such A Shares to B Shares. A determination by the Secretary of the Company that an Automatic<br>Conversion Event has occurred shall be conclusive.
---	---
3.2.5.	In the event that any A Shares shall be converted pursuant to this Article 3.2, the A Shares so converted<br>shall be cancelled and shall not be re-issuable by the Company.
---	---
3.2.6.	The Company shall procure that at all times there are sufficient unissued B Shares available to provide<br>for the conversion of A Shares into B Shares in accordance with this Article 3.2. Where any A Share remains capable of converting into<br>a B Share, the Company shall not consolidate or sub-divide the A Shares unless, at the same time, it also consolidates or sub-divides<br>the B Shares to the extent possible.
---	---
3.3.	Rights attaching to B Shares
---	---
3.3.1.	The B Shares shall rank pari passu with each other in all respects and shall, subject to the right of<br>the Company to set record dates for the purposes of determining the identity of members entitled to notice of and/or to vote at a general<br>meeting and the authority of the Board and chairperson of the meeting to maintain order and security, (i) include the right to attend<br>any general meeting of the Company and to vote on the basis set out in 3.3.2 below; (ii) include the right to participate pro rata<br>in all dividends declared by the Company; and (iii) include the right, in the event of the Company’s winding up, to participate<br>pro rata in the total assets of the Company.
---	---

A-9

3.3.2.	Each holder of B Shares shall be entitled to one (1) vote for each B Share held as of the applicable date<br>on any matter that is submitted to a vote or for the consent of members of the Company.
3.3.3.	The rights attaching to the B Shares may be subject to the terms of issue of any series or class of Preferred<br>Shares allotted by the Directors from time to time in accordance with Article 6.7.
---	---
3.4.	Class Voting of A and B Shares and Other Rights of A and B Shares
---	---
3.4.1.	Except as otherwise provided herein or by applicable law, the holder of A Shares and B Shares shall at<br>all times vote together as one class on all matters (including the election of directors) submitted to a vote or for the consent of members<br>of the Company.
---	---
3.4.2.	Except as expressly provided in this Article 3, A Shares and B Shares shall rank pari passu with each<br>other and have the same rights and preferences.
---	---

COMPANY SEAL

Without prejudice to the provisions of the Act in relation to the use of the seal of a company, any registered person authorised by the Board in accordance with the applicable provisions of the Act will be entitled to use the seal of the Company and may sign or countersign an instrument to which the seal is affixed, and an alternate who is not also a director will also be entitled to sign or countersign an instrument to which the seal is affixed, as if he were the director who appointed him.

OFFICIAL SEAL

5.	The Company may have for use in any place abroad an official seal which shall resemble the seal of the<br>Company with the addition on its face of the name of every place abroad where it is to be used.

ALLOTMENT OFSHARES

6.
6.1.	Subject to the provisions of these Articles relating to new shares, the shares shall be at the disposal<br>of the Directors, and they may (subject to the provisions of the Act) allot, grant options over or otherwise dispose of them to such persons,<br>on such terms and conditions and at such times as they may consider to be in the best interests of the Company and its shareholders, but<br>so that no share shall be issues at a discount save in accordance with the Act, and so that, in the case of shares offered to the public<br>for subscription, the amount payable on application on each such share shall not be less than one-quarter of the nominal amount of the<br>share and the whole of any premium thereon. To the extent permitted by the Act, shares may also be allotted by a committee of the Directors<br>or by any other person where such committee or person is so authorised by the Directors.
---	---
6.2.	Subject to any requirement to obtain the approval of shareholders under any laws, regulations or the rules<br>of any stock exchange on which any ordinary shares are admitted to trading, the Directors may grant from time to time options or awards<br>to purchase or subscribe for any number of shares of any class or classes or of any series of any class and other securities or ownership<br>interests of the Company any person, including Directors and other persons in the service or employment of the Company or any subsidiary<br>or associate company of the Company, on such terms and subject to such conditions as may be approved from time to time by the Directors<br>or by any committee thereof appointed by the Directors for the purpose of such approval and to cause warrants or other appropriate instruments<br>evidencing such options to be issued.
---	---

A-10

6.3.	The Directors are hereby generally and unconditionally authorised pursuant to Section 1021 of the Act,<br>in substitution for all existing such authorities, to exercise all powers of the Company to allot relevant securities (within the meaning<br>of Section 1021 of the Act) provided that such power shall be limited to the allotment of relevant securities up to the amount of the<br>Company’s authorised but unissued share capital and to allot and issue any shares acquired by or on behalf of the Company pursuant<br>to the provisions of Chapter 6 of Part 3 of the Act and held as treasury shares. Unless renewed, or a longer period of time is allowed<br>under applicable law, this authority shall expire on 14th September 2030, save that the Company may before such expiry date make an offer<br>or agreement which would or might require relevant securities<br>to be allotted after such authority has expired and the Directors may allot relevant securities in pursuance of such offer or agreement<br>as if the authority hereby conferred had not expired.
6.4.	The Directors are empowered pursuant to Section 1022 and Section 1023(3) of the Act, in substitution for<br>all existing such authorities, to allot equity securities (within the meaning of Section 1023 of the Act) for cash pursuant to the authority<br>conferred by Article 6.3 above as if Section 1022(1) of the Act, did not apply to any such allotment such power being limited to the allotment<br>of equity securities (including, without limitation, any shares purchased by the Company pursuant to the provisions of the Act and held<br>as treasury shares) up to an amount equal to the aggregate nominal value of the authorised but unissued share capital of the Company from<br>time to time. The authority hereby conferred shall expire on 14th September 2030, save that the Company may before such expiry, make an<br>offer or agreement which would or might<br>require relevant securities to be allotted after such authority has expired and the Directors may allot relevant securities in pursuance<br>of such offer or agreement notwithstanding that the power hereby conferred had not expired. The authority hereby conferred may be renewed,<br>revoked or varied by special resolution of the Company.
---	---
6.5.	The directors or any duly authorised committee thereof may execute and do all such documents, acts and<br>things as in their opinion are necessary or desirable in order to give effect to the authority conferred by this Article.
---	---
6.6.	For the purposes of this Article, shares includes a right to subscribe for shares or to convert securities<br>into shares and securities has the meaning given to such term in Section 64(1) of the Act.
---	---

Preferred Shares

6.7.	The Board is empowered to cause the Preferred Shares to be issued from time to time as shares of one or<br>more series of Preferred Shares, and in the resolution or resolutions providing for the issue of Preferred Shares of each particular series,<br>before issuance, the Board is expressly authorised to fix:
(a)	the distinctive designation of such series and the number of shares which shall constitute such series,<br>which number may be increased (except as otherwise provided by the Board in creating such series) or decreased (but not below the number<br>of shares thereof then in issue) from time to time by resolution of the Board;
---	---
(b)	the rate of dividends payable on shares of such series, if any, whether or not and upon what conditions<br>dividends on shares of such series shall be cumulative and, if cumulative, the date or dates from which dividends shall accumulate and<br>the preference or relation which such dividends shall bear to the dividends payable on any other class or classes or on any other series<br>of share capital;
---	---

A-11

(c)	the terms, if any, on which shares of such series may be redeemed, including without limitation, the redemption<br>price or prices for such series, which may consist of a redemption price or scale of redemption prices applicable only to redemption in<br>connection with a sinking fund (which term as used herein shall include any fund or requirement for the periodic purchase or redemption<br>of shares), and the same or a different redemption price or scale of redemption prices applicable to any other redemption;
(d)	the terms and amount of any sinking fund provided for the purchase or redemption of shares of such series;
---	---
(e)	the amount or amounts which shall be paid to the holders of shares of such series in case of liquidation,<br>dissolution or winding up of the Company, whether voluntary or involuntary;
---	---
(f)	the terms, if any, upon which the holders of shares of such series may convert shares thereof into shares<br>of any other class or classes or of any one or more series of the same class or of another class or classes;
---	---
(g)	the voting rights, full or limited, if any, of the shares of such series; and whether or not and<br>under what conditions the shares of such series (alone or together with the shares of one or more other series having similar provisions)<br>shall be entitled to vote separately as a single class, for the election of one or more additional Directors in case of dividend arrears<br>or other specified events, or upon other matters;
---	---
(h)	whether or not the holders of shares of such series, as such, shall have any pre-emptive or preferential<br>rights to subscribe for or purchase shares of any class or series of shares of the Company, now or hereafter authorised, or any securities<br>convertible into, or warrants or other evidences of optional rights to purchase or subscribe for, shares of any class or series of the<br>Company, now or hereafter authorised;
---	---
(i)	the limitations and restrictions, if any, to be effective while any shares of such series are outstanding<br>upon the payment of dividends, or the making of other distributions on, and upon the purchase, redemption or other acquisition by the<br>Company of, any other class or classes of shares ranking junior to the shares of such series either as to dividends or upon liquidation,<br>dissolution or winding up;
---	---
(j)	the conditions or restrictions, if any, upon the creation of indebtedness of the Company or upon the issuance<br>of any additional shares (including additional shares of such series or of any other class) ranking on a parity with or prior to the shares<br>of such series as to dividends or distribution of assets upon liquidation; and
---	---
(k)	such other rights, preferences and limitations as may be permitted to be fixed by the Board of the Company<br>under the laws of Ireland as in effect at the time of the creation of such series.
---	---

A-12

6.7.1.	The Board is authorised to change the designations, rights, preferences and limitations of any series<br>of Preferred Shares theretofore established, no shares of which have been issued.
6.7.2.	The rights conferred upon the member of any pre-existing shares in the share capital of the Company shall<br>be deemed not to be varied by the creation, issue and allotment of Preferred Shares in accordance with these Articles.
---	---

VARIATION OFRIGHTS ATTACHING TO SHARES

7.
7.1.	Without prejudice to the authority conferred on the directors pursuant to Article 6.7 to issue Preferred<br>Shares in the capital of the Company, if at any time the share capital of the Company is divided into different classes of shares, the<br>rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class) may, whether or not the Company<br>is being wound up, be varied or abrogated with the consent in writing of the holders of 75% in nominal value of the issued shares in that<br>class, or pursuant to a Special Resolution passed at a separate general meeting of the holders of the shares of that class. All the provisions<br>of these Articles relating to meetings of the Company shall apply mutatis mutandis to every separate general meeting of the holders<br>of any class of shares in the Company.
---	---
7.2.	The redemption or purchase of Preferred Shares or any class or series of Preferred Shares shall not constitute<br>a variation of rights of the holders of Preferred Shares.
---	---
7.3.	The issue, redemption or purchase of any of the Preferred Shares shall not constitute a variation of the<br>rights of the holders of A Shares or B Shares.
---	---
7.4.	The issue of Preferred Shares or any class or series of Preferred Shares which rank pari passu with, or<br>junior to, any existing Preferred Shares or class of Preferred Shares shall not constitute a variation of the existing Preferred Shares<br>or class of Preferred Shares.
---	---
7.5.	The rights conferred upon the holders of the shares of any class issued with preferred or other rights<br>shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation<br>or issue of further shares ranking pari passu or subordinate thereto or by a purchase, redemption by the Company of its own shares.
---	---

LIEN

8.
8.1.	The Company shall have a first and paramount lien on every share (not being a fully paid share) for all<br>moneys (whether presently payable or not) payable at a fixed time or called in respect of that share. The Directors, at any time, may<br>declare any share to be wholly or in part exempt from the provisions of this Article. The Company’s lien on a share shall extend<br>to all moneys payable in respect of it.
---	---
8.2.	The Company may sell in such manner as the Directors determine any share on which the Company has a lien<br>if a sum in respect of which the lien exists is presently payable and is not paid within fourteen Clear Days after notice demanding payment,<br>and stating that if the notice is not complied with the share may be sold, has been given to the Holder of the share or to the person<br>entitled to it by reason of the death or bankruptcy of the Holder.
---	---

A-13

8.3.	To give effect to a sale, the Directors may authorise some person to execute an instrument of transfer<br>of the share sold to, or in accordance with the directions of, the purchaser. The transferee shall be entered in the Register as the Holder<br>of the share comprised in any such transfer and he shall not be bound to see to the application of the purchase moneys nor shall his title<br>to the share be affected by any irregularity in or invalidity of the proceedings in reference to the sale, and after the name of the transferee<br>has been entered in the Register, the remedy of any person aggrieved by the sale shall be in damages only and against the Company exclusively.
8.4.	The net proceeds of the sale, after payment of the costs, shall be applied in payment of so much of the<br>sum for which the lien exists as is presently payable and any residue (upon surrender to the Company for cancellation of the certificate<br>for the shares sold and subject to a like lien for any moneys not presently payable as existed upon the shares before the sale) shall<br>be paid to the person entitled to the shares at the date of the sale.
---	---

8.3.

To give effect to a sale, the Directors may authorise some person to execute an instrument of transfer of the share sold to, or in accordance with the directions of, the purchaser. The transferee shall be entered in the Register as the Holder of the share comprised in any such transfer and he shall not be bound to see to the application of the purchase moneys nor shall his title to the share be affected by any irregularity in or invalidity of the proceedings in reference to the sale, and after the name of the transferee has been entered in the Register, the remedy of any person aggrieved by the sale shall be in damages only and against the Company exclusively.

8.4.

The net proceeds of the sale, after payment of the costs, shall be applied in payment of so much of the sum for which the lien exists as is presently payable and any residue (upon surrender to the Company for cancellation of the certificate for the shares sold and subject to a like lien for any moneys not presently payable as existed upon the shares before the sale) shall be paid to the person entitled to the shares at the date of the sale.

---

CALLS ON SHARES

9.
9.1.	Subject to the terms of allotment, the Directors may make calls upon the members in respect of any moneys<br>unpaid on their shares, including shares where the conditions of allotment provide for payment at fixed times, and each member (subject<br>to receiving at least fourteen Clear Days’ notice specifying when and where payment is to be made) shall pay to the Company as required<br>by the notice the amount called on his shares. A call may be required to be paid by instalments. A call may be revoked before receipt<br>by the Company of a sum due thereunder, in whole or in part and payment of a call may be postponed in whole or in part. A person upon<br>whom a call is made shall remain liable for calls made upon him notwithstanding the subsequent transfer of the shares in respect of which<br>the call was made.
---	---
9.2.	A call shall be deemed to have been made at the time when the resolution of the Directors authorising<br>the call was passed.
---	---
9.3.	The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof.
---	---
9.4.	If a call remains unpaid after it has become due and payable the person from whom it is due and payable<br>shall pay interest on the amount unpaid from the day it became due until it is paid at the rate fixed by the terms of allotment of the<br>share or in the notice of the call or, if no rate is fixed, at the appropriate rate (as defined by the Act) but the Directors may waive<br>payment of the interest wholly or in part.
---	---
9.5.	An amount payable in respect of a share on allotment or at any fixed date, whether in respect of nominal<br>value or as an instalment of a call, shall be deemed to be a call and if it is not paid the provisions of these Articles shall apply as<br>if that amount had become due and payable by virtue of a call.
---	---
9.6.	Subject to the terms of allotment, the Directors may make arrangements on the issue of shares for a difference<br>between the Holders in the amounts and times of payment of calls on their shares.
---	---
9.7.	The Directors, if they think fit, may receive from any member willing to advance the same all or any part<br>of the moneys uncalled and unpaid upon any shares held by him, and upon all or any of the moneys so advanced may pay (until the same would,<br>but for such advance, become payable) interest at such rate, not exceeding (unless the Company in general meeting otherwise directs) fifteen<br>percent per annum, as may be agreed upon between the Directors and the member paying such sum in advance.
---	---

A-14

9.8.
9.8.1.	If a member fails to pay any call or instalment of a call on the day appointed for payment thereof, the<br>Directors, at any time thereafter and during such times as any part of the call or instalment remains unpaid, may serve a notice on him<br>requiring payment of so much of the call or instalment as is unpaid together with any interest which may have accrued.
---	---
9.8.2.	The notice shall name a further day (not earlier than the expiration of fourteen Clear Days from the date<br>of service of the notice) on or before which the payment required by the notice is to be made, and shall state that in the event of non-payment<br>at or before the time appointed the shares in respect of which the call was made will be liable to be forfeited.
---	---
9.8.3.	If the requirements of any such notice as aforesaid are not complied with then, at any time thereafter<br>before the payment required by the notice has been made, any shares in respect of which the notice has been given may be forfeited by<br>a resolution of the Directors to that effect. The forfeiture shall include all dividends or other moneys payable in respect of the forfeited<br>shares and not paid before forfeiture. The Directors may accept a surrender of any share liable to be forfeited hereunder.
---	---
9.8.4.	On the trial or hearing of any action for the recovery of any money due for any call it shall be sufficient<br>to prove that the name of the member sued is entered in the Register as the holder, or one of the holders, of the shares in respect of<br>which such debt accrued, that the resolution making the call is duly recorded in the minute book and that notice of such call was duly<br>given to the member sued, in pursuance of these Articles, and it shall not be necessary to prove the appointment of the Directors who<br>made such call nor any other matters whatsoever, but the proof of the matters aforesaid shall be conclusive evidence of the debt.
---	---
9.9.	A forfeited share may be sold or otherwise disposed of on such terms and in such manner as the Directors<br>think fit and at any time before a sale or disposition the forfeiture may be cancelled on such terms as the Directors think fit. Where<br>for the purposes of its disposal such a share is to be transferred to any person, the Directors may authorise some person to execute an<br>instrument of transfer of the share to that person. The Company may receive the consideration, if any, given for the share on any sale<br>or disposition thereof and may execute a transfer of the share in favour of the person to whom the share is sold or disposed of and thereupon<br>he shall be registered as the Holder of the share and shall not be bound to see to the application of the purchase money, if any, nor<br>shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale or<br>disposal of the share.
---	---
9.10.	A person whose shares have been forfeited shall cease to be a member in respect of the forfeited shares,<br>but nevertheless shall remain liable to pay to the Company all moneys which, at the date of forfeiture, were payable by him to the Company<br>in respect of the shares, without any deduction or allowance for the value of the shares at the time of forfeiture but his liability shall<br>cease if and when the Company shall have received payment in full of all such moneys in respect of the shares.
---	---
9.11.	A statutory declaration that the declarant is a Director or the Secretary of the Company, and that a share<br>in the Company has been duly forfeited on the date stated in the declaration, shall be conclusive evidence of the facts therein stated<br>as against all persons claiming to be entitled to the share.
---	---

A-15

9.12.	The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which,<br>by the terms of issue of a share, becomes payable at a fixed time, whether on account of the nominal value of the share or by way of premium,<br>as if the same had been payable by virtue of a call duly made and notified.
9.13.	The Directors may accept the surrender of any share which the Directors have resolved to have been forfeited<br>upon such terms and conditions as may be agreed and, subject to any such terms and conditions, a surrendered share shall be treated as<br>if it has been forfeited.
---	---

TRANSFER OFSHARES

10.
10.1.	The instrument of transfer of any share may be executed for and on behalf of the transferor by the Secretary,<br>an Assistant Secretary or any such person that the Secretary or an Assistant Secretary nominates for that purpose (whether in respect<br>of specific transfers or pursuant to a general standing authorisation), and the Secretary, Assistant Secretary or the relevant nominee<br>shall be deemed to have been irrevocably appointed agent for the transferor of such share or shares with full power to execute, complete<br>and deliver in the name of and on behalf of the transferor of such share or shares all such transfers of shares held by the members in<br>the share capital of the Company. Any document which records the name of the transferor, the name of the transferee, the class and number<br>of shares agreed to be transferred, the date of the agreement to transfer shares and the price per share, shall, once executed by the<br>transferor or the Secretary, Assistant Secretary or the relevant nominee as agent for the transferor, and by the transferee where required<br>by the Act, be deemed to be a proper instrument of transfer for the purposes of the Act. The transferor shall be deemed to remain the<br>Holder of the share until the name of the transferee is entered on the Register in respect thereof, and neither the title of the transferee<br>nor the title of the transferor shall be affected by any irregularity or invalidity in the proceedings in reference to the sale should<br>the Directors so determine.
---	---
10.2.	The Company, at its absolute discretion, may, or may procure that a subsidiary of the Company shall, pay<br>Irish stamp duty arising on a transfer of shares on behalf of the transferee of such shares of the Company. If stamp duty resulting from<br>the transfer of shares in the Company which would otherwise be payable by the transferee is paid by the Company or any subsidiary of the<br>Company on behalf of the transferee, then in those circumstances, the Company shall, on its behalf or on behalf of its subsidiary (as<br>the case may be), be entitled to (i) seek reimbursement<br>of the stamp duty from the transferee, (ii) set-off the stamp duty against any dividends payable to the transferee of those shares and<br>(iii) claim a first and permanent lien on the shares on which stamp duty has been paid by the Company or its subsidiary for the amount<br>of stamp duty paid. The Company’s lien shall extend to all dividends paid on those shares.
---	---
10.3.	Notwithstanding the provisions of these Articles and subject to any provision of the Act, title to any<br>shares in the Company may also be evidenced and transferred without a written instrument in accordance with the Act or any regulations<br>made thereunder. The Directors shall have power to permit any class of shares to be held in uncertificated form and to implement any arrangements<br>they think fit for such evidencing and transfer which accord with such regulations and in particular shall, where appropriate, be entitled<br>to disapply or modify all or part of the provisions in these Articles with respect to the requirement for written instruments of transfer<br>and share certificates (if any), in order to give effect to such regulations.
---	---

A-16

10.4.	The Directors in their absolute discretion and without assigning any reason therefor may decline to register:
10.4.1.	any transfer of a share which is not fully paid; or
---	---
10.4.2.	any transfer to or by a minor or person of unsound mind;
---	---

but this shall not apply to a transfer of such a share resulting from a sale of the share through a stock exchange on which the share is listed.

10.5.	The directors may, in their absolute discretion, and without giving any reason for doing so, decline to<br>register any transfer of any share unless:
10.5.1.	the instrument of transfer is accompanied by the certificate of the shares to which it relates, and such<br>other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer; and
---	---
10.5.2.	the instrument of transfer is in respect of one class of share only.
---	---
10.6.	Section 95(1) of the Act shall not apply to any transfers made pursuant to this Article 10.
---	---
10.7.	The Directors may from time to time fix a record date for the purposes of determining the rights of members<br>to notice of and/or to vote at any general meeting of the Company. The record date shall not precede the date upon which the resolution<br>fixing the record date is adopted by the Directors, and the record date shall be not more than eighty nor less than ten days before the<br>date of such meeting. If no record date is fixed by the Directors, the record date for determining members entitled to notice of or to<br>vote at a meeting of the members shall be the close of business on the day next preceding the day on which notice is given. Unless the<br>Directors determine otherwise, the determination of those members of record entitled to notice of or to vote at a meeting of members shall<br>apply also to any adjournment or postponement of the meeting.
---	---
10.8.	In order that the Directors may determine the members entitled to receive payment of any dividend or other<br>distribution or allotment of any rights or the members entitled to exercise any rights in respect of any change, conversion or exchange<br>of shares, or for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date<br>upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 nor less than ten days prior<br>to such action. If no record date is fixed, the record date for determining members for such purpose shall be at the close of business<br>on the day on which the Directors adopt the resolution relating thereto.
---	---

ACQUISITIONOF OWN SHARES

11.
11.1.	Subject to Article 11.2, all ordinary shares allotted by the Company shall be deemed to be redeemable<br>shares on, and from the time of, the existence or creation of an agreement, transaction or trade between the Company (including any agent<br>or broker acting on behalf of the Company) and any person (who may or may not be a shareholder) pursuant to which the Company acquires<br>or will acquire ordinary shares, or any interest in ordinary shares, from the relevant person save for an acquisition for nil consideration<br>pursuant to section 102(1) of the Act. In these circumstances, the acquisition of such shares by the Company, save where acquired for<br>nil consideration in accordance with the Act, shall constitute the redemption of a redeemable share in accordance with Chapter 6 of Part<br>3 of the Act. No resolution, whether special or otherwise, shall be required to be passed to deem any ordinary share a redeemable share.
---	---

11.

11.1.

Subject to Article 11.2, all ordinary shares allotted by the Company shall be deemed to be redeemable shares on, and from the time of, the existence or creation of an agreement, transaction or trade between the Company (including any agent or broker acting on behalf of the Company) and any person (who may or may not be a shareholder) pursuant to which the Company acquires or will acquire ordinary shares, or any interest in ordinary shares, from the relevant person save for an acquisition for nil consideration pursuant to section 102(1) of the Act. In these circumstances, the acquisition of such shares by the Company, save where acquired for nil consideration in accordance with the Act, shall constitute the redemption of a redeemable share in accordance with Chapter 6 of Part 3 of the Act. No resolution, whether special or otherwise, shall be required to be passed to deem any ordinary share a redeemable share.

---

A-17

11.2.	If an ordinary share is listed on a securities market, a regulated market or another market recognised<br>for the purposes of section 1072 of the Act, within the meaning of the Act, the provisions of Article 11.1 shall apply unless the Board<br>resolves, prior to the existence or creation of any relevant arrangement, that the arrangement concerned is to be treated as a purchase<br>of shares pursuant to Article 11.3.3 in which case the arrangement shall be so executed.
11.3.	Subject to the provisions of Chapter 6 of Part 3 and Chapter 5 of Part 17 of the Act and any provisions<br>expressly provided otherwise in this Constitution or by the terms of issue in respect of any particular shares or class of shares, the<br>Company may:
---	---
11.3.1.	pursuant to section 66(4) of the Act, issue any shares (whether preferred or otherwise) of the Company<br>which are to be redeemed or are liable to be redeemed at the option of the Company or the shareholder on such terms and in such manner<br>as may be determined by the Company in general meeting (by special resolution) on the recommendation of the Board. No resolution, whether<br>special or otherwise, shall be required to deem any share a redeemable share;
---	---
11.3.2.	redeem shares (whether preferred shares or otherwise) of the Company on such terms as may be contained<br>in or determined pursuant to the provisions of these Articles. Subject as aforesaid, the Company may cancel any such shares so redeemed<br>or may hold them as treasury shares (as defined in section 106(1) of the Act) and re-issue such treasury shares as shares of any class<br>or classes, or cancel them.
---	---
11.3.3.	Subject to or in accordance with the provisions of the Act and without prejudice to any special rights<br>attached to any class of shares, pursuant to sections 105 and Chapter 5 of Part 17 of the Act, purchase any of its own shares (whether<br>preferred or otherwise and including any redeemable shares and without any obligation to purchase on any pro rata basis as between shareholders<br>or shareholders of the same class) and may cancel any such shares so purchased or hold them as treasury shares (as defined by section<br>106(1) of the Act) and may re-issue any such shares as shares of any class or classes or cancel them.
---	---
11.3.4.	Pursuant to section 83(3) of the Act, convert any of its shares into redeemable shares provided that the<br>total number of shares which shall be redeemable pursuant to this authority shall not exceed the limit in section 1071(1)(b) of the Act.<br>No resolution of the shareholders, whether special or otherwise, shall be required to be passed to convert any of the Company’s<br>shares into redeemable shares.
---	---
11.4.	The Company may make a payment in respect of the purchase or redemption of its own shares in any manner<br>permitted by the Act.
---	---
11.5.	The holder of the shares being purchased or redeemed shall be bound to deliver up to the Company the certificate(s)<br>if any thereof for cancellation and thereupon the Company shall pay to him or her the purchase or redemption monies or consideration in<br>respect thereof.
---	---

A-18

ALTERATION OFSHARE CAPITAL

12.	Increase of Capital
12.1.	The Company from time to time by ordinary resolution may increase the share capital by such sum, to be<br>divided into shares of such amount, as the resolution shall prescribe.
---	---
12.2.	Subject to the provisions of the Act and these Articles, the new shares shall be issued to such persons,<br>upon such terms and conditions and with such rights and privileges annexed thereto as the general meeting resolving upon the creation<br>thereof shall direct and, if no direction be given, as the Directors shall determine and in particular such shares may be issued with<br>a preferential or qualified right to dividends and in the distribution of the assets of the Company and with a special, or without any,<br>right of voting.
---	---
12.3.	Except so far as otherwise provided by the conditions of issue or by these Articles, any capital raised<br>by the creation of new shares shall be considered part of the pre-existing ordinary capital and shall be subject to the provisions herein<br>contained with reference to calls and instalments, transfer and transmission, forfeiture, lien and otherwise.
---	---
13.	Consolidation, Sub-Division and Cancellation of Capital
---	---

The Company may by ordinary resolution (save where the Directors resolve otherwise):

13.1.	consolidate and divide all or any of its share capital into shares of a larger nominal value than the<br>existing shares;
13.2.	subdivide the shares, or any of them, into shares of a smaller nominal value, so however that in the sub-division<br>the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in the case of<br>the share from which the reduced share is derived;
---	---
13.3.	cancel any Shares which, at the date of the passing of the relevant ordinary resolution have not been<br>taken or agreed to be taken by any person and reduce the amount of the Company's authorised share capital by the amount of the Shares<br>so cancelled;
---	---
13.4.	increase the nominal value of any of the shares by the addition to them of any undenominated capital;
---	---
13.5.	reduce the nominal value of any of the shares by the deduction from them of any part of that value, subject<br>to the crediting of the amount of the deduction to undenominated capital, other than the share premium account;
---	---
13.6.	convert any undenominated capital into shares for allotment as bonus shares to holders of existing shares;<br>and/or
---	---
13.7.	subject to applicable law, change the currency denomination of its share capital.
---	---
14.	Subject to the provisions of the Act, the Company may:
---	---
14.1.	by special resolution change its name, alter or add to the memorandum of association with respect to any<br>objects, powers or other matters specified therein or alter or add to these Articles;
---	---

A-19

14.2.	by special resolution reduce its company capital (including its share capital and any capital redemption<br>reserve or share premium account) in any way it thinks expedient and, without prejudice to the generality of the foregoing, may
i.	extinguish or reduce the liability on any of its shares in respect of share capital not paid up;
---	---
ii.	either with or without extinguishing or reducing liability on any of its shares, cancel any paid up company<br>capital which is lost or unrepresented by available assets; and
---	---
iii.	either with or without extinguishing or reducing liability on any of its shares, pay off any paid up company<br>capital which is in excess of the wants of the Company,
---	---

and in relation to such reductions, the Company may by special resolution determine the terms upon which the reduction is to be effected, including in the case of a reduction of part only of any class of shares, those shares to be affected; and

14.3.	by resolution of the Directors change the location of its<br>Office.

DIRECTORS

15.	Number of Directors
15.1.	Unless otherwise determined by the Company in General Meeting the number of Directors shall not be more<br>than fourteen nor less than two. The continuing Directors may act notwithstanding any vacancy in their body, provided that, and subject<br>as provided in these Articles, if the number of the Directors is reduced below the prescribed minimum the remaining Director or Directors<br>shall appoint forthwith an additional Director or additional Directors to make up such minimum or shall convene a general meeting of the<br>Company for the purpose of making such appointment. If there be no Director or Directors able or willing to act then any Member may summon<br>a general meeting for the purpose of appointing Directors. Any additional Director so appointed shall hold office (subject to the provisions<br>of the Act and these Articles) only until the conclusion of the annual general meeting of the Company next following such appointment<br>unless he is re-elected during such meeting and he shall not retire by rotation at such meeting or be taken into account in determining<br>the Directors who are to retire by rotation at such meeting.
---	---
15.2.	A Director is not required to hold shares in the Company. A Director (whether or not a member of the Company)<br>shall be entitled to attend and speak at general meetings.
---	---
16.	Remuneration of Directors
---	---
16.1.	The remuneration to be paid to the Directors shall be at such rate and basis as the Directors shall determine<br>from time to time. The Directors shall also be entitled to be paid their travelling, hotel and other expenses properly incurred by them<br>in attending and returning from meetings of the Directors or any committee of the Directors or general meetings of the Company or otherwise<br>in connection with the business of the Company, or to receive a fixed allowance in respect thereof as may be determined by the Directors<br>from time to time, or a combination partly of one such method and partly of the other. The amount, rate or basis of the fees, remuneration<br>or expenses paid or to be paid to the Directors shall not require the approval of or ratification by the Company in general meeting.
---	---

A-20

16.2.	The Board may approve additional remuneration to any Director undertaking any special work or services<br>for, or undertaking any special task on behalf of the Company including participating as a member of a committee, in addition to his ordinary<br>work as a Director. Any remuneration or fees paid to a Director who is also a legal adviser to the Company or otherwise serves the Company<br>in a professional capacity shall be in addition to any remuneration or fees paid to him as a Director of the Company.
17.	Powers of Directors
---	---
17.1.	The business of the Company shall be managed by the Directors, who may pay all expenses incurred in promoting<br>and registering the Company and may exercise all such powers of the Company as are not, by the Act or by these Articles, required to be<br>exercised by the Company in general meeting, subject, nevertheless, to any of these Articles and to the provisions of the Act.
---	---
17.2.	Subject to the Act, the Directors may exercise all the powers of the Company to borrow or raise money,<br>and to mortgage or charge its undertaking, property, assets and uncalled capital or any part thereof and to issue debentures, debenture<br>stock and other securities whether outright or as collateral security for any debt, liability or obligation of the Company or of any third<br>party, without any limitation as to amount.
---	---
17.3.	The Directors may from time to time and at any time by power of attorney appoint any company, firm or<br>person or body of persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys of the Company for<br>such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Directors under these<br>Articles) and for such period and subject to such conditions as they may think fit, and any such power of attorney may contain such provisions<br>for the protection of persons dealing with any such attorney as the Directors may think fit, and may also authorise any such attorney<br>to delegate all or any of the powers, authorities and discretions vested in him.
---	---
17.4.	The Directors shall cause minutes to be made in books provided for the purpose of:
---	---
17.4.1.	all appointments of officers made by the Directors;
---	---
17.4.2.	the names of the Directors present at each meeting of the Directors and of any committee of the Directors;<br>and
---	---
17.4.3.	all resolutions and proceedings at all meetings of the Company and of the Directors and of committees<br>of Directors.
---	---
18.	Appointment of Directors
---	---
18.1.	At every Annual General Meeting of the Company all of the Directors shall retire from office unless re-elected<br>by ordinary resolution at the annual general meeting. A Director retiring at a meeting shall retain office until the close or adjournment<br>of the meeting.
---	---
18.2.	If, before the expiration of his or her term of office, a Director should be replaced for whatever reason,<br>the term of office of the newly elected member of the Board shall expire at the end of the term of office of his or her predecessor.
---	---
18.3.	A retiring Director shall be eligible for re-election.
---	---
18.4.	The Company, at the meeting at which a Director retires in manner aforesaid, may fill the vacated office<br>by electing a person thereto, and in default the retiring Director shall, if offering himself for re-election. be deemed to have been<br>re-elected, unless at such meeting it is expressly resolved not to fill such vacated office, or unless a resolution for the re-election<br>of such Director has been put to the meeting and lost.
---	---

A-21

18.5.	No person other than a Director retiring at the meeting shall, unless recommended by the Directors, be<br>eligible for election to the office of Director at any general meeting unless not less than seven days before the day appointed for the<br>meeting there shall have been left at the office notice in writing signed by a member duly qualified to attend and vote at the meeting<br>for which such notice is given, of his intention to propose such person for election and also notice in writing signed by that person<br>of his willingness to be elected.
18.6.	The Company may from time to time by Ordinary Resolution increase or reduce the number of Directors.
---	---
18.7.	The Directors shall have power at any time and from time to time to appoint any person who is willing<br>to act to be a Director, either to fill a casual vacancy or as an addition to the existing Directors, but so that the total number of<br>Directors shall not at any time exceed the number fixed in accordance with these Articles. Any Director so appointed shall, unless the<br>appointment is subsequently approved or ratified by ordinary resolution prior to the next following annual general meeting, hold office<br>only until the next following annual general meeting. If not re-appointed at such annual general meeting, such Director shall vacate office<br>at the conclusion thereof.
---	---
18.8.	Subject as provided in these Articles, the Company by ordinary resolution may appoint a person to be a<br>Director, either to fill a vacancy or as an additional Director.
---	---
19.	Vacation of Office of Director
---	---
19.1.	The office of a Director shall, in addition to the circumstances in which it shall be vacated described<br>in Section 148(1) of the Act (bankruptcy and disqualification), also be vacated automatically if the Director dies in office, or if the<br>Director:
---	---
19.1.1.	becomes subject to a declaration of restriction made pursuant to Chapter 3 of Part 14 of the Act;<br>or
---	---
19.1.2.	is sentenced to a term of imprisonment following conviction of any indictable offence, unless the term<br>of imprisonment is suspended, such that he is not imprisoned in respect of the offence; or
---	---
19.1.3.	is absent for more than six consecutive months without the permission of the Directors from meetings of<br>the Directors or any committee thereof held during that period and his alternate Director (if any) shall not have attended any such meetings<br>in his place during such period, and his co-Directors resolve that, by reason of such absence, he has vacated his office; or
---	---
19.1.4.	is removed from office by notice in writing served upon him signed by a majority of his co-Directors (any<br>such removal being deemed to be an act of the Company); or
---	---
19.1.5.	is no longer reasonably regarded by his co-Directors as possessing an adequate decision- making capacity<br>for reasons of health, and a majority of his co-Directors have accordingly resolved that his office be vacated on this ground;
---	---
19.1.6.	resigns his office by notice in writing to the Company; or
---	---
19.1.7.	makes any arrangement or composition in Ireland or elsewhere with his creditors generally, and his co-Directors<br>resolve, for that reason, that his office be vacated.
---	---

A-22

19.2.	The provisions of paragraphs 19.1.1 to 19.1.7 of this Article shall apply to the exclusion of the provisions<br>of Section 148(2) of the Act.
19.3.	The Company may by Ordinary Resolution, which extended notice has been given in accordance with Section<br>146 of the Act, remove any Director before the expiration of his period of office notwithstanding anything in these Articles or in any<br>agreement between the Company and such Director. Such removal shall be without prejudice to any claim such Director may have for damages<br>for breach of any contract of service between him and the Company.
---	---
19.4.	The Company may, by Ordinary Resolution, appoint another person in place of a Director removed from office<br>under Article 19.3 and without prejudice to the powers of the Directors under Article 18.7 the Company in general meeting may appoint<br>any person to be a Director either to fill a casual vacancy or as an additional Director. A person appointed in place of a Director so<br>removed or to fill such a vacancy shall be subject to retirement at the same time as if he had become a Director on the day on which the<br>Director in whose place he is appointed was last elected a Director.
---	---
20.	Alternate Directors
---	---
20.1.	Any Director (the appointer) may at any time and from time to time appoint by notice in writing to the<br>Company any person (including another Director) to be his alternate, provided always that no such appointment of a person other than a<br>Director as an alternate will be effective unless and until such appointment is approved by resolution of the Directors.
---	---
20.2.	A person may act as an alternate for more than one Director and while he is so acting will be entitled<br>to a separate vote for each Director he is representing and, if he is himself a Director, his vote or votes as an alternate will be in<br>addition to his own vote.
---	---
20.3.	An alternate will be counted for the purpose of reckoning whether a quorum is present at any meeting attended<br>by him at which he is entitled to vote, but where he is himself a Director or is the alternate of more than one Director he will only<br>be counted once for such purpose.
---	---
20.4.	An alternate will be entitled, subject to his giving to the Company an address to receive notice of all<br>meetings of the Directors and of all meetings of committees of which his appointer is a member, to receive notice of and attend and vote<br>at any meeting of the Directors (or of a committee of which his appointer is a member) at which the appointer is not personally present.<br>An alternate shall not be entitled to be remunerated or paid fees otherwise than out of the remuneration or fees as the case may be paid<br>to the appointer.
---	---
20.5.	The alternate will be entitled, in the absence of the appointer, to exercise all the powers, rights, duties<br>and authorities of the appointer as a Director (other than the right to appoint an alternate hereunder).
---	---
20.6.	An alternate's appointment will automatically come to an end if for any reason the appointer ceases to<br>be a Director, but if a Director retires but is re-appointed or deemed to have been re-appointed at the meeting at which he retires, any<br>appointment of an alternate made by him which was in force immediately prior to his retirement will continue after his re-appointment.<br>Section 165(5) and (6) of the Act in relation to revocation of appointment shall apply.
---	---

A-23

21.	Proceedings of Directors
21.1.	The Directors may meet together for the dispatch of business, adjourn and otherwise regulate their meetings<br>as they may think fit. The quorum necessary for the transaction of the business of the Directors shall be a majority of the Directors<br>in office at the time when the meeting is convened. Questions arising at any meeting shall be decided by a majority of votes. Each Director<br>present and voting shall have one vote.
---	---
21.2.	Where there is an equality of votes, the Chairman shall not have a second or casting vote.
---	---
21.3.	Any Director may participate in a meeting of the Directors by means of telephonic or other such communication<br>whereby all persons participating in the meeting can hear each other speak, and participation in a meeting in this manner shall be deemed<br>to constitute presence in person at such meeting and any Director may be situated in any part of the world for any such meeting.
---	---
21.4.	The Chairman or a majority of the Directors may, and the Secretary on the requisition of the Chairman<br>or a majority of the Directors shall, at any time summon a meeting of the Directors. Any provision of an enactment permitting the Secretary<br>to summon a meeting of the Directors on the requisition of a Director acting alone shall not apply to the Company.
---	---
21.5.	The continuing Directors may act notwithstanding any vacancy in their number but, if and so long as their<br>number is reduced below the number fixed by or pursuant to these Articles as the minimum number of Directors, the continuing Directors<br>or Director may act for the purpose of increasing the number of Directors to that number or of summoning a general meeting of the Company<br>but for no other purpose.
---	---
21.6.	The Directors may elect a Chairman of their meetings and determine the period for which he is to hold<br>office. Any Director may be elected no matter by whom he was appointed but if no such Chairman is elected, or if at any meeting the Chairman<br>is not present within five minutes after the time appointed for holding the same, the Directors present may choose one of their number<br>to be Chairman of the meeting.
---	---
21.7.	The Board may from time to time designate committees of the Board, with such powers and duties as the<br>Board may decide to confer on such committees (including the power to subdelegate), and shall, for those committees and any others provided<br>for herein, elect a Director or Directors to serve as the member or members, designating, if it desires, other Directors as alternate<br>members who may replace any absent or disqualified member at any meeting of the committee. Adequate provision shall be made for notice<br>to members of all meetings; a majority of the members shall constitute a quorum and all matters shall be determined by a majority<br>vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing,<br>and the writing or writings are filed with the minutes of the proceedings of such committees.
---	---
21.8.	A committee may elect a chairman of its meeting. If no such chairman is elected, or if at any meeting<br>the chairman is not present within five minutes after the time appointed for holding the same, the members present may choose one of their<br>number to be chairman of the meeting.
---	---
21.9.	All acts done by any meeting of the Directors or of a committee of Directors or by any person acting as<br>a Director shall, notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director<br>or person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such person had been duly appointed<br>and was qualified to be a Director.
---	---

A-24

21.10.	Notwithstanding anything in these Articles or in the Act which might be construed as providing to the<br>contrary, notice of every meeting of the Directors shall be given to all Directors either by mail not less than 48 hours before the date<br>of the meeting, by telephone, email, or any other electronic means on not less than 24 hours’ notice, or on such shorter notice<br>as person or persons calling such meeting may deem necessary or appropriate and which is reasonable in the circumstances. Any Director<br>may waive any notice required to be given under these Articles, and the attendance of a Director at a meeting shall be deemed to be a<br>waiver by such Director.
21.11.	A resolution or other document in writing (in electronic form or otherwise) signed (whether by electronic<br>signature, advanced electronic signature or otherwise as approved by the Directors) by (a) all of the Directors entitled to receive notice<br>of a meeting of Directors or of a committee of Directors or (b) a majority of the Directors where notice in accordance with Article 21.10<br>of the resolution or other document in writing has been given to all Directors entitled to receive notice of a meeting of Directors or<br>of a committee of Directors, shall be as valid as if it had been passed at a meeting of Directors or (as the case may be) a committee<br>of Directors duly convened and held, and may consist of several documents in the like form each signed by one or more Directors, and such<br>resolution or other document or documents when duly signed may be delivered or transmitted (unless the Directors shall otherwise determine<br>either generally or in any specific case) by facsimile transmission, electronic mail or some other similar means of transmitting the contents<br>of documents.
---	---
22.	Offices and Remuneration of Directors
---	---
22.1.	Subject to the other provisions of these Articles, the Directors may from time to time appoint one or<br>more of themselves to be chief executive officer or any other category of executive director (by whatever name called) for such period,<br>and on such terms as to remuneration or otherwise, as they think fit and, subject to the terms of any agreement entered into in any particular<br>case, may revoke such appointment. The Directors may entrust to and confer upon any Director so appointed any of the powers exercisable<br>by them upon such terms and conditions and with such restrictions (if any) as they may think fit, and either concurrently with or to the<br>exclusion of their own powers, and may from time to time revoke, withdraw, alter or vary all or any conferral of such powers.
---	---
22.2.	The appointment of any Director to the office of chairperson or chief executive shall determine automatically<br>if he ceases to be a Director but without prejudice to any claim for damages for breach of any contract of services between him and the<br>Company.
---	---
22.3.	A Director may hold any other office or place of profit under the Company (except that of statutory auditor)<br>in conjunction with his office of Director, and may act in a professional capacity to the Company, on such terms as to remuneration and<br>otherwise as the Directors shall approve.
---	---
23.	Voting by Directors
---	---
23.1.	A Director or shadow director of the Company who is in any way, whether directly or indirectly, interested<br>in a contract or proposed contract with the Company shall comply with the provisions of section 231 of the Act with regard to the disclosure<br>of such interest by declaration or notice in accordance with and subject to the provisions of the said section 231. Subject to compliance<br>with the foregoing, a director may vote in respect of any contract, appointment or arrangement in which he is interested, and he shall<br>be counted in the quorum present at any meeting at which such matters are considered. Any such director shall not thereby be deemed to<br>be in breach of his duty under Section 1113 of the Act. Subject to the provisions of the Act and provided that he has disclosed to the<br>Directors the nature and extent of any material interest of his, a Director notwithstanding his office:-
---	---

A-25

23.1.1.	may be a party to, or otherwise interested in, any transaction or arrangement with the Company or any<br>subsidiary thereof or in which the Company or any subsidiary thereof is otherwise interested;
23.1.2.	may be a director or other officer of, or employed by or provide services to or have an interest in any<br>service provider or contractual counterparty to the Company from time to time;
---	---
23.1.3.	may be a Director or other officer of, or employed by, or a party to any transaction or arrangement with,<br>or otherwise interested in, any body corporate promoted by the Company or in which the Company or any subsidiary or Associated Company<br>thereof is otherwise interested; and
---	---
23.1.4.	shall not be accountable, by reason of his office, to the Company for any benefit which he derives from<br>any such office or employment or from any such transaction or arrangement or from any interest in any such body corporate and no such<br>transaction or arrangement shall be liable to be avoided on the ground of any such interest or benefit.
---	---
23.2.	No Director or intending Director shall be disqualified by his office from contracting with the Company<br>either as vendor, purchaser or otherwise, nor shall any such contract or any contract or arrangement entered into by or on behalf of the<br>other Company in which any Director shall be in any way interested be avoided, nor shall any Director so contracting or being so interested<br>be liable to account to the Company for any profit or benefit realised by any such contract or arrangement by reason of such Director<br>holding that office or of the fiduciary relationship thereby established. For the avoidance of doubt a Director shall be entitled to vote<br>at a meeting of the Directors or a committee of Directors on any resolution concerning a matter in which he has, directly or indirectly<br>or together with any person or persons connected with him, an interest, provided he has disclosed the nature of that interest to his fellow<br>Directors prior to such vote and the Director will be counted in the quorum present at the meeting at which such vote takes place.
---	---
23.3.	A Director is expressly permitted (for the purposes of section 228(1)(d) of the Act) to use the Company's<br>property pursuant to or in connection with: the exercise or performance of his duties, functions and powers as Director or employee;<br>the terms of any contract of service or employment or letter of appointment; and, or in the alternative, any other usage authorised<br>by the Directors (or a person authorised by the Directors) from time to time; and including in each case for a Director's own benefit<br>or for the benefit of another person.
---	---
23.4.	Nothing in section 228(1)(e) of the Act shall restrict a Director from entering into any commitment which<br>has been approved by the Board or has been approved pursuant to such authority as may be delegated by the Board in accordance with these<br>Articles. It shall be the duty of each Director to obtain the prior approval of the Board, before entering into any commitment permitted<br>by sections 228(1)(e)(ii) and 228(2) of the Act.
---	---
23.5.	A Director who has been validly appointed or nominated for appointment by a particular member or members<br>may (i) be a director or other officer of, employed by or otherwise interested (including by the holding of shares) in, any such member<br>or members, or of any body corporate owned or controlled by any such member or members, and (ii) have regard to the interests of that<br>member or members, and shall not be deemed to have a conflict of interest or to be in breach of his duty under Section 228(1)(f) of the<br>Act in any such circumstances.
---	---

A-26

24.	Directors’ Resolutions in Writing
24.1.	Notwithstanding the provisions of Section 161(1) of the Act, a resolution in writing signed by each Director<br>or by his alternate will be as valid as if it had been passed at a meeting of the Directors duly convened and held.
---	---
24.2.	A resolution in writing signed by each member of a committee (or, in the case of a Director, his alternate)<br>will be as valid as if it had been passed at a meeting of that committee duly convened and held.
---	---
24.3.	Any such resolution as is referred to in this Article may consist of one document or two or more documents<br>in like form to the same effect, each signed by one or more of the signatories, and for all purposes shall take effect from the time that<br>it is signed by the last such signatory.
---	---

GENERAL MEETINGS

25.	General Meetings
25.1.	The Company shall in each year hold a general meeting as its annual general meeting in addition to any<br>other meeting in that year, and shall specify the meeting as such in the notices calling it. Not more than fifteen months shall elapse<br>between the date of one annual general meeting of the Company and that of the next. This Article shall not apply in the case of the first<br>general meeting, in respect of which the Company shall convene the meeting within the time periods required by the Act.
---	---
25.2.	Subject to the Act, all general meetings of the Company may be held outside of Ireland, provided that<br>the Company shall at its own expense make all necessary arrangements to ensure that members can, by technological means, participate in<br>any such meeting without leaving Ireland.
---	---
25.3.	All general meetings other than annual general meetings shall be called extraordinary general meetings.
---	---
25.4.	The Directors may, whenever they think fit, convene an extraordinary general meeting, and extraordinary<br>general meetings shall also be convened on such requisition, or in default may be convened by such requisitionists, as provided in the<br>Act. Where any enactment confers rights on the members of a company to convene a general meeting and expresses such rights to apply save<br>where a company’s articles of association or constitution provides otherwise, including, but not limited to, section 178(2) of the<br>Act, such rights shall not apply to the members of the Company.
---	---
25.5.	A Director shall be entitled, notwithstanding that he is not a member, to attend and speak at any general<br>meeting and at any separate meeting of the Holders of any class of shares in the Company.
---	---
26.	Notice of General Meetings
---	---
26.1.	Subject to the provisions of the Act allowing a general meeting to be called by shorter notice, an annual<br>general meeting and an extraordinary general meeting for the passing of a Special Resolution shall be called by not more than 60 Clear<br>Days’ notice and not less than 21 Clear Days’ notice and all other extraordinary general meetings shall be called by not less<br>than 14 Clear Days’ notice.
---	---

A-27

26.2.	Any notice convening a general meeting shall specify the time and place of the meeting and, in the case<br>of special business, the general nature of that business and, in reasonable prominence, that a member entitled to attend and vote is entitled<br>to appoint a proxy to attend, speak and vote in his place and that a proxy need not be a member of the Company. It shall also give particulars<br>of any Directors who are to retire at the meeting and of any persons who are recommended by the Directors for appointment or re-appointment<br>as Directors at the meeting or in respect of whom notice has been duly given to the Company of the intention to propose them for appointment<br>or re- appointment as Directors at the meeting. Provided that the latter requirement shall only apply where the intention to propose the<br>person has been received by the Company in accordance with the provisions of these Articles. Subject to any restrictions imposed on any<br>shares, the notice of the meeting shall be given to all the members of the Company as of the record date set by the Directors and to the<br>Directors and the statutory auditors.
26.3.	The accidental omission to give notice of a meeting to, or the non-receipt of notice of a meeting by,<br>any person entitled to receive notice shall not invalidate the proceedings at the meeting.
---	---
26.4.	Where, by any provision contained in the Act, notice of a greater length than that required by Article<br>26.1 is required of a resolution, the resolution shall not be effective (except where the Directors of the Company have resolved to submit<br>it) unless notice of the intention to move it has been given to the Company not less than 28 days (or such period as the Act permit) before<br>the meeting at which it is moved, and the Company shall give to the members notice of any such resolution as required by and in accordance<br>with the provisions of the Act.
---	---
27.	Proceedings at General Meetings
---	---
27.1.	Without prejudice to the powers of the directors to include on the agenda of any annual general meeting<br>of the Company such other matters as they may, in their absolute discretion, think fit, the business of the annual general meeting of<br>the Company shall include:
---	---
27.1.1.	Declaring a dividend;
---	---
27.1.2.	the consideration of the Company's statutory financial statements and the report of the directors and<br>the report of the statutory auditors on those statements;
---	---
27.1.3.	the review by the members of the Company's affairs;
---	---
27.1.4.	the appointment or re-appointment of statutory auditors and the authorisation of the Directors to fix<br>the remuneration of the statutory auditors;
---	---
27.1.5.	the election of Directors in place of those retiring; and
---	---
27.1.6.	the review of the members of the Company’s affairs (to the extent required by the Act).
---	---

A-28

27.2.	At any annual general meeting, only such nominations of persons for election to the Board shall be made,<br>and only such other business shall be conducted or considered, as shall have been properly brought before the meeting. For nominations<br>to be properly made at an annual general meeting, and proposals of other business to be properly brought before an annual meeting, nominations<br>and proposals of other business must be: (a) specified in the Company’s notice of meeting (or any supplement thereto) given by or<br>at the direction of the Board, (b) otherwise properly made at the annual general meeting, by or at the direction of the Board or (c) otherwise<br>properly requested to be brought before the annual general meeting by a member of the Company in accordance with these Articles. For nominations<br>of persons for election to the Board or proposals of other business to be properly requested by a member to be made at an annual general<br>meeting, a member must (i) be a member at the time of giving of notice of such annual general meeting by or at the direction of the Board<br>and at the time of the annual general meeting, (ii) be entitled to vote at such annual general meeting and (iii) comply with the procedures<br>set forth in these Articles as to such business or nomination. The immediately preceding sentence shall be the exclusive means for a member<br>to make nominations or other business proposals (other than matters properly brought under the applicable rules of any stock exchange<br>to which the Company’s shares are admitted to trading and included in the Company’s notice of meeting) before an annual general<br>meeting of members.
27.3.	At any extraordinary general meeting of the members, only such business shall be conducted or considered,<br>as shall have been properly brought before the meeting pursuant to the Company’s notice of meeting. To be properly brought before<br>an extraordinary general meeting, proposals of business must be (a) specified in the Company’s notice of meeting (or any supplement<br>thereto) given by or at the direction of the Board, (b) otherwise properly brought before the extraordinary general meeting, by or at<br>the direction of the Board, or (c) otherwise properly brought before the meeting by any members of the Company pursuant to the valid exercise<br>of power granted to them under the Act.
---	---
27.4.	No shareholder shall be entitled to propose any person to be appointed, elected or re-elected as Director<br>at any extraordinary general meeting.
---	---
27.5.	Except as otherwise provided by the Act, the memorandum of association or these Articles, the Chairman<br>of any general meeting shall have the power to determine whether a nomination or any other business proposed to be brought before the<br>general meeting was made or proposed, as the case may be, in accordance with these Articles and, if any proposed nomination or other business<br>is not in compliance with these Articles, to declare that no action shall be taken on such nomination or other proposal and such nomination<br>or other proposal shall be disregarded.
---	---
27.6.	No business shall be transacted at any general meeting unless a quorum is present at the time when the<br>meeting proceeds to business. Three persons entitled to attend and to vote upon the business to be transacted, each being a member or<br>a proxy for a member, shall constitute a quorum. Abstentions and broker non-votes will be regarded as present for the purposes of establishing<br>the presence of a quorum.
---	---
27.7.	Any general meeting duly called at which a quorum is not present shall be adjourned and the Company shall<br>provide notice pursuant to Article 26.4 in the event that such meeting is to be reconvened.
---	---
27.8.	The Chairman, if any, of the Board shall preside as Chairman at every general meeting of the Company,<br>or if there is no such Chairman, or if he is not present within fifteen minutes after the time appointed for the holding of the meeting<br>or is unwilling to act, the Directors present shall elect one of their number to be Chairman of the meeting.
---	---

A-29

27.9.	If at any meeting no Director is willing to act as Chairman or if no Director is present within fifteen<br>minutes after the time appointed for holding the meeting, the members present shall choose one of their number to be Chairman of the meeting.
27.10.	The Chairman may, with the consent of any meeting at which a quorum is present, and shall if so directed<br>by the meeting, adjourn the meeting from time to time and from place to place without notice other than by announcement of the time and<br>place of the adjourned meeting by the Chairman of the meeting. The Chairman of the meeting may at any time without the consent of the<br>meeting adjourn the meeting to another time and/or place if, in his opinion, it would facilitate the conduct of the business of the meeting<br>to do so or if he is so directed by the Board. Save as aforesaid, it shall not be necessary to give any notice of an adjournment or of<br>the business to be transacted at an adjourned meeting.
---	---
27.11.	At any general meeting a resolution put to the vote of the meeting shall be decided by poll.
---	---
27.12.	A poll shall be taken in such manner as the Chairman directs, and the result of the poll shall be deemed<br>to be the resolution of the meeting at which the poll was taken.
---	---
27.13.	Unless the Directors otherwise determine, no member shall be entitled to vote at any general meeting or<br>any separate meeting of the Holders of any class of shares in the Company, either in person or by proxy, or to exercise any privilege<br>as a member in respect of any share held by him unless all monies then payable by him in respect of that share have been paid.
---	---
28.	Advance Notice of Member Business and Nominations
---	---
28.1.	Without qualification or limitation, subject to Article 28.11, for any nominations or any other business<br>to be properly brought before an annual general meeting by a member pursuant to Article 27.2, the member must have given timely notice<br>thereof (including, in the case of nominations, the completed and signed questionnaire, representation and agreement required by Article<br>28.12), and timely updates and supplements thereof, in writing to the Secretary, and such other business must otherwise be a proper matter<br>for member action.
---	---
28.2.	To be timely, a member’s notice for any nominations or any other business to be properly brought<br>before an annual general meeting by a member pursuant to Article 28.1, shall be delivered to the Secretary at the Office by close of business<br>on that day that is not less than 120 days prior to the first anniversary of the day of release to shareholders of the Company’s<br>proxy statement, issued pursuant to the applicable rules of any stock exchange to which the Company’s shares are admitted to trading,<br>in respect of the preceding year’s annual general meeting; provided, however, that in the event that the date of the annual<br>general meeting is changed by more than 30 days from the date contemplated at the time of the previous year’s proxy statement, notice<br>by the member must be so delivered by close of business on the day that is not less than the later of (a) 150 days prior to the day of<br>the contemplated annual general meeting or (b) ten days after the day on which public announcement of the date of the contemplated annual<br>general meeting is first made by the Company; provided, further, that with respect to the first annual general meeting of the Company,<br>notice by the member must be so delivered by close of business on the day that is not less than ten days after the day on which public<br>announcement of the date of such meeting is first made by the Company. In no event shall any adjournment or postponement of an annual<br>general meeting, or the public announcement thereof, commence a new time period for the giving of a member’s notice as described<br>above.
---	---

A-30

28.3.	Notwithstanding anything in Article 28.12 to the contrary, in the event that the number of directors to<br>be elected to the Board is increased by the Board, and there is no public announcement by the Company naming all of the nominees for director<br>or specifying the size of the increased Board at least 130 days prior to the first anniversary of the day of release to shareholders of<br>the Company’s proxy statement issued pursuant to the applicable rules of any stock exchange to which the Company’s shares<br>are admitted to trading in respect of the preceding year’s annual general meeting, a member’s notice required by Articles<br>28.1– 28.4 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if<br>it shall be delivered to the Secretary at the Office not later than the close of business on the day that is ten days after the day on<br>which such public announcement is first made by the Company.
28.4.	In addition, to be considered timely, a member’s notice shall further be updated and supplemented,<br>if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date<br>for the meeting and as of the date that is ten business days prior to the meeting or any adjournment or postponement thereof, and such<br>update and supplement shall be delivered to the Secretary at the Office not later than five business days after the record date for the<br>meeting in the case of the update and supplement required to be made as of the record date, and not later than eight business days prior<br>to the date for the meeting or any adjournment or postponement thereof in the case of the update and supplement required to be made as<br>of ten business days prior to the meeting or any adjournment or postponement thereof.
---	---
28.5.	Subject to Article 28.11, in the event the Company calls an extraordinary general meeting of members for<br>the purpose of electing one or more directors to the Board, any member may nominate a person or persons (as the case may be) for election<br>to such position(s) as specified in the Company’s notice of meeting, provided that the member gives timely notice thereof (including<br>the completed and signed questionnaire, representation and agreement required by Article 28.12), and timely updates and supplements thereof,<br>in writing, to the Secretary.
---	---
28.6.	To be timely, a member’s notice for any nomination to be properly brought before such an extraordinary<br>general meeting shall be delivered to the Secretary at the Office by close of business on the day that is not less than 120 days prior<br>to the date of such extraordinary general meeting or, if the first public announcement of the date of such extraordinary general meeting<br>is less than 130 days prior to the date of such extraordinary general meeting, by close of business on the day that is ten days after<br>the day on which public announcement of the date of the extraordinary general meeting and of the nominees proposed by the Board to be<br>elected at such meeting is first made by the Company. In no event shall any adjournment or postponement of an extraordinary general meeting,<br>or the public announcement thereof, commence a new time period for the giving of a member’s notice as described above.
---	---
28.7.	In addition, to be considered timely, a member’s notice shall further be updated and supplemented,<br>if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date<br>for the meeting and as of the date that is ten business days prior to the meeting or any adjournment or postponement thereof, and such<br>update and supplement shall be delivered to the Secretary at the Office not later than five business days after the record date for the<br>meeting in the case of the update and supplement required to be made as of the record date, and not later than eight business days prior<br>to the date for the meeting, any adjournment or postponement thereof in the case of the update and supplement required to be made as of<br>ten business days prior to the meeting or any adjournment or postponement thereof.
---	---

A-31

28.8.	To be in proper form, a member’s notice (whether given pursuant to Articles 28.1– 28.4 or<br>Articles 28.5– 28.7) to the Secretary must include the following, as applicable:
28.8.1.	As to the member giving the notice and the beneficial owner, if any, on whose behalf the nomination or<br>proposal is made, a member’s notice must set forth: (i) the name and address of such member, as they appear on the Company’s<br>books, of such beneficial owner, if any, and of their respective affiliates or associates or others acting in concert therewith, (ii)<br>(A) the class or series and number of shares of the Company which are, directly or indirectly, owned beneficially and of record by such<br>member, such beneficial owner and their respective affiliates or associates or others acting in concert therewith, (B) any option, warrant,<br>convertible security, share appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism<br>at a price related to any class or series of shares of the Company or with a value derived in whole or in part from the value of any class<br>or series of shares of the Company, or any derivative or synthetic arrangement having the characteristics of a long position in any class<br>or series of shares of the Company, or any contract, derivative, swap or other transaction or series of transactions designed to produce<br>economic benefits and risks that correspond substantially to the ownership of any class or series of shares of the Company, including<br>due to the fact that the value of such contract, derivative, swap or other transaction or series of transactions is determined by reference<br>to the price, value or volatility of any class or series of shares of the Company, whether or not such instrument, contract or right shall<br>be subject to settlement in the underlying class or series of shares of the Company, through the delivery of cash or other property, or<br>otherwise, and without regard to whether the member, the beneficial owner, if any, or any affiliates or associates or others acting in<br>concert therewith, may have entered into transactions that hedge or mitigate the economic effect of such instrument, contract or right,<br>or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares<br>of the Company (any of the foregoing, a “Derivative Instrument”) directly or indirectly owned beneficially by such member,<br>the beneficial owner, if any, or any affiliates or associates or others acting in concert therewith, (C) any proxy, contract, arrangement,<br>understanding, or relationship pursuant to which such member has a right to vote any class or series of shares of the Company, (D) any<br>agreement, arrangement, understanding, relationship or otherwise, including any repurchase or similar so-called “stock borrowing”<br>agreement or arrangement, involving such member, directly or indirectly, the purpose or effect of which is to mitigate loss to, reduce<br>the economic risk (of ownership or otherwise) of any class or series of the shares of the Company by, manage the risk of share price changes<br>for, or increase or decrease the voting power of, such member with respect to any class or series of the shares of the Company, or which<br>provides, directly or indirectly, the opportunity to profit or share in any profit derived from any decrease in the price or value of<br>any class or series of the shares of the Company (any of the foregoing, a “Short Interest”), (E) any rights to dividends on<br>the shares of the Company owned beneficially by such member that are separated or separable from the underlying shares of the Company,<br>(F) any proportionate interest in shares of the Company or Derivative Instruments held, directly or indirectly, by a general or limited<br>partnership in which such member is a general partner or, directly or indirectly, beneficially owns an interest in a general partner of<br>such general or limited partnership, (G) any performance-related fees (other than an asset-based fee) that such member is entitled to<br>base on any increase or decrease in the value of shares of the Company or Derivative Instruments, if any, including without limitation<br>any such interests held by members of such member’s immediate family sharing the same household, (H) any significant equity interests<br>or any Derivative Instruments or Short Interests in any principal competitor of the Company held by such member, and (I) any direct or<br>indirect interest of such member in any contract with the Company, any affiliate of the Company or any principal competitor of the Company<br>(including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), and (iii) any other<br>information relating to such member and beneficial owner, if any, that would be required to be disclosed in a proxy statement and form<br>or proxy or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for<br>the election of directors in a contested election pursuant to the applicable rules of any stock exchange to which the Company’s<br>shares are admitted to trading and the regulations promulgated thereunder.
---	---
28.8.2.	If the notice relates to any business other than a nomination of a director or directors that the member<br>proposes to bring before the meeting, a member’s notice must, in addition to the matters set forth in Article 28.8.1 above, also<br>set forth: (i) a brief description of the business desired to be brought before the meeting, the reasons for conducting such business<br>at the meeting and any material interest of such member and beneficial owner, if any, in such business, (ii) the text of the proposal<br>or business (including the text of any resolutions proposed for consideration and, in the event that such proposal or business includes<br>a proposal to amend these Articles, the text of the proposed amendment), and (iii) a description of all agreements, arrangements and understandings<br>between such member and beneficial owner, if any, and any other person or persons (including their names) in connection with the proposal<br>of such business by such member.
---	---

A-32

28.8.3.	As to each person, if any, whom the member proposes to nominate for election or re- election to the Board,<br>a member’s notice must, in addition to the matters set forth in Article 28.8.1 above, also set forth: (i) all information relating<br>to such person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations<br>of proxies for election of directors in a contested election pursuant to the applicable rules of any stock exchange to which the Company’s<br>shares are admitted to trading and the rules and regulations promulgated thereunder (including such person’s written consent to<br>being named in the proxy statement as a nominee and to serving as a director if elected) and (ii) a description of all direct and indirect<br>compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material<br>relationships, between or among such member and beneficial owner, if any, and their respective affiliates and associates, or others acting<br>in concert therewith, on the one hand, and each proposed nominee, and his or her respective affiliates and associates, or others acting<br>in concert therewith, on the other hand, including, without limitation all information that would be required to be disclosed pursuant<br>to the applicable rules of any stock exchange to which the Company’s shares are admitted to trading if the member making the nomination<br>and any beneficial owner on whose behalf the nomination is made, if any, or any affiliate or associate thereof or person acting in concert<br>therewith, were the “registrant” for purposes of such rule and the nominee were a director or executive officer of such registrant.
28.9.	With respect to each person, if any, whom the member proposes to nominate for election or re-election<br>to the Board, a member’s notice must, in addition to the matters set forth in Articles 28.8.1 and 28.8.3 above, also include a completed<br>and signed questionnaire, representation and agreement required by Article 28.12 of these Articles. The Company may require any proposed<br>nominee to furnish such other information as may reasonably be required by the Company to determine the eligibility of such proposed nominee<br>to serve as an independent director of the Company or that could be material to a reasonable member’s understanding of the independence,<br>or lack thereof, of such nominee.
---	---
28.10.	Notwithstanding the provisions of these Articles, a member shall also comply with all applicable requirements<br>of the applicable rules of any stock exchange to which the Company’s shares are admitted to trading and the rules and regulations<br>thereunder with respect to the matters set forth in these Articles 28.1– 28.12.
---	---
28.11.	Nothing in these Articles shall be deemed to affect any rights (i) of members to request inclusion of<br>proposals in the Company’s proxy statement pursuant to the applicable rules of any stock exchange to which the Company’s shares<br>are admitted to trading, (ii) of the holders of any series of preferred shares if and to the extent provided for under law, the memorandum<br>of association or these Articles or (iii) of members of the Company to bring business before an extraordinary general meeting pursuant<br>to the valid exercise of power granted to them under the Act. Subject to the applicable rules of any stock exchange to which the Company’s<br>shares are admitted to trading, nothing in these Articles shall be construed to permit any member, or give any member the right, to include<br>or have disseminated or described in the Company’s proxy statement any nomination of director or directors or any other business<br>proposal.
---	---

A-33

28.12.	Subject to the rights of members of the Company to propose nominations at an extraordinary general meeting<br>pursuant to the valid exercise of power granted to them under the Act, to be eligible to be a nominee for election or re-election as a<br>director of the Company, a person must deliver (in accordance with the time periods prescribed for delivery of notice under Articles 28.1<br>- 28.11) to the Secretary at the Office a written questionnaire with respect to the background and qualification of such person and the<br>background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary<br>upon written request), and a written representation and agreement (in the form provided by the Secretary upon written request) that such<br>person (A) is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment<br>or assurance to, any person or entity as to how such person, if elected as a director of the Company, will act or vote on any issue or<br>question (a “Voting Commitment”) that has not been disclosed to the Company or (2) any Voting Commitment that could<br>limit or interfere with such person’s ability to comply, if elected as a director of the Company, with such person’s fiduciary<br>duties under applicable law, (B) is not and will not become a party to any agreement, arrangement or understanding with any person or<br>entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with<br>service or action as a director that has not been disclosed therein, and (C) in such person’s individual capacity and on behalf<br>of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the Company,<br>and will comply with all applicable corporate governance, conflict of interest, confidentiality and share ownership and trading policies<br>and guidelines of the Company publicly disclosed from time to time.
29.	Votes of Members
---	---
29.1.	Subject to any special rights or restrictions as to voting for the time being attached by or in accordance<br>with these Articles to any class of shares, on a poll every member who is present in person or by proxy shall have one vote for each share<br>of which he is the Holder.
---	---
29.2.	When there are joint Holders, the vote of the senior who tenders a vote, whether in person or by proxy,<br>shall be accepted to the exclusion of the votes of the other joint Holders; and for this purpose, seniority shall be determined by<br>the order in which the names stand in the Register.
---	---
29.3.	A member of unsound mind, or in respect of whom an order has been made by any court having jurisdiction<br>(whether in Ireland or elsewhere) in matters concerning mental disorder, may vote by his committee, receiver, guardian or other person<br>appointed by that court and any such committee, receiver, guardian or other person may vote by proxy on a poll. Evidence to the satisfaction<br>of the Directors of the authority of the person claiming to exercise the right to vote shall be received at the Office or at such other<br>address as is specified in accordance with these Articles for the receipt of appointments of proxy, not less than forty-eight hours before<br>the time appointed for holding the meeting or adjourned meeting at which the right to vote is to be exercised and in default the right<br>to vote shall not be exercisable.
---	---
29.4.	No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting<br>at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes. Any<br>such objection made in due time shall be referred to the Chairman of the meeting, whose decision shall be final and conclusive.
---	---

A-34

28.8.3.	As to each person, if any, whom the member proposes to nominate<br>for election or re- election to the Board, a member’s notice must, in addition to the matters set forth in Article 28.8.1 above,<br>also set forth: (i) all information relating to such person that would be required to be disclosed in a proxy statement or other filings<br>required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to the applicable<br>rules of any stock exchange to which the Company’s shares are admitted to trading and the rules and regulations promulgated thereunder<br>(including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected)<br>and (ii) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings<br>during the past three years, and any other material relationships, between or among such member and beneficial owner, if any, and their<br>respective affiliates and associates, or others acting in concert therewith, on the one hand, and each proposed nominee, and his or her<br>respective affiliates and associates, or others acting in concert therewith, on the other hand, including, without limitation all information<br>that would be required to be disclosed pursuant to the applicable rules of any stock exchange to which the Company’s shares are<br>admitted to trading if the member making the nomination and any beneficial owner on whose behalf the nomination is made, if any, or any<br>affiliate or associate thereof or person acting in concert therewith, were the “registrant” for purposes of such rule and<br>the nominee were a director or executive officer of such registrant.
28.9.	With respect to each person, if any, whom the member proposes to nominate for election or re-election<br>to the Board, a member’s notice must, in addition to the matters set forth in Articles 28.8.1 and 28.8.3 above, also include a completed<br>and signed questionnaire, representation and agreement required by Article 28.12 of these Articles. The Company may require any proposed<br>nominee to furnish such other information as may reasonably be required by the Company to determine the eligibility of such proposed nominee<br>to serve as an independent director of the Company or that could be material to a reasonable member’s understanding of the independence,<br>or lack thereof, of such nominee.
---	---
28.10.	Notwithstanding the provisions of these Articles, a member shall also comply with all applicable requirements<br>of the applicable rules of any stock exchange to which the Company’s shares are admitted to trading and the rules and regulations<br>thereunder with respect to the matters set forth in these Articles 28.1– 28.12.
---	---
28.11.	Nothing in these Articles shall be deemed to affect any rights (i) of members to request inclusion of<br>proposals in the Company’s proxy statement pursuant to the applicable rules of any stock exchange to which the Company’s shares<br>are admitted to trading, (ii) of the holders of any series of preferred shares if and to the extent provided for under law, the memorandum<br>of association or these Articles or (iii) of members of the Company to bring business before an extraordinary general meeting pursuant<br>to the valid exercise of power granted to them under the Act. Subject to the applicable rules of any stock exchange to which the Company’s<br>shares are admitted to trading, nothing in these Articles shall be construed to permit any member, or give any member the right, to include<br>or have disseminated or described in the Company’s proxy statement any nomination of director or directors or any other business<br>proposal.
---	---

A-35

28.12.	Subject to the rights of members of the Company to propose nominations at an extraordinary general meeting<br>pursuant to the valid exercise of power granted to them under the Act, to be eligible to be a nominee for election or re-election as a<br>director of the Company, a person must deliver (in accordance with the time periods prescribed for delivery of notice under Articles 28.1<br>- 28.11) to the Secretary at the Office a written questionnaire with respect to the background and qualification of such person and the<br>background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary<br>upon written request), and a written representation and agreement (in the form provided by the Secretary upon written request) that such<br>person (A) is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment<br>or assurance to, any person or entity as to how such person, if elected as a director of the Company, will act or vote on any issue or<br>question (a “Voting Commitment”) that has not been disclosed to the Company or (2) any Voting Commitment that could<br>limit or interfere with such person’s ability to comply, if elected as a director of the Company, with such person’s fiduciary<br>duties under applicable law, (B) is not and will not become a party to any agreement, arrangement or understanding with any person or<br>entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with<br>service or action as a director that has not been disclosed therein, and (C) in such person’s individual capacity and on behalf<br>of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the Company,<br>and will comply with all applicable corporate governance, conflict of interest, confidentiality and share ownership and trading policies<br>and guidelines of the Company publicly disclosed from time to time.
29.	Votes of Members
---	---
29.1.	Subject to any special rights or restrictions as to voting for the time being attached by or in accordance<br>with these Articles to any class of shares, on a poll every member who is present in person or by proxy shall have one vote for each share<br>of which he is the Holder.
---	---
29.2.	When there are joint Holders, the vote of the senior who tenders a vote, whether in person or by proxy,<br>shall be accepted to the exclusion of the votes of the other joint Holders; and for this purpose, seniority shall be determined by<br>the order in which the names stand in the Register.
---	---
29.3.	A member of unsound mind, or in respect of whom an order has been made by any court having jurisdiction<br>(whether in Ireland or elsewhere) in matters concerning mental disorder, may vote by his committee, receiver, guardian or other person<br>appointed by that court and any such committee, receiver, guardian or other person may vote by proxy on a poll. Evidence to the satisfaction<br>of the Directors of the authority of the person claiming to exercise the right to vote shall be received at the Office or at such other<br>address as is specified in accordance with these Articles for the receipt of appointments of proxy, not less than forty-eight hours before<br>the time appointed for holding the meeting or adjourned meeting at which the right to vote is to be exercised and in default the right<br>to vote shall not be exercisable.
---	---
29.4.	No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting<br>at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes. Any<br>such objection made in due time shall be referred to the Chairman of the meeting, whose decision shall be final and conclusive.
---	---

A-36

29.5.	Votes may be given either personally or by proxy.
29.6.	Every member entitled to attend and vote at a general meeting may appoint a proxy or (subject to these<br>provisions) proxies to attend, speak and vote on his behalf provided, however, that:
---	---
29.6.1.	a member may appoint more than one proxy provided that each proxy is appointed to exercise the rights<br>attached to shares held in different securities accounts; and
---	---
29.6.2.	a member acting as an intermediary on behalf of a client in relation to shares may appoint that client<br>or any third party designated by that client as a proxy in relation to those shares.
---	---

subject to such requirements and restrictions as the Directors may from time to time specify. A body corporate must sign a form of proxy under its common seal (if applicable) or under the hand of a duly authorised officer thereof. A proxy need not be a member of the Company. The appointment of a proxy in electronic or other form shall only be effective in such manner as the Directors may approve, subject to any requirements of the Act.

29.7.	The instrument of proxy and the power of attorney or other authority, if any, under which it is signed,<br>or a notarially certified copy of that power or authority, shall be received by the Company;
29.7.1.	if in physical form, when deposited at the registered office of the Company or at such other place within<br>Ireland as is specified for that purpose in the notice convening the meeting of the Company; or
---	---
29.7.2.	if in electronic form, if received in accordance with Article 29.8,
---	---

and shall be so deposited not later than before the commencement of the meeting or adjourned meeting at which the person named in the instrument proposes to vote or, in the case of a poll, before the commencement of the taking of the poll.

29.8.

Without limiting the foregoing, the Directors shall facilitate appointments of a proxy to be made by means of an electronic or internet communication or facility and may in a similar manner facilitate supplements to, or amendments or revocations of, any such electronic or internet communication or facility to be made. For the avoidance of doubt, such appointments of proxy as made by electronic or internet communication or facility will be deemed to be deposited at the place specified for such purpose once received by the Company. The Directors may in addition prescribe the method of determining the time at which any such electronic or internet communication or facility is to be treated as deposited at the place specified for such purpose. The Directors may treat any such electronic or internet communication or facility which purports to be or is expressed to be sent on behalf of a Holder of a share as sufficient evidence of the authority of the person sending that instruction to send it on behalf of that Holder.

29.9.

A body corporate which is a member of the Company may authorise such person as it thinks fit to act as its representative at any meeting of the Company or of any class of members of the Company and the person so authorised shall be entitled to exercise the same powers on behalf of the body corporate which he represents as that body corporate could exercise if it were an individual member of the Company. The Company may require evidence from the body corporate of the due authorisation of such person to act as the representative of the relevant body corporate.

---

A-37

29.10.	An appointment of proxy relating to more than one meeting (including any adjournment thereof) having once<br>been received by the Company for the purposes of any meeting shall not require to be delivered, deposited or received again by the Company<br>for the purposes of any subsequent meeting to which it relates.
29.11.	Receipt by the Company of an appointment of proxy in respect of a meeting shall not preclude a member<br>from attending and voting at the meeting or at any adjournment thereof. An appointment proxy shall be valid, unless the contrary is stated<br>therein, as well for any adjournment of the meeting as for the meeting to which it relates.
---	---
29.12.
---
29.12.1.	A vote given or poll demanded in accordance with the terms of an appointment of proxy or a resolution<br>authorising a representative to act on behalf of a body corporate shall be valid notwithstanding the death or insanity of the principal,<br>or the revocation of the appointment of proxy or of the authority under which the proxy was appointed or of the resolution authorising<br>the representative to act or transfer of the share in respect of which the proxy was appointed or the authorisation of the representative<br>to act was given, provided that no intimation in writing (whether in electronic form or otherwise) of such death, insanity, revocation<br>or transfer shall have been received by the Company at the Office, before the commencement of the meeting or adjourned meeting at which<br>the appointment of proxy is used or at which the representative acts, provided, however, that where such intimation is given in electronic<br>form it shall have been received by the Company before the commencement of the meeting
---	---
29.12.2.	The Directors may send, at the expense of the Company, by post, electronic mail or otherwise, to the members<br>forms for the appointment of a proxy (with or without stamped envelopes for their return) for use at any general meeting or at any class<br>meeting, either in blank or nominating any one or more of the Directors or any other persons in the alternative.
---	---
30.	Class Meetings
---	---
30.1.	The quorum for general meetings of holders of a particular class of shares shall be one or more members<br>present in person or by proxy holding not less than a majority of the issued and outstanding shares of the class entitled to vote at the<br>meeting in question. All other provisions of these Articles relating to general meetings of the Company shall, mutatis mutandis, apply<br>to every separate general meeting of the Holders of any class of shares in the capital of the Company.
---	---

A-38

31.	Right to Demand a Poll

Subject to the provisions of the Act, a poll may be demanded by:

31.1.	the chairperson of the meeting;
31.2.	at least three members present (in person or by proxy) having the right to vote at the meeting;
---	---
31.3.	any member or members present (in person or by proxy) and representing not less than 10 per cent of the<br>total voting rights of all the members of the Company having the right to vote at the meeting; or
---	---
31.4.	a member or members present (in person or by proxy) holding shares in the Company conferring the right<br>to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than 10 per cent of the total sum paid<br>up on all the shares conferring that right.
---	---
32.	Restriction on Voting
---	---

For so long as the Company holds any shares as treasury shares, or any subsidiary of the Company holds shares in the Company, then the Company or the subsidiary (as the case may be) shall not exercise any voting rights in respect of the shares.

33.	Unanimous Written Resolutions

Subject to the provisions of the Act, a resolution in writing signed by all of the Members for the time being entitled to attend and vote on such resolution at a general meeting (or being bodies corporate by their duly authorised representatives) shall be as valid and effective for all purposes as if the resolution had been passed at a general meeting of the Company duly convened and held, and may consist of several documents in like form each signed by one or more persons, and if described as a special resolution shall be deemed to be a special resolution within the meaning of the Act. Any such resolution shall be served on the Company.

NOTICES

34.	Notices
34.1.	Any notice to be sent ,given, served or delivered under these Articles shall be in writing whether in<br>electronic form or otherwise as permitted by these Articles.
---	---
34.2.	Any notice or document to be sent, given, served or delivered in pursuance of these Articles, the Act<br>or otherwise may be sent, given to, served on or delivered to any shareholder by the Company or any agent/the registrar acting on its<br>behalf :-
---	---
34.2.1.	if given personally or delivered to the member;
---	---
34.2.2.	if left at the registered address of the member;
---	---
34.2.3.	by sending same by the post in a pre-paid cover addressed to him at his registered address;
---	---
34.2.4.	by delivering or making the same available in electronic form, whether as an electronic communication<br>or otherwise subject to and in accordance with the provisions of these Articles; or
---	---
34.2.5.	by sending the same via (i) the messaging system of a central securities depository or (ii) by email to<br>the nominated representatives or nominated email account(s) of a central securities depository, in such manner as may be approved by the<br>Directors.
---	---

A-39

34.3.	A notice or document given or served in a manner referred to in this paragraph shall be deemed to have<br>been given or served as follows:
34.3.1.	if given personally, when so given;
---	---
34.3.2.	if left at the last-known postal address of the person, when so left at that address;
---	---
34.3.3.	if posted using ordinary pre-paid post to the last-known postal address of the other person on any day<br>other than a Friday, 48 hours after the cover containing it was posted, and if so posted on a Friday, 72 hours after it was so posted;<br>and
---	---
34.3.4.	if served on or delivered to the other person by electronic mail, 12 hours after the time it was sent;<br>and
---	---
34.3.5.	if sent in accordance with Article 34.2.5 at the time it was sent to the messaging system of the central<br>securities depository or at the time it was sent by email to the nominated representatives of the central securities depository.
---	---
34.4.	Without prejudice to any provision of the Act or of these Articles concerning the sending of notices or<br>other documents to the Company, any notice or other document which is required to be served on or given to the Company by a member or<br>by any other person under the Act or this Constitution shall be in writing and in the English language, and may be served on or given<br>to the Company by giving or delivering it personally to the secretary of the Company or by posting it using ordinary pre-paid post to<br>the registered office of the Company marked for the attention of the secretary, and will be deemed to have been served on or given to<br>the Company;
---	---
34.4.1.	if given or delivered personally, when so given or delivered; and
---	---
34.4.2.	if posted in the manner described in this paragraph on any day other than a Friday, 48 hours after the<br>cover containing it was posted, and if so posted on a Friday, 72 hours after it was so posted.
---	---
34.5.	A shareholder shall automatically be deemed to have given its consent to receive any notice or information<br>from the Company, pursuant to these Articles or otherwise, using electronic means, unless it has notified the Secretary to the contrary.
---	---

A-40

CAPITALISATIONOF PROFITS AND RESERVES

35.
35.1.	The Directors may resolve that any sum for the time being standing to the credit of any of the Company's<br>reserves (including any capital redemption reserve fund, undenominated capital account or share premium account) or to the credit of the<br>profit and loss account be capitalised and applied on behalf of the shareholders who would have been entitled to receive that sum if it<br>had been distributed by way of dividend and in the same proportions either in or towards paying up amounts for the time being unpaid on<br>any shares held by them respectively, or in paying up in full unissued shares or debentures of the Company of a nominal amount equal to<br>the sum capitalised (such shares or debentures to be allotted and distributed credited as fully paid up to and amongst such Holders in<br>the proportions aforesaid) or partly in one way and partly in another, so, however, that the only purposes for which such sum standing<br>to the credit of the capital redemption reserve fund or the share premium account shall be applied shall be those permitted by the Act.
---	---
35.2.	The Directors may resolve that it is desirable to capitalise any part of the amount for the time being<br>standing to the credit of any of the Company's reserve accounts or to the credit of the profit and loss account which is not available<br>for distribution by applying such sum in paying up in full unissued shares to be allotted as fully paid bonus shares to those shareholders<br>of the Company who would have been entitled to that sum if it were distributable and had been distributed by way of dividend (and in the<br>same proportions) and the Directors shall give effect to such resolution.
---	---
35.3.	Whenever such a resolution is passed in pursuance of either of the two immediately preceding Articles<br>the Directors shall make all appropriations and applications of the undivided profits resolved to be capitalised thereby and all allotments<br>and issues of fully paid shares or debentures, if any, and generally shall do all acts and things required to give effect thereto with<br>full power to the Directors to make such provisions as they shall think fit for the case of shares or debentures becoming distributable<br>in fractions (and, in particular, without prejudice to the generality of the foregoing, either to disregard such fractions or to sell<br>the shares or debentures represented by such fractions and distribute the net proceeds of such sale to and for the benefit of the Company<br>or to and for the benefit of the shareholders otherwise entitled to such fractions in due proportions) and to authorise any person to<br>enter on behalf of all the shareholders concerned into an agreement with the Company providing for the allotment to them respectively,<br>credited as fully paid up, of any further shares or debentures to which they may become entitled on such capitalisation or, as the case<br>may require, for the payment up by the application thereto of their respective proportions of the profits resolved to be capitalised of<br>the amounts remaining unpaid on their existing shares and any agreement made under such authority shall be binding on all such shareholders.
---	---

A-41

DIVIDENDS ANDRESERVES

36.
36.1.	The Company in general meeting may declare dividends, but no dividends shall exceed the amount recommended<br>by the Directors.
---	---
36.2.	The Directors may from time to time pay to the members such interim dividends as appear to the Directors<br>to be justified by the profits of the Company.
---	---
36.3.	No dividend or interim dividend shall be paid otherwise than in accordance with the provisions of the<br>Act.
---	---
36.4.	The Directors may, before recommending any dividend, set aside out of the profits of the Company such<br>sums as they think proper as a reserve or reserves which shall, at the discretion of the Directors, be applicable for any purpose to which<br>the profits of the Company may be properly applied and pending such application may at the like discretion either be employed in the business<br>of the Company or be invested in such investments as the Directors may lawfully determine. The Directors may also, without placing the<br>same to reserve, carry forward any profits which they may think it prudent not to distribute.
---	---
36.5.	Subject to the rights of persons, if any, entitled to shares with special rights as to dividend, all dividends<br>shall be declared and paid according to the amounts paid or credited as paid on the shares in respect whereof the dividend is paid. All<br>dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions<br>of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it shall rank for dividend<br>as from a particular date, such share shall rank for dividend accordingly.
---	---
36.6.	The Directors may deduct from any dividend payable to any member all sums of money (if any) immediately<br>payable by him to the Company in relation to the shares of the Company.
---	---
36.7.	Any general meeting declaring a dividend or bonus and any resolution of the Directors declaring an interim<br>dividend may direct payment of such dividend or bonus or interim dividend wholly or partly by the distribution of specific assets and<br>in particular of paid up shares, debentures or debenture stocks of any other company or in any one or more of such ways, and the Directors<br>shall give effect to such resolution, and where any difficulty arises in regard to such distribution, the Directors may settle the same<br>as they think expedient, and in particular may fix the value for distribution of such specific assets or any part thereof and may determine<br>that cash payments shall be made to any members upon the footing of the value so fixed, in order to adjust the rights of all the parties,<br>and may vest any such specific assets in trustees as may seem expedient to the Directors.
---	---
36.8.	Any dividend or other moneys payable in respect of any share may be paid by cheque or warrant sent by<br>post, at the risk of the person or persons entitled thereto, to the registered address of the Holder or, where there are joint Holders,<br>to the registered address of that one of the joint Holders who is first named on the members Register or to such person and to such address<br>as the Holder or joint Holders may in writing direct. Every such cheque or warrant shall be made payable to the order of the person to<br>whom it is sent and payment of the cheque or warrant shall be a good discharge to the Company. Any joint Holder or other person jointly<br>entitled to a share as aforesaid may give receipts for any dividend or other moneys payable in respect of the share. Any such dividend<br>or other distribution may also be paid by any other method (including payment in a currency other than $, electronic funds transfer, direct<br>debit, bank transfer or by means of a relevant system) which the Directors consider appropriate and any member who elects for such method<br>of payment shall be deemed to have accepted all of the risks inherent therein. The debiting of the Company’s account in respect<br>of the relevant amount shall be evidence of good discharge of the Company’s obligations in respect of any payment made by any such<br>methods.
---	---
36.9.	No dividend shall bear interest against the Company.
---	---
36.10.	If the Directors so resolve, any dividend which has remained unclaimed for twelve years from the date<br>of its declaration shall be forfeited and cease to remain owing by the Company. The payment by the Directors of any unclaimed dividend<br>or other moneys payable in respect of a share into a separate account shall not constitute the Company a trustee in respect thereof.
---	---

A-42

SHAREHOLDERRIGHTS PLAN

37.
37.1.	Subject to applicable law, the Directors are hereby expressly authorised to adopt any shareholder rights<br>plan (a “Rights Plan”), upon such terms and conditions as the Directors deem expedient and in the best interests of the Company,<br>including, without limitation, where the Directors are of the opinion that a Rights Plan could grant them additional time to gather relevant<br>information or pursue strategies in response to or anticipation of, or could prevent, a potential change of control of the Company or<br>accumulation of shares in the Company or interests therein.
---	---
37.2.	The Directors may exercise any power of the Company to grant rights (including approving the execution<br>of any documents relating to the grant of such rights) to subscribe for ordinary shares or preferred shares in the share capital of the<br>Company (“Rights”) in accordance with the terms of a Rights Plan.
---	---
37.3.	For the purposes of effecting an exchange of Rights for ordinary shares or preferred shares in the share<br>capital of the Company (an “Exchange”), the Directors may:
---	---
37.3.1.	resolve to capitalise an amount standing to the credit of<br>the reserves of the Company (including, but not limited to, the share premium account, capital redemption reserve, any undenominated<br>capital and profit and loss account), whether or not available for distribution, being an amount equal to the nominal value of the ordinary<br>shares or preferred shares which are to be exchanged for the Rights; and
---	---
37.3.2.	apply that sum in paying up in full ordinary shares or preferred shares and allot such shares, credited<br>as fully paid, to those holders of Rights who are entitled to them under an Exchange effected pursuant to the terms of a Rights Plan.
---	---
37.4.	The duties of the Directors to the Company under applicable law, including, but not limited to, the Act<br>and common law, are hereby deemed amended and modified such that the adoption of a Rights Plan and any actions taken thereunder by the<br>Directors (if so approved by the Directors) shall be deemed to constitute an action in the best interests of the Company in all circumstances,<br>and any such action shall be deemed to be immediately confirmed, approved and ratified.
---	---

WINDING UP

38.

If the Company shall be wound up and the assets available for distribution among the members as such shall be insufficient to repay the whole of the paid up or credited as paid up share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the members in proportion to the capital paid up or credited as paid up at the commencement of the winding up on the shares held by them respectively. And if in a winding up the assets available for distribution among the members shall be more than sufficient to repay the whole of the share capital paid up or credited as paid up at the commencement of the winding up, the excess shall be distributed among the members in proportion to the capital at the commencement of the winding up paid up or credited as paid up on the said shares held by them respectively; provided that this Article shall not affect the rights of the holders of shares issued upon special terms and conditions.

A-43

39.	Distribution In Specie

If the Company is wound up, the liquidator, with the sanction of a special resolution of the Company and any other sanction required by the Act, may divide among the members in specie or kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and, for such purpose, may value any assets and determine how the division shall be carried out as between the members or different classes of members. The liquidator, with the like sanction, may vest the whole or any part of such assets in trustees upon such trusts for the benefit of the contributories as, with the like sanction, he determines, but so that no member shall be compelled to accept any assets upon which there is a liability.

40.	Sale by a Liquidator

In case of a sale by the liquidator under section 601 of the Act, the liquidator may by the contract of sale agree so as to bind all the members for the allotment to the members direct of the proceeds of sale in proportion to their respective interests in the Company and may further by the contract limit a time at the expiration of which obligations or shares not accepted or required to be sold shall be deemed to have been irrevocably refused and be at the disposal of the Company, but so that nothing herein contained shall be taken to diminish, prejudice or affect the rights of dissenting members conferred by the said section.

The power of sale of the liquidator shall include a power to sell wholly or partially for debentures, debenture stock, or other obligations of another company, either then already constituted or about to be constituted for the purpose of carrying out the sale.

INDEMNITY

41.	Indemnity
41.1.	Subject to the provisions of the Act, every director, managing director, chief executive officer, secretary<br>and other officer for the time being of the Company shall be indemnified out of the assets of the Company against any liability incurred<br>by him:
---	---
41.2.	in defending any proceedings, whether civil or criminal, in relation to his acts or omissions while acting<br>in such office, in which judgment is given in his favour or in which he is acquitted; or
---	---
41.3.	in connection with any proceedings or application referred to in, or under, Sections 233 or 234 of the<br>Act in which relief is granted to him by the court.
---	---

A-44

A-45

Exhibit 4.3

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

FORM OF STRATEGIC ADVISOR PRE-FUNDEDCLASS B ORDINARY SHARE PURCHASE WARRANT

BRERA HOLDINGS PLC

Warrant Shares:	Issue Date: September [ ], 2025

THIS STRATEGIC ADVISOR PRE-FUNDED CLASS B ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [date hereof/third (3rd) anniversary of Closing Date] (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), up to [_____] Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and, on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF or DocuSign copy submitted by e-mail (or e- mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 1(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 1(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice and only for the purpose avoiding violation of the Beneficial Ownership Limitation (as defined below). The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.

b) Exercise Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of US$0.05 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of US$0.05 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per Warrant Share shall be US$0.05, subject to adjustment hereunder (the “Exercise Price”).

c) Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) =

as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Class B Ordinary Shares on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of “regular trading hours” on such Trading Day;

(B) =

the Exercise Price of this Warrant, as adjusted hereunder, in effect on the date of exercise; and

(X) =

the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised and any holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. For the avoidance of doubt, in the absence of an effective registration statement registering the issuance of the Warrant Shares, the Company shall issue, and the Holder agrees to receive, unregistered Warrant Shares upon a cashless exercise of this Warrant pursuant to this Section 1(c). The Company agrees not to take any position contrary to this Section 1(c).

“Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Class B Ordinary Shares are then listed or quoted on a Trading Market, the bid price of the Class B Ordinary Shares for the time in question (or the nearest preceding date) on the Trading Market on which the Class B Ordinary Shares are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Class B Ordinary Shares are not then listed or quoted for trading on a Trading Market and if the Class B Ordinary Shares are then listed or quoted on OTCQB or OTCQX, the volume weighted average price of the Class B Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Class B Ordinary Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Class B Ordinary Shares are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Class B Ordinary Share so reported, or (d) in all other cases, the fair market value of a Class B Ordinary Share as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

“Trading Day” means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for trading for a period of time less than the customary time. If the Class B Ordinary Shares are not then listed or quoted on a Trading Market, Trading Day means a Business Day.

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Class B Ordinary Shares are then listed or quoted on a Trading Market, the daily volume weighted average price of the Class B Ordinary Shares for such date (or the nearest preceding date) on the Trading Market on which the Class B Ordinary Shares are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Class B Ordinary Shares are not then listed or quoted for trading on a Trading Market and if the Class B Ordinary Shares are then listed or quoted on OTCQB or OTCQX, the volume weighted average price of the Class B Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Class B Ordinary Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Class B Ordinary Shares are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Class B Ordinary Share so reported, or (d) in all other cases, the fair market value of a Class B Ordinary Share as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 1(c), subject to the limitations in Section 1(e) hereof.

d) Mechanics of Exercise.

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each US$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Class B Ordinary Shares on the date of the applicable Notice of Exercise), US$10 per Trading Day (increasing to US$20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or the Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Class B Ordinary Shares as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 1(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 1(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, Class B Ordinary Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Class B Ordinary Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Class B Ordinary Shares having a total purchase price of US$11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of US$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder US$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Class B Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole Class B Ordinary Share.

vi. Charges, Taxes and Expenses. To the extent permitted by law, the issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form, attached hereto as Exhibit B, duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 1 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder’s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates, and (iii) any other Persons whose beneficial ownership of the Class B Ordinary Shares would or could be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the number of Class B Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Class B Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 1(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 1(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrants that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding Class B Ordinary Shares that was provided by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrants that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding Class B Ordinary Shares that was provided by the Company. For purposes of this Section 1(e), in determining the number of outstanding Class B Ordinary Shares, a Holder may rely on the number of outstanding Class B Ordinary Shares as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Class B Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number of Class B Ordinary Shares then outstanding. In any case, the number of outstanding Class B Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Class B Ordinary Shares was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of the Class B Ordinary Shares outstanding immediately after giving effect to the issuance of Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 1(e), provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of the Class B Ordinary Shares outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 1(e) shall continue to apply, provided further that an Affiliate of the Company may suspend the Beneficial Ownership Limitation in its entirety if, and for so long as, such Beneficial Ownership Limitation is not required to be in effect to ensure compliance with applicable Nasdaq listing requirements with respect to shareholder approval. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall not be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder’s Beneficial Ownership Limitation, no alternative consideration is owing to the Holder.

Section 2. Certain Adjustments.

a) Share Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on its Class B Ordinary Shares or any other equity or equity equivalent securities payable in Class B Ordinary Shares (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Class B Ordinary Shares into a larger number of shares, (iii) combines (including by way of reverse share split) outstanding Class B Ordinary Shares into a smaller number of shares, or (iv) issues by reclassification of the Class B Ordinary Shares any share capital of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Class B Ordinary Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Class B Ordinary Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 2(a) above, if at any time the Company grants, issues or sells any Class B Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of Class B Ordinary Shares (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Class B Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Class B Ordinary Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Class B Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Class B Ordinary Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Class B Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Class B Ordinary Shares are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Class B Ordinary Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person in which the Company is not the surviving entity (other than a reincorporation in a different state), (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Class B Ordinary Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of more than 50% of the outstanding shares of the aggregate voting power of all classes of equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Class B Ordinary Shares or any compulsory share exchange pursuant to which the Class B Ordinary Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of the aggregate voting power of all classes of equity of the Company (each a “Fundamental Transaction”), then, the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 2(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of share capital of such Successor Entity (or its parent entity) equivalent to the Class B Ordinary Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such share capital (but taking into account the relative value of the Class B Ordinary Shares pursuant to such Fundamental Transaction and the value of such share capital, such number of share capital and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

e) [Reserved].

f) Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 2, the number of Class B Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Class B Ordinary Shares (excluding treasury shares, if any) issued and outstanding.

g) Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution in whatever form) on the Class B Ordinary Shares, (B) the Company declares a special nonrecurring cash dividend on, or a redemption of, the Class B Ordinary Shares, (C) the Company authorizes the granting to all holders of the Class B Ordinary Shares rights or warrants to subscribe for or purchase any share capital of any class or of any rights, (D) the approval of any shareholders of the Company is required in connection with a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register (as defined below) of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Class B Ordinary Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Class B Ordinary Shares of record shall be entitled to exchange their Class B Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form 6-K. The issuance of a press release or the filing of a Form 6-K or other suitable filing with the Commission shall satisfy this notice requirement. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

h) Voluntary Adjustment by the Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company provided that in no circumstances shall an Exercise Price reduction result in the Exercise Price per Warrant Share being less than the nominal value of a Warrant Share from time to time and no Warrant Share shall be issued upon exercise of a Warrant unless such Share is fully paid up in cash as to at least its nominal value.

Section 3. Transfer of Warrant.

a) Transferability. Subject to compliance with any applicable securities laws, the conditions set forth in Section 3(d) hereof, and the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

b) New Warrants. Subject to compliance with applicable securities laws, this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.

e) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

Section 4. Miscellaneous.

a) No Rights as Shareholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 1(d)(i), except as expressly set forth in Section 2. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 1(c) or to receive cash payments pursuant to Section 1(d)(i) and Section 1(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company will make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

d) Authorized Shares.

The Company covenants that, from and after the Shareholder Approval and during the period the Warrant is outstanding, it will reserve from its authorized and unissued Class B Ordinary Shares a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Class B Ordinary Shares may be listed. Assuming Shareholder Approval, the Company covenants that all Warrant Shares which may be issued and delivered upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its constitution or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the nominal value of any Class B Ordinary Shares above the amount payable therefor upon such exercise immediately prior to such increase in nominal value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Class B Ordinary Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof that would require the application of the laws of any other jurisdiction. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws, and in such case, by the acceptance hereof, represents and warrants that the Holder will acquire such Warrant Shares issuable upon such exercise for its own account and not with a view to or for distributing or reselling Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Class B Ordinary Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGE TO STRATEGIC ADVISOR PRE-FUNDED WARRANT]

EXHIBIT A

NOTICE OF EXERCISE

TO: BRERA HOLDINGS PLC

(1) The undersigned hereby elects to purchase _________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States; or

☐ if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 1(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(c).

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant,execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:

Dated: ,

Holder’s Signature:

Holder’s Address:

Exhibit 4.4

FORM OF STRATEGIC ADVISOR CLASS B ORDINARY SHARECOMMON PURCHASE WARRANT 1

BRERA HOLDINGS PLC

Warrant Shares: [_____]	Issue Date: September [__], 2025

THIS STRATEGIC ADVISOR CLASS B ORDINARY SHARE COMMON PURCHASE WARRANT 1 (the “Warrant”) certifies that, for value received, [_______] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [date hereof/third (3rd) anniversary of Closing Date] (the “Initial Exercise Date”) until the earlier of the date that this Warrant has been exercised in full or the fifth (5th) anniversary of the Issue Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), up to [____] Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated September 18, 2025, among the Company and the Holder and the other Purchasers named therein or that certain Strategic Advisor Agreement (the “Strategic Advisor Agreement”), dated September 18, 2025, among the Company and the signatories named therein.

For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.

b) Exercise Price. The exercise price per Warrant Share under this Warrant shall be equal to one hundred fifty percent (150%) of the cash Per Share Purchase Price, subject to adjustment hereunder (the “Exercise Price”).

(A) =

as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Class B Ordinary Shares on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of “regular trading hours” on such Trading Day;

(B) =

the Exercise Price of this Warrant, as adjusted hereunder, in effect on the date of exercise; and

(X) =

d) Mechanics of Exercise.

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 1(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, Class B Ordinary Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy- In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Class B Ordinary Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Class B Ordinary Shares having a total purchase price of US$11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of US$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder US$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Class B Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 2. Certain Adjustments.

e) [Reserved].

g) Notice to Holder.

Section 3. Transfer of Warrant.

Section 4. Miscellaneous.

d) Authorized Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGE TO STRATEGIC ADVISOR COMMON WARRANT 1]

EXHIBIT A

NOTICE OF EXERCISE

TO: BRERA HOLDINGS PLC

(1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant,execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:

Dated: ,

Holder’s Signature:

Holder’s Address:

Exhibit 4.5

FORM OF STRATEGIC ADVISOR CLASS B ORDINARYSHARE COMMON PURCHASE WARRANT 2

BRERA HOLDINGS PLC

Warrant Shares:	Issue Date: September [_], 2025

THIS STRATEGIC ADVISOR CLASS B ORDINARY SHARE COMMON PURCHASE WARRANT 2 (the “Warrant”) certifies that, for value received, [______] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until the earlier of the date that this Warrant has been exercised in full or the fifth (5th) anniversary of the Issue Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), up to [____] Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and, on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF or DocuSign copy submitted by e-mail (or e- mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the “Notice of Exercise”). Exercise of this Warrant shall be made in accordance with the following conditions: (i) one-third of the purchase rights represented by this Warrant shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than one hundred fifty percent (150%) of the cash Per Share Purchase Price; (ii) one-third of the purchase rights represented by this Warrant shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than two hundred percent (200%) of the cash Per Share Purchase Price; and (iii) one-third of the purchase rights represented by this Warrant shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than two hundred fifty percent (250%) of the cash Per Share Purchase Price (each, a “Performance Metric”). Within one (1) Trading Day following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 1(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice and only for the purpose avoiding violation of the Beneficial Ownership Limitation (as defined below). The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.

b) Exercise Price. The exercise price per Warrant Share under this Warrant shall be the closing market price of the Class B Ordinary Shares on the Trading Day on which the applicable Performance Metric is achieved, subject to adjustment hereunder (the “Exercise Price”).

(A) =

as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Class B Ordinary Shares on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of “regular trading hours” on such Trading Day;

(B) =

the Exercise Price of this Warrant, as adjusted hereunder, in effect on the date of exercise; and

(X) =

-2-

d) Mechanics of Exercise.

-3-

-4-

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

-5-

Section 2. Certain Adjustments.

-6-

-7-

e) [Reserved].

g) Notice to Holder.

-8-

Section 3. Transfer of Warrant.

Section 4. Miscellaneous.

-9-

d) Authorized Shares.

-10-

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

-11-

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGE TO STRATEGIC ADVISOR COMMON WARRANT 2]

-12-

EXHIBIT A

NOTICE OF EXERCISE

TO: BRERA HOLDINGS PLC

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

-13-

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant,execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:

Dated: ,

Holder’s Signature:

Holder’s Address:

-14-

Exhibit 10.3

EMPLOYMENT AGREEMENT

THIS EMPLOYMENTAGREEMENT (this “Agreement”) is made and entered into as of September 11, 2025 (the “Effective Date”), by and between Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the “Company”), and Marco Santori (“Executive”).

W I T N E S S E T H:

WHEREAS, the Company and Executive desire to memorialize the terms of Executive’s employment with the Company as Chief Executive Officer of the Company in accordance with the terms and conditions of this Agreement as of the Effective Date.

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and obligations hereinafter set forth, and for good and valuable consideration the receipt of which is hereby acknowledged by the parties hereto, and to provide the inducements set forth above, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Employment. The Company hereby offers Executive employment in accordance with the terms and conditions set forth herein, and Executive hereby accepts such employment, in each case on the date hereof. Executive’s employment with the Company shall commence on the date of closing of the transactions contemplated by that certain Securities Purchase Agreement, dated on or about the Effective Date, with the purchasers named therein, for the private placement (the “Private Placement”) of the Company’s Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”) (the “Commencement Date”). The Company shall not terminate or revoke this Agreement prior to the Commencement Date.

Position and Duties.

2.1 Position. During the Term (as defined below), Executive will be employed on a full-time basis as Chief Executive Officer of the Company and shall have the duties and responsibilities assigned by the Company’s Board of Directors (the “Board”) from time to time consistent with such position. Executive shall perform faithfully and diligently all duties assigned to Executive by the Board. During the Term and beginning with the earlier of the next annual meeting of the Company’s shareholders following the date of this Agreement, and provided that Executive remains continuously employed by the Company through the date of the applicable annual meeting of shareholders, Executive shall be nominated for election to the Board at each such meeting. During the Term, Executive’s primary work location will be Executive’s home office. For the avoidance of doubt, nothing under this Agreement requires Executive to maintain any particular professional license as a condition to continued employment and Executive will not serve as legal counsel to the Company in any capacity.

2.2 Best Efforts/Full-time. Executive shall expend Executive’s reasonable best efforts on behalf of the Company and shall abide by all policies of the Company applicable to Executive and all lawful decisions made by the Board. Executive shall act in the best interest of the Company at all times. Executive shall devote such time and efforts as are necessary and appropriate in order for Executive to perform his assigned duties for the Company; provided, that nothing herein shall preclude Executive (a) from managing Executive’s and Executive’s family’s personal affairs (financial or otherwise), (b) from assisting Pantera Capital (“Pantera”) in the completion of any fundraising activity for Fund V or providing other services to Pantera at Pantera’s reasonable request, including serving in a part-time venture partner capacity for Pantera, or (c) subject to prior written approval by the Board which shall not be unreasonably withheld, (i) from serving on the boards of directors of or an advisor to other for-profit or non-profit companies (that are not engaged in a Competitive Business (as defined below)), provided that Executive prioritizes his work for the Company, or (ii) from engaging in charitable activities, including serving on the boards of directors of non-profit organizations, as long as such activities in clauses (a) through (c) individually or in the aggregate do not materially interfere or conflict with Executive’s duties hereunder or violate the provisions of Section 8 hereof.

2.3 Compliance with Company Policies. Executive shall comply with all Company policies, rules and regulations governing benefits and the conduct of Company employees, now in effect, or as subsequently adopted or amended, provided such policies, rules and regulations are provided to Executive in writing.

3. Term. The term of Executive’s employment under this Agreement shall be for the period beginning on the Commencement Date and ending on the date that the employment of Executive is terminated by either party in accordance with Section 7 of this Agreement. Executive’s employment pursuant to this Agreement may be terminated in accordance with Section 7 below. The period from the Commencement Date through the termination of Executive’s employment pursuant to this Agreement, regardless of the time or reason for such termination, shall be referred to herein as the “Term.” If the closing of the Private Placement does not occur by October 15, 2025, then this Agreement shall be null and void.

Compensation.

4.1 Salary. As compensation for Executive’s performance of Executive’s duties hereunder, the Company shall pay to Executive a salary at the annualized rate of $650,000 (the “Salary”), or such greater amount as may be determined by the Board from time to time, payable in substantially equal payments in accordance with the Company’s normal payroll practices as in effect from time to time, by direct deposit to a bank account selected by Executive or by another method and at the place authorized by Executive. The Company shall deduct from each such installment all amounts required or permitted to be deducted or withheld under applicable law or under any employee benefit plan or program in which Executive participates.

4.2 Bonus. In addition to the Salary, for each calendar year ending during the Term, Executive shall be eligible to participate in the Company’s annual discretionary bonus plan, subject to the specific terms and conditions of the bonus plan. Executive’s bonus target is 100% of the Salary, or such other higher amount as may be determined by the Board from time to time not to exceed 200% of the Salary (the “TargetBonus”), provided that if the Target Bonus is set at less than 200% of the Salary, Executive shall remain eligible to achieve a bonus of up to 200% of the Salary (the “Stretch Bonus”) based on performance in excess of the Target Bonus criteria.

For the annual bonuses with respect to calendar years 2025 and 2026, the Target Bonus shall be 100% of the Salary. The Target Bonus will be based on the following performance metrics: (i) 50% of the Target Bonus amount shall be earned upon the Company’s SOL per-share (“SPS”) exceeding the weighted- average SPS of a peer cohort designated by the Board or a committee thereof, in each case, as measured as of December 31 of the applicable calendar year, by at least a certain percentage benchmark determined by the Board or a committee thereof, and (ii) the remaining 50% of the Target Bonus shall be earned upon the Company raising at least $500,000,000 in equity capital during the applicable calendar year. The Stretch Bonus will be based on the following performance metrics: (x) 50% of the Stretch Bonus amount shall be earned upon the Company’s SPS exceeding the weighted-average SPS of a peer cohort designated by the Board or a committee thereof, in each case, as measured as of December 31 of the applicable calendar year, by at least a certain percentage benchmark determined by the Board or a committee thereof, and (y) the remaining 50% of the Stretch Bonus shall be earned upon the Company raising at least $1,000,000,000 of equity capital during the applicable calendar year. With respect to the 2025 bonus, both the amount of the bonus payable and the criteria described in this paragraph will be adjusted on a pro-rata basis based on the ratio determined by dividing (a) the number of days in 2025 remaining in 2025 after and including the Effective Date, by (b) 365. For purposes of determining SPS and SOL AUM under this Agreement, the Company’s SOL shall be valued, as of any specified date, using the Time-Weighted Average Price (TWAP) of SOL over the 15 calendar-day period ending on the day immediately preceding such date, which shall mean, with respect to each such day, the CME CF Solana-Dollar Reference Rate New York Variant (SOLUSD_NY) (“CF Benchmarks Index”) for such day or, if the CF Benchmarks Index is unavailable, the rate determined pursuant to such other index, benchmark or other method of determining the fair value of SOL as may be selected by the Company and approved in good faith by Executive.

-2-

In addition to the Salary, the Target Bonus and the Stretch Bonus, for each calendar year ending during the Term, Executive shall be eligible to receive an additional annual cash bonus (the “AUM Bonus”) as follows:

i. 0.1429% per annum of the amount of the Company’s SOL AUM as of December 31 of the applicable calendar year, up to $1,000,000,000 of SOL AUM; and

ii. 0.0714% per annum of the amount by which the Company’s SOL AUM as of December 31 of the applicable calendar year exceeds $1,000,000,000.

The annual bonuses shall be earned, based on the performance achieved, as of December 31 of the applicable calendar year, provided that Executive remains employed with the Company through such date. Any annual bonus, to the extent earned, shall be paid in a lump sum, less applicable deductions and withholdings. Each earned annual bonus shall be paid during the calendar year following the calendar year to which the applicable annual bonus relates, in accordance with Company payroll practices, at the same time annual bonuses are paid to similarly situated employees of the Company generally with respect to the applicable calendar year, and in all events within a reasonable period of time following the completion of the audit of the Company’s books and records for the applicable calendar year to which the applicable bonus relates. In the event that Executive’s employment is terminated for any reason prior to the 10 year anniversary of the Commencement Date, then for the period (the “Advisory Period”) beginning on Executive’s date of termination and continuing through the Advisory Termination Date (defined below), the Company will engage Executive as a strategic adviser on terms mutually agreed by Executive and the Company and as consideration therefor, Executive shall receive an annual fee equal to the amount that would have been payable in respect of the AUM Bonus had Executive remained employed during the Advisory Period, payable on the first business day of February of each year during the Advisory Period; provided, that, it shall not be a violation of the foregoing if the Company pays the AUM Bonus later than such date but within the same taxable year. The term “Advisory Termination Date” shall mean the earlier of the 10-year anniversary of the Commencement Date or the date on which Executive ceases to be a strategic advisor due to death or termination for Cause. The Advisory Period may be extended by mutual written agreement of the Company and Executive.

4.3 Signing Bonus. The Company shall pay Executive a signing bonus of $1 million (the “Signing Bonus”) within ten (10) business days after the Commencement Date. Executive agrees to repay the Signing Bonus to the Company within ten (10) business days after termination of employment if Executive voluntarily resigns from employment with the Company without Good Reason or is terminated for Cause; provided that the amount to be repaid shall be reduced on a pro-rata basis based on the ratio determined by dividing (a) the excess of (i) 365, over (ii) the number of days between and including the Commencement Date through the last day of Executive’s employment, by (b) 365.

4.4 Equity Incentive. As a material inducement to Executive’s decision to commence employment with the Company, within thirty (30) calendar days after the Effective Date, subject to the approval of the Board and the compensation committee thereof, the Company will grant to Executive a restricted shares unit award with an award value of $15,000,000 (the “RSU Award”), which award value shall be converted to a number of units (rounded down to the nearest whole unit) by dividing (i) the award value, by (ii) the price per share at which the Class B Ordinary Shares are sold in the Private Placement. The RSU award shall vest as follows: (i) one-half (1/2) of the RSU Award will be subject to time-based vesting conditions (the “Time-Based VestingUnits”) with one-forty-eighth (1/48) of such Time-Based Vesting Units vesting on each monthly anniversary of the Effective Date, in each case subject to Executive’s continued employment with the Company and (ii) one-half (1/2) of the RSU Award will be subject to performance-based vesting conditions (the “Performance-Based Vesting Units”), which shall vest based on the following criteria: 50% of the Performance-Based Vesting Units amount shall vest as follows: 20% of the Performance-Based Vesting Units shall vest upon the Company’s SOL AUM exceeding 1.0x the gross proceeds raised in the Private Placement, 20% of the Performance-Based Vesting Units shall vest upon the Company’s SOL AUM exceeding 2.0x the gross proceeds raised in the Private Placement, 20% of the Performance-Based Vesting Units shall vest upon the Company’s SOL AUM exceeding 3.0x the gross proceeds raised in the Private Placement, 20% of the Performance-Based Vesting Units shall vest upon the Company’s SOL AUM exceeding 4.0x the gross proceeds raised in the Private Placement, 20% of the Performance-Based Vesting Units shall vest upon the Company’s SOL AUM exceeding 5.0x the gross proceeds raised in the Private Placement, in each case, on or prior to the fourth anniversary of the RSU Award grant date, and the remaining 50% of the Performance-Based Vesting Units shall vest upon the Company raising at least $500,000,000 of equity capital on or prior to the fourth anniversary of the RSU Award grant date. Subject to the foregoing, the RSU Award shall be granted on the terms, and subject to the conditions, of the standard restricted shares units award agreement approved for use under the Brera Holdings Limited 2022 Equity Incentive Plan, as amended.

-3-

Benefits.

5.1 Employee Benefits. Executive will be eligible for all welfare and retirement benefits generally available to employees of the Company, in effect from time to time, subject to the terms and conditions of the Company’s benefit plan documents. The Company reserves the right to change or eliminate employee benefits or change contribution levels, at any time and from time to time in its sole and absolute discretion.

5.2 Paid Time Off. Unless and until the Company adopts and unlimited PTO policy, Executive shall be entitled to accrue up to six (6) weeks of paid vacation, sick and personal time (“PTO”) as well as paid holidays in accordance with the policies, programs and practices of the Company in effect from time to time. Such PTO shall be taken at such intervals as shall be appropriate and consistent with the proper performance of Executive’s duties hereunder.

6. Business Expenses. Executive will be reimbursed for reasonable, out-of-pocket business expenses incurred in the performance of Executive’s duties on behalf of the Company in accordance with and subject to the Company’s expense reimbursement policy in effect from time to time. In addition, at Executive’s request, the Company shall pay or reimburse Executive for all annual fees owed to maintain Executive’s active license under the New York state bar. Further, notwithstanding anything herein or in any Company policy to the contrary, when Executive is required to travel in the performance of Executive’s duties on behalf of the Company, the Company shall pay or reimburse Executive for business class travel or better (when available) and for five-star lodging accommodations.

Termination of Executive’s Employment.

7.1 Termination by the Company or Executive. Subject to the terms of this Section 7.1, the Company may terminate Executive’s employment under this Agreement at any time with or without Cause (as defined above), upon written notice to Executive. Executive may terminate Executive’s employment with the Company without Good Reason under this Agreement upon four (4) weeks written notice to the Board.

-4-

(a) If Executive’s employment is terminated by the Company for Cause, or by Executive without Good Reason (as defined below), Executive shall be entitled to receive, and the Company’s sole obligation to Executive under this Agreement or otherwise shall be to pay or provide to Executive, the following (collectively, the “Accrued Obligations”):

(i) Executive’s earned, but unpaid, Salary through Executive’s date of separation (the “Termination Date”), payable in accordance with the Company’s standard payroll practices;

(ii) Executive’s accrued, but unused, vacation (to the extent payable pursuant to, and in accordance with, the Company’s policies and applicable law);

(iii) expenses reimbursable under Section 6 above incurred on or prior to the Termination Date but not yet reimbursed; and

(iv) amounts or benefits (if any) that are vested amounts or vested benefits or that Executive is otherwise entitled to receive under any plan, program, policy or practice on the Termination Date, in accordance with such plan, program, policy, or practice.

(b) For purposes of this Agreement, “Cause” shall mean (i) commission of a felony crime; (ii) repeated, willful failure to comply with instructions given by the Board; or (iii) misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of the Company’s property for personal purposes, as determined in the reasonable discretion of the Board.

(c) For purposes of this Agreement, “Good Reason” shall mean, any of the following without Executive’s written consent: (i) a material diminution of Executive’s title, duties or responsibilities; (ii) a reduction of 10% or more in Executive’s Salary (other than in connection with an across-the-board reduction by an amount (on a percentage basis) equal to or greater than the diminution applicable to Executive that applies proportionately to all other senior executives); (iii) a requirement that Executive’s primary work location is anywhere other than Executive’s home office (which the parties hereto agree would be a material breach by the Company of this Agreement); or (iv) any other material breach by the Company of this Agreement; provided that, any assertion by Executive of a termination for Good Reason shall not be effective unless all of the following conditions are satisfied: (A) the condition giving rise to Executive’s termination of employment must have arisen without Executive’s written consent; (B) Executive must provide written notice to the Board of the existence of such condition(s) within thirty(30) days after Executive first becomes aware of the existence of such conditions; (C) the condition(s) specified in such notice must remain uncorrected for thirty (30) days following the Board’s receipt of such written notice; and (D) the date of Executive’s termination of employment must occur within thirty (30) days after the end of the Company’s cure period described in item (C).

(d) In the event Executive’s employment is terminated by the Company without Cause or by Executive for Good Reason, then, subject to the terms below, in addition to the Accrued Obligations, Executive shall be entitled to receive as severance the following:

(i) an amount equal to twenty-four months of his then-current Salary (prior to any reduction that triggers Good Reason) less applicable withholdings and deductions, payable in three substantially equal installments, with the first such installment paid within ten (10) calendar days following the date the Release Agreement (as defined below) becomes effective and irrevocable (the “FirstInstallment Date”), the second installment paid on the date that is six (6) months after the First Installment Date and the third installment paid on the date that is twelve (12) months after the First Installment Date;

-5-

(ii) the pro rata portion of Executive’s annual bonus payable pursuant to Section 4.2 based on the number of days elapsed in the current calendar year through (and including) the Termination Date; and

(iii) each outstanding equity award of the Company granted to Executive shall be treated as provided in the applicable Company equity plan and award agreement; provided, however, that, unless the applicable equity plan and award agreement would provide a greater benefit, (x) all outstanding and unvested time-based equity awards of the Company granted to Executive will become immediately vested and, if applicable, exercisable (without pro-ration), and (y) all outstanding and unvested performance-based equity awards of the Company granted to Executive will vest based on actual Company performance during the entire performance period, assuming any service requirement applicable to such performance-based equity awards was fully satisfied and without regard to any discretionary adjustments that have the effect of reducing the amount of the payout (other than discretionary adjustments applicable to all senior executives who did not terminate employment), and will become payable at the same time that the applicable awards are payable to similarly-situated executives who did not terminate employment during that performance period, but in no event later than March 15 of the calendar year following the calendar year in which such performance-based equity awards vest.

(e) Unless otherwise specified herein, the amounts in clauses (i) and (ii) above will be paid within thirty (30) days following the date that Release Agreement (defined below) becomes effective and irrevocable.

7.2 Termination of Employment due to Executive’s Death or Disability. Executive’s employment under this Agreement shall terminate automatically upon Executive’s death. The Company may terminate Executive’s employment under this Agreement due to Executive’s Disability (as defined below) at any time upon written notice. If Executive’s employment under this Agreement terminates due to his death or Disability, Executive or Executive’s estate, as the case may be, shall receive the Accrued Obligations. For purposes of this Agreement “Disability” shall mean Executive’s physical or mental illness, which prevents Executive from performing Executive’s material duties, with or without reasonable accommodation, for a period of (A) ninety (90) consecutive calendar days or (B) an aggregate of one hundred twenty (120) calendar days out of any consecutive six (6) month period, as permitted by law.

7.3 Release Agreement. In order to receive the payments and benefits set forth in Section 7.1(d) associated with a termination by the Company without Cause or by Executive for Good Reason, Executive must timely execute (and not revoke) the Company’s form of separation agreement and general release (the “Release Agreement”) within the later of (i) sixty (60) days following the Termination Date, or (ii) the expiration of any applicable revocation period following Company’s delivery of the release of claims to Executive. Notwithstanding anything in this Agreement to the contrary, in the event any such sixty (60) day period spans two (2) calendar years, then the amounts payable under clauses (i) and (ii) of Section 7.1(d) shall be payable in the second (2nd) calendar year within the time that such payment would otherwise have been made absent this proviso or, if later, the first pay date in such second (2nd) calendar year.

7.4 Post-Termination Breach. Notwithstanding anything to the contrary contained in this Agreement, the Company’s obligations to provide any severance payments shall immediately cease if Executive materially breaches this Agreement, the Release Agreement, or any other written agreement Executive has with the Company.

-6-

Covenants.

8.1 Confidentiality

(a) “CompanyConfidential Information” includes information (including any and all combinations of individual items of information) that the Company has or will develop, acquire, create, compile, discover or own, that has value in or to the Company’s business which is not generally known and which the Company wishes to maintain as confidential. Company Confidential Information includes both information disclosed by the Company to Executive, and information developed or learned by Executive during the course of employment. By example, and without limitation, Company Confidential Information includes any and all non-public information that relates to the actual or anticipated business and/or products, research or development of the Company, or to the Company’s technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the Company’s products or services and markets therefor, customer lists and customers (including, but not limited to, customers of the Company on which Executive called or with which Executive may become acquainted during his employment), software, developments, inventions, discoveries, ideas, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and other business information disclosed by the Company either directly or indirectly in writing, orally or by drawings or inspection of premises, parts, equipment, or other Company property. Notwithstanding the foregoing, Company Confidential Information shall not include any such information which Executive can establish (i) was publicly known or made generally available prior to the time of disclosure by the Company to Executive; (ii) becomes publicly known or made generally available after disclosure by the Company to Executive through no wrongful action or omission by Executive; or (iii) is in Executive’s rightful possession, without confidentiality obligations, at the time of disclosure by the Company as shown by Executive’s then-contemporaneous written records; provided that any combination of individual items of information shall not be deemed to be within any of the foregoing exceptions merely because one or more of the individual items are within such exception, unless the combination as a whole is within such exception. Executive understands that nothing in this Agreement is intended to limit employees’ rights to discuss the terms, wages, and working conditions of their employment, as protected by applicable law.

(b) Executive agrees that during and after his employment with the Company, Executive will hold in the strictest confidence, and take all reasonable precautions to prevent any unauthorized use or disclosure of Company Confidential Information, and Executive will not (i) use Company Confidential Information for any purpose whatsoever other than for the benefit of the Company in the course of his employment, or (ii) disclose Company Confidential Information to any third party outside of the course of Executive’s duties to the Company without the prior written authorization of the Board. Prior to disclosure when compelled by applicable law, Executive shall provide prior written notice to the Board. Executive agrees that he obtains no title to any Company Confidential Information, and that as between the Company and himself, the Company retains all Company Confidential Information as the sole property of the Company. Executive understands that his unauthorized use or disclosure of Company Confidential Information during his employment may lead to disciplinary action, up to and including immediate termination and legal action by the Company. Executive’s obligation not to use or disclose Company Confidential Information shall continue after termination of his employment.

(c) Executive agrees that during his employment with the Company, Executive will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any former employer or other person or entity with which Executive has an obligation to keep in confidence. Executive further agrees that he will not bring onto the Company’s premises or transfer onto the Company’s technology systems any unpublished document, proprietary information, or trade secrets belonging to any such third party unless disclosure to, and use by, the Company has been consented to in writing by such third party.

-7-

(d) Executive recognizes that the Company has received and in the future will receive from third parties associated with the Company, e.g., the Company’s customers, suppliers, licensors, licensees, partners, or collaborators (“Associated Third Parties”), their confidential or proprietary information (“Associated Third Party Confidential Information”) subject to a duty on the Company’s part to maintain the confidentiality of such Associated Third Party Confidential Information and to use it only for certain limited purposes. By way of example, Associated Third Party Confidential Information may include the habits or practices of Associated Third Parties, the technology of Associated Third Parties, requirements of Associated Third Parties, and information related to the business conducted between the Company and such Associated Third Parties. Executive agrees at all times during his employment with the Company and thereafter, that Executive owes the Company and its Associated Third Parties a duty to hold all such Associated Third Party Confidential Information in the strictest confidence, and not to use it or to disclose it to any person, entity, or other third party except as necessary in carrying out his work for the Company consistent with the Company’s agreement with such Associated Third Parties. Executive further agrees to comply with any and all Company policies and guidelines that may be adopted from time to time regarding Associated Third Parties and Associated Third Party Confidential Information.

(e) Executive acknowledges receipt of the following notice under the Defend Trade Secrets Act of 2016: An individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret if he/she (i) makes such disclosure in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and such disclosure is made solely for the purpose of reporting or investigating a suspected violation of law; or (ii) such disclosure was made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Further, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the employer’s trade secrets to the attorney and use the trade secret information in the court proceeding if the individual: (i) files any document containing the trade secret under seal; and (ii) does not disclose the trade secret, except pursuant to court order. Nothing contained herein will waive, limit or affect any rights of the Company under any applicable trade secrets laws, including Defend Trade Secrets Act of 2016, which will be enforceable separate and apart from this Agreement.

8.2 Assignment of Inventions.

(a) Executive agrees that all right, title, and interest in and to any and all copyrightable material, notes, records, ideas, drawings, designs, inventions, improvements, developments, discoveries and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by Executive, solely or in collaboration with others, during the Term and within the scope of Executive’s duties, or with the use of the Company’s equipment, supplies, facilities, or Company Confidential Information, and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing, except as provided below (collectively, “Inventions”), are the sole property of the Company. Executive also agrees to promptly make full written disclosure to the Company of any Inventions, and to deliver and assign and hereby irrevocably assigns fully to the Company all of his right, title and interest in and to Inventions. Executive agrees that this assignment includes a present conveyance to the Company of ownership of Inventions that are not yet in existence. Executive further acknowledges that all original works of authorship that are made by Executive (solely or jointly with others) within the scope of and during the Term and that are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act. Executive understands and agrees that the decision whether or not to commercialize or market any Inventions is within the Company’s sole discretion and for the Company’s sole benefit, and that no royalty or other consideration will be due to Executive as a result of the Company’s efforts to commercialize or market any such Inventions.

-8-

(b) Executive will inform the Company in writing before incorporating any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by Executive or in which Executive has an interest prior to, or separate from, his employment with the Company, including without limitation, any such inventions that meet the criteria set forth herein (collectively, “Prior Inventions”) into any Invention or otherwise utilizing any such Prior Inventions in the course of his employment with the Company, and the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection with such Prior Inventions, and to practice any method related thereto. Executive will not incorporate any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by any third party into any Invention without the Company’s prior written permission. Executive has attached to this Agreement a list describing all Prior Inventions or, if no such list is attached, Executive represents and warrants that there are no such Prior Inventions.

(c) Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively, “Moral Rights”). To the extent that Moral Rights cannot be assigned under applicable law, Executive hereby waives and agrees not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under applicable law.

(d) Executive agrees to keep and maintain adequate, current, accurate, and authentic written records of all Inventions made by Executive (solely or jointly with others) during the Term. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any other format that may be specified by the Company. The records are and will be available to and remain the sole property of the Company at all times.

(e) Executive agrees to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, and all other instruments that the Company shall deem proper or necessary in order to apply for, register, obtain, maintain, defend, and enforce such rights, and in order to deliver, assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to all Inventions, and testifying in a suit or other proceeding relating to such Inventions. Executive further agrees that his obligations under this Section shall continue after the termination of his employment.

(f) Executive agrees that, if the Company is unable because of Executive’s unavailability, mental or physical incapacity, or for any other reason to secure his signature with respect to any Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf to execute and file any papers and oaths, and to do all other lawfully permitted acts with respect to such Inventions to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by him. This power of attorney shall be deemed coupled with an interest, and shall be irrevocable.

-9-

(g) Executive understands that, the provisions of this Agreement requiring assignment of Inventions to the Company do not apply to any invention that Executive has developed entirely on his own time without using the Company’s equipment, supplies, facilities, trade secret information or Company Confidential Information (an “Other Invention”) except for those Other Inventions that either (i) relate at the time of conception or reduction to practice of such Other Invention to the Company’s business, or actual or anticipated research or development of the Company or (ii) result from or relate to any work that Executive performed for the Company or to any Company Confidential Information or Inventions. Executive will not incorporate, or permit to be incorporated, any Other Invention owned by him or in which he has an interest into a Company product, process or service without the Company’s prior written consent. Notwithstanding the foregoing sentence, if, in the course of his employment with the Company, Executive incorporates into a Company product, process, or service an Other Invention owned by him or in which he has an interest, Executive hereby grants to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, transferable, sublicensable, worldwide license to reproduce, make derivative works of, distribute, perform, display, import, make, have made, modify, use, sell, offer to sell, and exploit in any other way such Other Invention, and to practice any method related thereto.

8.3 Covenants Against Competition and Solicitation. Executive acknowledges and agrees that to protect the Company’s legitimate protectable interests in, among other things, the Company Confidential Information, Inventions, customer relationships and goodwill, during the Term and for the period of twelve (12) months after the Termination Date, regardless of the reason for the termination (the “Restricted Period”), anywhere in the world (the “Restricted Area”), he shall not, directly or indirectly:

(a) whether as owner, partner, shareholder, director, consultant, agent, broker, employee, co- venturer, investor, or otherwise, engage, participate, assist, or invest in or plan to assist or invest in or work for or provide services to any Competitive Business in the Restricted Area. Given Executive’s role with the Company, Executive’s access to Company Confidential Information and Company trade secrets throughout the world, and Executive’s provision of services or material presence or influence on the Company throughout the world;

(b) hire, employ, attempt to hire or employ, recruit, or otherwise solicit or induce any person to terminate their employment with the Company (other than terminations of employment of subordinate employees undertaken in the course of Executive’s employment with the Company); and

(c) solicit or transact business with any customer, client, or vendor of the Company with whom Executive had material contact during Executive’s employment or about whom Executive has trade secret or Company Confidential Information, for purposes of providing products or services that are competitive with those provided by the Company.

(d) “CompetitiveBusiness” means any publicly traded entity (other than the Company) that is primarily engaged in, or planning to primarily engage in, a digital currency accumulation strategy for the native currency of a permissionless, base-layer blockchain or other decentralized ledger-based network that both: (i) ranks within the ten (10) largest networks by market capitalization, calculated by multiplying the circulating supply of a network’s native token by the volume-weighted average price of such token over any given twenty-four (24) hour period during Executive’s employment or the Restricted Period as provided by an industry-recognized pricing oracle determined by the Company in its sole, reasonable discretion; and (ii) provides for the deployment and use of self-executing software or code that is capable of autonomous execution upon the satisfaction of one or more programmed conditions (commonly referred to as a smart contract).

(e) The parties acknowledge and agree that this Agreement is intended to comply with the Florida Choice Act so as to allow the Company to avail itself of all rights and remedies permitted under the Florida Choice Act. If for any reason a court or arbitrator were to find that the conditions of the Florida Choice Act have not been met, this Agreement shall be interpreted under applicable Florida law, including Section 542.335.

-10-

8.4 Executive represents and warrants that, except with respect to Executive’s employment or service relationship with Pantera, he has no other agreements, relationships, or commitments to any other person or entity that conflict with the provisions of this Agreement, his obligations to the Company under this Agreement, or his ability to become employed and perform the services for which he is being hired by the Company. Executive further agrees that if he has signed a confidentiality agreement or similar type of agreement with any former employer or other entity, he will comply with the terms of any such agreement to the extent that its terms are lawful under applicable law. Except with respect to Executive’s employment or service relationship with Pantera, Executive represents and warrants that after undertaking a careful search (including searches of his computers, cell phones, electronic devices, and documents), he has returned all property and confidential information belonging to all prior employers (and/or other third parties he has performed services for in accordance with the terms of his applicable agreement).

8.5 Non-Disparagement. Executive shall not directly or indirectly disparage, or induce or encourage others to disparage the reputation of the Company, its services, its products or any of its current or former affiliates or any of their respective members, officers, directors, employees, or agents. The Company agrees to instruct its Board and senior executives (upon the separation of Executive’s employment) not to directly or indirectly disparage or induce or encourage others to disparage the reputation of Executive (provided, however, the Board may provide bona fide performance feedback to Executive in the course of his performing his duties for the Company).

9. Cooperation. In the event that any action, suit, claim, hearing, proceeding, arbitration, mediation, audit, assessment, inquiry or investigation (whether civil, criminal, administrative or otherwise) (each, a “Proceeding”) is commenced by any governmental authority or other person or entity in connection with the Company or any of its affiliates, Executive agrees to cooperate in good faith with the Company or any such affiliate to defend against such Proceeding.

General Provisions.

(a) Parties in Interest. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns. Nothing in this Agreement, express or implied, is intended to confer upon any person or entity other than the Company and its affiliates and Executive, or their successors or permitted assigns, any rights or remedies under or by reason of this Agreement.

(b) Amendment; Waiver. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Company and Executive, or in the case of a waiver, by the party against whom the waiver is to be effective. No oral amendment or modification shall be effective under any circumstances whatsoever. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege, and no waiver in any one instance shall be effective with respect to any other instance or create a course of dealing.

(c) Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any term or other provision of this Agreement, or the application thereof to any person or entity or any circumstance, is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other persons, entities or circumstances shall not be affected by such invalidity, illegality or unenforceability, nor shall such invalidity, illegality or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction.

-11-

(d) Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Florida.

(e) Dispute Resolution. Except with respect to the Company’s and Executive’s right to seek injunctive or other equitable relief, any controversy, dispute or claim arising out of or relating to this Agreement or breach thereof or any other dispute between the parties, including claims of harassment and discrimination, shall first be settled through good faith negotiation. If the dispute cannot be settled through negotiation, the parties agree to attempt in good faith to settle the dispute by mediation administered by JAMS. If the parties are unsuccessful at resolving the dispute through mediation, the parties agree to arbitration administered by JAMS pursuant to its Employment Arbitration Rules & Procedures and subject to JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness. Judgment on the Award may be entered in any court having jurisdiction. THE PARTIES WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY JURY.

(f) Notices. All notices or other communications hereunder shall be deemed to have been duly given and effective upon delivery if in writing and if served by personal delivery upon the party for whom it is intended, if delivered by registered or certified mail, return receipt requested, or by a national courier service, or if sent by electronic mail.

(g) Counterparts. This Agreement may be executed in one or more counterparts (including by electronic .pdf submission), each of which shall be deemed an original, and all of which shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by portable document format (.pdf) or otherwise) to the other party, it being understood that both parties need not sign the same counterpart.

(h) Assignment. This Agreement is personal to Executive and shall not be assigned by Executive, including by operation of law or otherwise, without the prior written consent of the Company. The Company may assign its rights under this Agreement without Executive’s consent to a successor in interest.

(i) Entire Agreement. This Agreement contains the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to the subject matter hereof.

-12-

Code Section 409A Compliance.

This Agreement is intended to first be exempt from Section 409A of the Internal Revenue Code of 1986 as amended, and any regulations and Treasury guidance promulgated thereunder (collectively, “Section 409A of the Code”) to the maximum permissible extent and will be interpreted and construed consistently with such intent. To the extent that any amounts or benefits under this Agreement are not exempt from the requirements of Section 409A of the Code, then all such amounts and benefits are intended to be paid or provided in compliance with Section 409A of the Code such that there will be no adverse tax consequences, interest, or penalties imposed on Executive under Section 409A of the Code. The Company shall not be liable to Executive for any payment made under this Agreement which is determined to result in an additional tax, penalty or interest under Section 409A of the Code, nor for reporting in good faith any payment made under this Agreement as an amount includible in gross income under Section 409A of the Code. Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A of the Code. With respect to any reimbursement of expenses or any provision of in-kind benefits to Executive specified under this Agreement, such reimbursement of expenses or provision of in-kind benefits shall be subject to the following conditions: (a) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangements providing for the reimbursement of expenses referred to in Section 105(b) of the Code; (b) the reimbursement of an eligible expense shall be made no later than the end of the year following the year in which such expense was incurred; and (c) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit. Notwithstanding anything in this Agreement to the contrary, if a payment obligation arises on account of Executive’s separation from service while Executive is a “specified employee” as described in Section 409A of the Code and the Treasury Regulations thereunder and as determined by the Company in accordance with its procedures, by which determination Executive is bound, any payment of “deferred compensation” (as defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12)) shall be made on the first (1st) business day of the seventh (7^th^) month following the date of Executive’s separation from service, or, if earlier, within fifteen (15) days after the appointment of the personal representative or executor of Executive’s estate following Executive’s death. Notwithstanding anything contained herein to the contrary, Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement unless Executive would be considered to have incurred a “termination of employment” from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii). In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on Executive by Section 409A of the Code or damages for failing to comply with Section 409A of the Code.

THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT AS OF THE DATE FIRST ABOVE WRITTEN.

[The remainder of this page is intentionallyleft blank.]

-13-

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

COMPANY:
BRERA HOLDINGS PLC
By:	/s/ Daniel J. McClory
Name:	Daniel J. McClory
Title:	Executive Chairman
EXECUTIVE:
By:	/s/ Marco Santori
	MARCO SANTORI

-14-

Exhibit 10.4

STRATEGIC ADVISOR AGREEMENT

THIS STRATEGICADVISOR AGREEMENT (this “Agreement”) is made and entered into as of the Closing Date (as defined in the Securities Purchase Agreements, each dated September 18, 2025) (the “Effective Date”) by and among Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), and each of the signatories to this Agreement (each a “Strategic Advisor”, and collectively the “Strategic Advisors”, and together with the Company, the “Parties”).

WHEREAS, each of the Strategic Advisors has been vital to the success of the Company’s recent private offering transaction (the “PIPE Transaction”), and the Company wishes to secure the continued commitment of each of the Strategic Advisors to offer consulting services to the Company, and each of the Strategic Advisors wishes to offer such a commitment.

NOW, THEREFORE, in consideration of the premises and of the covenants and undertakings specified herein, the Company and each of the Strategic Advisors hereby agree as follows:

Engagement and Services.

**1.1.**Engagement. The Company hereby engages each of the Strategic Advisors, and each of the Strategic Advisors hereby accepts such engagement, to serve as a strategic advisor to the Company on the terms and conditions set forth in this Agreement.

**1.2.**Services. Each of the Strategic Advisors shall provide the Company with strategic advice and guidance relating to the Company’s business, operations and growth initiatives, and industry trends in the crypto technology sector (the “Services”). Each of the Strategic Advisors shall perform the Services at such times and places as are mutually agreed upon by the Company and the Strategic Advisors, with no specific minimum time commitment required.

2. Term. The initial term of this Agreement shall commence on the date hereof and continue for a period of ten (10) years unless earlier terminated in accordance with Section 5. The term may be extended by mutual written agreement of the Parties.

Compensation.

**3.1.**In connection with each of the Strategic Advisors’ provision of the Services, each of the Strategic Advisors shall be entitled to receive their respective percentage advisory share (“Advisory Share”), as set forth in Schedule A attached hereto.

**3.2.**In connection with each of the Strategic Advisors’ provision of the Services, immediately following the PIPE Transaction, the Company will issue to each of the Strategic Advisors (i) pre-funded warrants (the “Strategic Advisor Pre-Funded Warrants”) to purchase an amount of the Company’s Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), equal to, in the aggregate, 10.0% of the aggregate number of Class B Ordinary Shares and pre-funded warrants issued pursuant to those certain Securities Purchase Agreements (the “Securities Purchase Agreements”), dated September 18, 2025, between the Company and each of the Purchasers (as defined therein) (the “Strategic Advisor Pre-Funded Warrant Shares”), and (ii) warrants (the “Strategic Advisor Common Warrants 1”) to purchase an amount of Class B Ordinary Shares equal to, in the aggregate, 50.0% of the aggregate number of Strategic Advisor Pre-Funded Warrant Shares, each to be issued to each of the Strategic Advisors in accordance with Schedule B attached hereto, as of the Effective Date. The exercise price per share of the Strategic Advisor Pre-Funded Warrants shall be set at a price equal to US$0.05. The exercise price per share of the Strategic Advisor Common Warrants 1 shall be set at a price equal to one hundred fifty percent (150%) of the cash Per Share Purchase Price (as defined in the Securities Purchase Agreements). Half of the Strategic Advisor Pre-Funded Warrants shall be exercisable, in whole or in part, at any time and from time to time, until all of such Strategic Advisor Pre-Funded Warrants are exercised in full. The remaining half of the Strategic Advisor Pre-Funded Warrants shall be exercisable, in whole or in part, at any time and from time to time, beginning on the third (3rd) anniversary of the Closing Date and until all of such Strategic Advisor Pre-Funded Warrants are exercised in full. Half of the Strategic Advisor Common Warrants 1 shall be exercisable, in whole or in part, at any time and from time to time, until the five (5) year anniversary of the issuance thereof. The remaining half of the Strategic Advisor Common Warrants 1 shall be exercisable, in whole or in part, at any time and from time to time, beginning on the third (3rd) anniversary of the Closing Date and until the five (5) year anniversary of the issuance thereof. The Strategic Advisor Pre-Funded Warrants shall be subject to the terms and conditions set forth in the Strategic Advisor Pre-Funded Warrant to be issued by the Company to each of the Strategic Advisors, substantially in the form attached hereto as Exhibit A. The Strategic Advisor Common Warrants 1 shall be subject to the terms and conditions set forth in the Strategic Advisor Common Warrant 1 to be issued by the Company to each of the Strategic Advisors, substantially in the form attached hereto as Exhibit B.

**3.3.**In connection with each of the Strategic Advisors’ provision of the Services, immediately following the PIPE Transaction, the Company will issue to each of the Strategic Advisors additional warrants (the “Strategic Advisor Common Warrants 2”, and together with the Strategic Advisor Pre-Funded Warrants and the Strategic Advisor Common Warrants 1, the “Strategic Advisor Warrants”) to purchase, in the aggregate, an amount of Class B Ordinary Shares equal to 9.0% of the aggregate number of Class B Ordinary Shares and pre-funded warrants issued pursuant to the Securities Purchase Agreements, to be issued to each of the Strategic Advisors in accordance with Schedule B attached hereto, as of the Effective Date. The Strategic Advisor Common Warrants 2 shall be exercisable pursuant to the following performance based metrics: (i) one-third of the purchase rights represented by the Strategic Advisor Common Warrants 2 shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than one hundred fifty percent (150%) of the cash Per Share Purchase Price; (ii) one-third of the purchase rights represented by the Strategic Advisor Common Warrants 2 shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than two hundred percent (200%) of the cash Per Share Purchase Price; and (iii) one-third of the purchase rights represented by the Strategic Advisor Common Warrants 2 shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than two hundred fifty percent (250%) of the cash Per Share Purchase Price (each, a “Performance Metric”). The exercise price per share of the Strategic Advisor Common Warrants 2 shall be equal to the closing market price of the Class B Ordinary Shares on the trading day on which the applicable Performance Metric is achieved. The Strategic Advisor Common Warrants 2 will each have a term of five (5) years from the date of issuance thereof and will be subject to the terms and conditions set forth in the Strategic Advisor Common Warrant 2 to be issued by the Company to each of the Strategic Advisors, substantially in the form attached hereto as Exhibit C.

**3.4.**Immediately following the issuance of the Strategic Advisor Warrants, the Parties will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit D (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights in respect of the Class B Ordinary Shares issuable upon exercise of the Strategic Advisor Warrants under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

**3.5.**The Company will also reimburse reasonable expenses reasonably and necessarily incurred by each of the Strategic Advisors in the course of providing the Services, including airfare, lodging and meals, subject to the Company’s receipt of documentation for such expenses reasonably satisfactory to the Company.

4. Statusas an Independent Contractor. Each of the Strategic Advisors and the Company hereby specifically agree that, throughout the term of this Agreement, each of the Strategic Advisors’ relationship with the Company hereunder will be solely and exclusively that of an independent contractor. The Strategic Advisors shall not be deemed and shall not hold themselves out to be employees or agents of the Company, nor shall the Parties be deemed to be engaged in any partnership, joint venture, or other business relationship other than that of principal and independent contractor. Nothing contained in this Agreement shall be construed so as to make any of the Strategic Advisors an employee of the Company or any of its parents, subsidiaries or affiliates (collectively, the “Company Entities”), or to entitle any of the Strategic Advisors to any rights or fringe benefits offered to employees of the Company or the Company Entities, including, but not limited to, any retirement, savings, health, medical, welfare, life insurance, disability, vacation, share purchase, share option, incentive, or other benefit plans or programs maintained for employees by or on behalf of the Company or the Company Entities.

Termination.

**5.1.**Termination. The Company and any individual Strategic Advisor may terminate this Agreement upon mutual written consent executed by the Company and such Strategic Advisor, solely as it pertains to the engagement of such Strategic Advisor, with, for the avoidance of doubt, this Agreement remaining in full force and effect with respect to the Company and the other Strategic Advisors. Notwithstanding Section 2 hereof, the Company or any individual Strategic Advisor, solely with respect to itself, may terminate this Agreement at any time, effective immediately upon notice, if it has good cause for termination. Without limiting applicable law, good cause for termination includes a situation in which another Party is in material breach of any of its obligations under this Agreement and has failed to cure such breach within thirty (30) days, after receiving written notice from another Party of the existence of such breach. The Strategic Advisor Pre-Funded Warrants shall be deemed fully earned as of the Effective Date and are not subject to revocation or clawback in the event of termination by the Company. The Strategic Advisor Common Warrants shall be deemed fully earned as of the trading day on which the applicable performance metric for the applicable Strategic Advisor Common Warrants is achieved and, once earned, are not subject to revocation or clawback in the event of termination by the Company. The Advisory Share shall accrue daily and shall be deemed fully earned on a pro rata basis for each day of the year prior to termination.

**5.2.**Survival of Accrued Obligations. Termination of this Agreement will not relieve any Party of its obligations hereunder accruing prior to such termination, including, without limitation, payment of any pro rata portion of the Advisory Share earned prior to termination. Each Party will diligently continue to perform its obligations hereunder through the date of termination even if it has received notice of the other Party’s election to terminate.

Confidentiality and Non-Disclosure.

**6.1.**Obligations of Confidentiality. Each of the Strategic Advisors hereby acknowledges that all of the Proprietary Information (as hereinafter defined) now or hereafter known to each of the Strategic Advisors is of substantial value to the Company and is and has been maintained in confidence as trade secrets of the Company. Each of the Strategic Advisors hereby covenants and agrees:

(i) to keep such Proprietary Information confidential as herein provided.

(ii) not to disclose, divulge or furnish such Proprietary Information to any third party except as authorized by the Company, and then only on the understanding that such third party is made aware of and undertakes to observe the provisions of this Section 6.

(iii) not to copy or reduce Proprietary Information to writing, except as may be strictly necessary for purposes of performing the Services; and

(iv) upon termination of this Agreement for any reason, to return to the Company within twenty (20) business days of receipt of written demand from the Company, all copies of Proprietary Information reduced to writing or other permanent form, or to otherwise delete all copies of Proprietary Information in electronic form and to destroy all notes and any other written or electronic reports or documents which may have been made by any of the Strategic Advisors in performance of the Services to the extent they contain any Proprietary Information in whole or part, except as authorized by the Company or as is strictly necessary to complete any outstanding obligations relating to this Agreement, after which such Proprietary Information will be returned or destroyed as aforesaid

**6.2.**Definition. For purposes of this Agreement, “Proprietary Information” means any strategic, technical, business, commercial, legal, financial or other information provided to each of the Strategic Advisors by the Company (or by a third party on the Company’s behalf); provided, however, that Proprietary Information will not include any information which: (i) is in or comes into the public domain otherwise than through a breach of this Agreement or through any act or omission of any of the Strategic Advisors; or (ii) has been lawfully received by any of the Strategic Advisors from a third party without restriction as to its use or disclosure; or (iii) was already in any of the Strategic Advisors’ possession free of any such restriction prior to receipt from or on behalf of the Company; or (iv) was independently developed by any of the Strategic Advisors without making use of the Proprietary Information; or (v) has been approved for unconditional release or use by written authorization of the Company.

Representations and Warranties.

**7.1.**Mutual Representations. Each Party represents and warrants to each other that: (a) it has the full right, power, and authority to enter into and perform its obligations under this Agreement; and (b) its performance under this Agreement will not violate any applicable laws or regulations.

**7.2.**Disclaimer. Except as expressly set forth in this Agreement, each of the Strategic Advisors makes no warranties, express or implied, including any warranties of merchantability, fitness for a particular purpose, or non-infringement.

**7.3.**No Fiduciary Role. Each of the Strategic Advisor is not, and shall not be deemed to be, acting as a fiduciary or investment adviser to the Company, or any of their respective affiliates, shareholders, or partners in connection with this Agreement or any matter contemplated herein. The Company acknowledges that it is not relying on any of the Strategic Advisors as a fiduciary or for investment advice, and that all decisions made by the Company are based on its own independent evaluation and judgment.

**7.4.**No Investment Advice. The Company acknowledges and agrees that each of the Strategic Advisors is not registered or licensed as an investment adviser, broker-dealer, or other regulated financial institution under the U.S. Investment Advisers Act of 1940 (the “Advisers Act”), the U.S. Securities Exchange Act of 1934, or any other applicable securities laws. Each of the Strategic Advisors does not, and shall not, provide investment advice to the Company, nor shall any of the Services rendered under this Agreement be construed as investment advice, investment management, or a solicitation to buy or sell any security or financial instrument. The Company further acknowledges and agrees that it shall not be considered an “advisory client” of any of the Strategic Advisors for purposes of the Advisers Act or any other applicable securities law, and shall not be entitled to the protections afforded to advisory clients thereunder. Each of the Strategic Advisors’ role under this Agreement is strictly limited to providing strategic advice and guidance relating to the Company’s business, operations and growth initiatives, and industry trends in the crypto technology sector.

**7.5.**Regulatory Status; No Securities Activities. Each of the Strategic Advisors shall not, and is not expected or authorized to: (i) solicit investors, (ii) participate in the negotiation or execution of securities transactions, or (iii) receive any transaction-based compensation related to the purchase or sale of securities. Each of the Strategic Advisors is not required and shall not engage in the purchase, sale, or trading of securities, including securities of the Company or its affiliates, whether for its own account or on behalf of any third party, in connection with this Agreement. Each of the Strategic Advisors shall not provide recommendations, strategies, or advice concerning the purchase or sale of any securities. The Company shall not request, and each of the Strategic Advisors shall not be required to provide, any services that would require registration as an investment adviser, broker-dealer, or similar regulated role.

**7.6.**Company Acknowledgements. The Company acknowledges that each of the Strategic Advisors will not, in connection with the Services or otherwise:

(a) provide investment advice, price forecasts, trading recommendations, or any other form of guidance relating to the valuation, market performance, or expected returns of SOL or any other digital asset;

(b) act in the capacity of, or hold itself out as, an investment adviser, broker dealer, fiduciary, or any other person or entity subject to registration or licensing under applicable securities, commodities, or financial services laws and regulations; or

(c) utilize, rely upon, or disseminate any material non-public information, trade secrets, or other confidential or proprietary information concerning SOL, Solana, the Solana Foundation or any of their respective affiliates, operations, or business plans.

Each of the Strategic Advisors’ role is limited to providing non-fiduciary, nondiscretionary strategic support based solely on publicly available information and general industry knowledge.

Limitation of Liability.

**8.1.**Each Party’s total liability under this Agreement, whether in contract, tort, or otherwise, shall be limited to the total compensation paid under this Agreement. For the avoidance of doubt, this limitation shall not apply to the Company’s liability for fraud, willful misconduct, bad faith, or gross negligence.

**8.2.**Except in the cases of willful misconduct or fraud (each, a “Disqualifying Action”), none of the Strategic Advisors, their respective affiliates or their respective officers, directors, agents and employees (collectively, the “Covered Persons”) shall have any liability (whether direct or indirect, in contract or tort or otherwise) for any claims, liabilities, losses, damages, penalties, obligations or expenses of any kind whatsoever, including reasonable and documented attorneys’ fees and court costs (“Losses”) suffered by the Company as the result of any act or omission by any of the Strategic Advisors in connection with, arising out of or relating to the performance of its services hereunder. The Company further agrees that no Covered Person shall be liable for any Losses caused, directly or indirectly, by any act or omission of the Company or by any other non-party. Under no circumstances shall any of the Strategic Advisors or any Covered Person be liable for any special, incidental, exemplary, consequential, punitive, lost profits or indirect damages.

9. Indemnification. Subject to Section 8.1, the Company shall indemnify and hold harmless the Covered Persons from and against any and all Losses (including reasonable attorneys’ fees) arising out of or in connection with the performance of the Services, including without limitation, arising out of, directly or indirectly, with (i) the operations, business or affairs of the Company, or any actions taken by each of the Strategic Advisors or failure by it to act (even if negligent) in connection with this Agreement, (ii) a Disqualifying Action by the Company, (iii) any regulatory, governmental, or law enforcement inquiry, investigation, examination, proceeding, or enforcement action relating to or arising from the Company’s operations, business, or affairs, or (iv) the Company’s breach of this Agreement or the Strategic Advisor Warrants, in each case except to the extent that such Losses are determined by a court of competent jurisdiction, upon entry of a final judgment, to be attributable to a Disqualifying Action of such Covered Person.

Miscellaneous.

**10.1.**Notices. Any notice or approval required or permitted under this Agreement will be in writing and will be sent by registered or certified mail, postage prepaid, or by email, to the addresses designated by prior written notice. Any notice sent by mail will be deemed received three (3) business days after its mailing.

**10.2.**Entire Agreement. This Agreement contains the entire understanding of the Parties regarding all matters contained herein, and supersedes all prior oral or written agreements, arrangements and understandings relating thereto.

**10.3.**Amendment. This Agreement may be amended only in writing signed by the Company and a majority of the Strategic Advisors, provided that if any amendment disproportionately and adversely impacts a Strategic Advisor, the consent of such disproportionately and adversely impacted Strategic Advisor shall also be required. The failure by any Party to enforce compliance with any provision of this Agreement by another Party will not operate or be construed as a waiver of such provision or of any other provision of this Agreement, or of any subsequent breach by such Party of a provision of this Agreement.

**10.4.**Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect, all other provisions hereof will continue in full force and effect.

**10.5.**Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to each other Party, it being understood that the Parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof.

11. ApplicableLaw; Dispute Resolution. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to its conflicts of law principles. Any dispute arising between the Parties out of or in connection with this Agreement will be finally resolved in state or federal court in New York, New York.

[Signature pages follow]

IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the date first above written.

Brera Holdings PLC
By:	/s/ Daniel McClory
Name:	Daniel McClory
Title:	Executive Chairman
/s/ Guy Hirsch
Guy Hirsch
/s/ Keren Maimon
Keren Maimon
/s/ Ron Sade
Ron Sade
/s/ Alyazi Almheiri
Alyazi Almheiri
/s/ Tarek Alnuaimi
Tarek Alnuaimi

[Strategic Advisor Agreement Signature Page]

Schedule A

Compensation

In connection with the Services to be provided under the Agreement, each of the Strategic Advisors, as listed below, shall be entitled to receive their respective Advisory Share, for each year during the term of the Agreement, in accordance with the below:

a.	Tarek Alnuaimi shall receive an amount equal to:
i.	0.2857% per annum of the amount of the Company’s SOL Assets Under Management (“SOL AUM”)<br>as of the anniversary date of the Effective Date of the applicable year, up to US$1,000,000,000 of SOL AUM, and
---	---
ii.	0.1429% per annum of the amount by which the Company’s SOL AUM as of the anniversary date of the<br>Effective Date of the applicable year exceeds US$1,000,000,000.
---	---
b.	Guy Hirsch shall receive an amount equal to:
---	---
i.	0.1429% per annum of the amount of the Company’s SOL AUM as of the anniversary date of the Effective<br>Date of the applicable year, up to US$1,000,000,000 of SOL AUM, and
---	---
ii.	0.0714% per annum of the amount by which the Company’s SOL AUM as of the anniversary date of the<br>Effective Date of the applicable year exceeds US$1,000,000,000.
---	---
c.	Keren Maimon shall receive an amount equal to:
---	---
i.	0.1429% per annum of the amount of the Company’s SOL AUM as of the anniversary date of the Effective<br>Date of the applicable year, up to US$1,000,000,000 of SOL AUM, and
---	---
ii.	0.0714% per annum of the amount by which the Company’s SOL AUM as of the anniversary date of the<br>Effective Date of the applicable year exceeds US$1,000,000,000.
---	---
d.	Ron Sade shall receive an amount equal to:
---	---
i.	0.1429% per annum of the amount of the Company’s SOL AUM as of the anniversary date of the Effective<br>Date of the applicable year, up to US$1,000,000,000 of SOL AUM, and
---	---
ii.	0.0714% per annum of the amount by which the Company’s SOL AUM as of the anniversary date of the<br>Effective Date of the applicable year exceeds US$1,000,000,000.
---	---
e.	Alyazi Almheiri shall receive an amount equal to:
---	---
i.	0.1429% per annum of the amount of the Company’s SOL AUM as of the anniversary date of the Effective<br>Date of the applicable year, up to US$1,000,000,000 of SOL AUM, and
---	---
ii.	0.0714% per annum of the amount by which the Company’s SOL AUM as of the anniversary date of the<br>Effective Date of the applicable year exceeds US$1,000,000,000.
---	---

For purposes of determining SOL AUM under this Agreement, the Company’s SOL shall be valued, as of any specified date, using the Time-Weighted Average Price (TWAP) of SOL over the 15 calendar-day period ending on the day immediately preceding such date, which shall mean, with respect to each such day, the CME CF Solana-Dollar Reference Rate New York Variant (SOLUSD_NY) (“CF Benchmarks Index”) for such day or, if the CF Benchmarks Index is unavailable, the rate determined pursuant to such other index, benchmark or other method of determining the fair value of SOL as may be selected by the Company and approved in good faith by a majority of the Strategic Advisors.

f.	Each Advisory Share shall be calculated annually as of the anniversary date of the Effective Date of the<br>applicable year and shall be payable annually in arrears.
g.	Each Advisory Share shall be due and payable by the Company within thirty (30) calendar days following<br>the end of each calculation period.
---	---
h.	In the event of termination of the Agreement for any Strategic Advisor, such Strategic Advisor’s<br>Advisory Share shall be calculated on a pro rata basis up to and including the effective date of termination, as of such date, and shall<br>be payable within thirty (30) calendar days thereafter.
---	---
i.	The Company shall make all payments under this Agreement without withholding or deduction of, or in respect<br>of tax unless required by law. If any such withholding or deduction is required, the Company shall, when making the payment to which the<br>withholding or deduction relates, pay to each of the Strategic Advisors such additional amount as will ensure that each of the Strategic<br>Advisors receives the same total amount that it would have received if no such withholding or deduction had been required.
---	---

Schedule B

StrategicAdvisor Warrants Schedule

Strategic Advisor
Tarek Alnuaimi	33.33	%	33.33	%	33.33	%
Guy Hirsch	16.66	%	16.66	%	16.66	%
Keren Maimon	16.66	%	16.66	%	16.66	%
Ron Sade	16.66	%	16.66	%	16.66	%
Alyazi Almheiri	16.66	%	16.66	%	16.66	%

Exhibit A

Formof Strategic Advisor Pre-Funded Warrant

[see attached]

FORM OF STRATEGIC ADVISOR PRE-FUNDEDCLASS B ORDINARY SHARE PURCHASE WARRANT

BRERA HOLDINGS PLC

Warrant Shares: [ ]	Issue Date: [ ], 2025

THIS STRATEGIC ADVISOR PRE-FUNDED CLASS B ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [date hereof/third (3rd) anniversary of Closing Date] (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), up to [●] Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and, on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF or DocuSign copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 1(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 1(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice and only for the purpose avoiding violation of the Beneficial Ownership Limitation (as defined below). The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.

(A) =	as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable<br> Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is<br> not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of<br> “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on<br> such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the<br> applicable Notice of Exercise or (z) the Bid Price of the Class B Ordinary Shares on the principal Trading Market as reported by<br> Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise<br> if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2)<br> hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to<br> Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a<br> Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of<br> “regular trading hours” on such Trading Day;
(B) =	the Exercise Price of this Warrant, as adjusted hereunder, in<br>effect on the date of exercise; and
---	---
(X) =	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with<br> the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.
---	---

-2-

d) Mechanics of Exercise.

-3-

-4-

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

-5-

Section 2. Certain Adjustments.

-6-

e) [Reserved].

-7-

g) Notice to Holder.

Section 3. Transfer of Warrant.

-8-

Section 4. Miscellaneous.

-9-

d) Authorized Shares.

-10-

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

-11-

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGE TO STRATEGIC ADVISOR PRE-FUNDED WARRANT]

EXHIBIT A

NOTICE OF EXERCISE

TO: BRERAHOLDINGS PLC

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, executethis form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:
Dated: ,
Holder’s Signature:
Holder’s Address:

Exhibit B

Formof Strategic Advisor Common Warrant 1

[see attached]

FORM OF STRATEGIC ADVISOR CLASSB ORDINARY SHARE COMMON PURCHASE WARRANT 1

BRERA HOLDINGS PLC

Warrant Shares: [ ]	Issue Date: [ ], 2025

THIS STRATEGIC ADVISOR CLASS B ORDINARY SHARE COMMON PURCHASE WARRANT 1 (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [date hereof/third (3rd) anniversary of Closing Date] (the “Initial Exercise Date”) until the earlier of the date that this Warrant has been exercised in full or the fifth (5th) anniversary of the Issue Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), up to [●] Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated September [●], 2025, among the Company and the Holder and the other Purchasers named therein or that certain Strategic Advisor Agreement (the “Strategic Advisor Agreement”), dated September [●], 2025, among the Company and the signatories named therein.

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and, on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF or DocuSign copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 1(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 1(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice and only for the purpose avoiding violation of the Beneficial Ownership Limitation (as defined below). The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.

(A) =	as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable<br> Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is<br> not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of<br> “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on<br> such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the<br> applicable Notice of Exercise or (z) the Bid Price of the Class B Ordinary Shares on the principal Trading Market as reported by<br> Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise<br> if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2)<br> hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to<br> Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a<br> Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of<br> “regular trading hours” on such Trading Day;
(B) =	the Exercise Price of this Warrant, as adjusted hereunder, in<br>effect on the date of exercise; and
---	---
(X) =	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with<br> the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.
---	---

-2-

d) Mechanics of Exercise.

-3-

-4-

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

-5-

Section 2. Certain Adjustments.

-6-

e) [Reserved].

-7-

g) Notice to Holder.

Section 3. Transfer of Warrant.

-8-

Section 4. Miscellaneous.

d) Authorized Shares.

-9-

-10-

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

-11-

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGE TO STRATEGIC ADVISOR COMMON WARRANT 1]

EXHIBIT A

NOTICE OF EXERCISE

TO: BRERAHOLDINGS PLC

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, executethis form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:
Dated: ,
Holder’s Signature:
Holder’s Address:

Exhibit C

Formof Strategic Advisor Common Warrant 2

[see attached]

FORM OF STRATEGIC ADVISOR CLASSB ORDINARY SHARE COMMON PURCHASE WARRANT 2

BRERA HOLDINGS PLC

Warrant Shares: [ ]	Issue Date: [ ], 2025

THIS STRATEGIC ADVISOR CLASS B ORDINARY SHARE COMMON PURCHASE WARRANT 2 (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until the earlier of the date that this Warrant has been exercised in full or the fifth (5th) anniversary of the Issue Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), up to [●] Class B ordinary shares, nominal value US$0.05 per share (the “Class B Ordinary Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated September [●], 2025, among the Company and the Holder and the other Purchasers named therein or that certain Strategic Advisor Agreement (the “Strategic Advisor Agreement”), dated September [●], 2025, among the Company and the signatories named therein.

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and, on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF or DocuSign copy submitted by e-mail (or e- mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the “Notice of Exercise”). Exercise of this Warrant shall be made in accordance with the following conditions: (i) one-third of the purchase rights represented by this Warrant shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than one hundred fifty percent (150%) of the cash Per Share Purchase Price; (ii) one-third of the purchase rights represented by this Warrant shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than two hundred percent (200%) of the cash Per Share Purchase Price; and (iii) one-third of the purchase rights represented by this Warrant shall be exercisable on and after the first date on which the closing trading price of the Class B Ordinary Shares on the Company’s principal stock exchange is equal to or greater than two hundred fifty percent (250%) of the cash Per Share Purchase Price (each, a “Performance Metric”). Within one (1) Trading Day following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 1(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice and only for the purpose avoiding violation of the Beneficial Ownership Limitation (as defined below). The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.

(A) =	as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable<br> Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is<br> not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of<br> “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on<br> such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the<br> applicable Notice of Exercise or (z) the Bid Price of the Class B Ordinary Shares on the principal Trading Market as reported by<br> Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise<br> if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2)<br> hours thereafter (including until two (2) hours after the close of “regular<br>trading hours” on a Trading Day) pursuant to Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise<br>if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section<br>1(a) hereof after the close of “regular trading hours” on such Trading Day;
(B) =	the Exercise Price of this Warrant, as adjusted hereunder, in<br>effect on the date of exercise; and
---	---
(X) =	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with<br> the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.
---	---

-2-

d) Mechanics of Exercise.

-3-

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 1(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, Class B Ordinary Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy- In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Class B Ordinary Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Class B Ordinary Shares having a total purchase price of US$11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of US$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder US$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Class B Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.

-4-

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

-5-

Section 2. Certain Adjustments.

-6-

-7-

e) [Reserved].

g) Notice to Holder.

Section 3. Transfer of Warrant.

-8-

Section 4. Miscellaneous.

-9-

d) Authorized Shares.

-10-

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

-11-

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGE TO STRATEGIC ADVISOR COMMON WARRANT 2]

EXHIBIT A

NOTICE OF EXERCISE

TO: BRERAHOLDINGS PLC

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, executethis form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:
Dated: ,
Holder’s Signature:
Holder’s Address:

Exhibit D

Registration Rights Agreement

[see attached]

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of September [●], 2025, by and between Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of September [●], 2025, between the Company and the Purchasers named therein (the “Purchase Agreement”).

The Company and each Purchaser hereby agrees as follows:

1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Advice” shall have the meaning set forth in Section 6(c).

“Common Warrants” means, collectively, the Ordinary Share purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) of the Purchase Agreement, which Common Warrants shall be exercisable immediately upon issuance thereof at Closing and shall expire upon the earlier of (i) 36 months after the Closing Date, or (ii) when exercised in full, in the form of Exhibit B attached to the Purchase Agreement.

“Common Warrant Shares” means the Ordinary Shares issued or issuable upon exercise of the Common Warrants.

“Effectiveness Date” means, when the Company is notified by the Commission that one or more of the Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified; provided, that if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.

“Effectiveness Period” shall have the meaning set forth in Section 2(a).

“Event” shall have the meaning set forth in Section 2(d).

“Event Date” shall have the meaning set forth in Section 2(d).

“Filing Date” means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the Closing Date. With respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), “Filing Date” means the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.

“Holder” or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

“Indemnified Party” shall have the meaning set forth in Section 5(c).

“Indemnifying Party” shall have the meaning set forth in Section 5(c).

“Initial Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

“Losses” shall have the meaning set forth in Section 5(a).

“Ordinary Shares” means the Class B ordinary shares of the Company, nominal value US$0.05 per share.

“Plan of Distribution” shall have the meaning set forth in Section 2(a).

“Pre-Funded Warrants” means, collectively, the pre-funded Ordinary Share purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) of the Purchase Agreement, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in full, in the form of Exhibit C attached to the Purchase Agreement.

“Pre-Funded Warrant Shares” means the Ordinary Shares issued or issuable upon exercise of the Pre-Funded Warrants.

“Prospectus” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

“Registrable Securities” means, as of any date of determination, (a) the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Common Warrants, the Common Warrant Shares, the Strategic Advisor Warrants and the Strategic Advisor Warrant Shares, and (b) any securities issued or then issuable upon any share split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities has been declared effective by the Commission under the Securities Act and such Registrable Securities have been sold, transferred, exchanged, or disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders and any restrictive legend is removed to permit the delivery of the securities via the facilities of DTC (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company, as reasonably determined by the Company, upon the advice of counsel to the Company).

“Registration Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.

“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“Selling Shareholder Questionnaire” shall have the meaning set forth in Section 3(a).

“SEC Guidance” means (i) any publicly available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.

-2-

“Shares” means the Ordinary Shares issued or issuable to each Purchaser pursuant to the Purchase Agreement.

“Strategic Advisor Warrants” means the warrants to purchase Ordinary Shares, to be issued pursuant to the Strategic Advisor Agreement.

“Strategic Advisor Warrant Shares” means the Ordinary Shares issued or issuable upon exercise of the Strategic Advisor Warrants.

Registration.

(a) On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 (or any successor or similar provision adopted by the Commission then in effect). Each Registration Statement filed hereunder shall be on Form F-3 or such other appropriate form of registration statement as is then available to effect a registration of Registrable Securities and shall contain a Prospectus in such form as to permit the Holders to sell such Registrable Securities pursuant to Rule 415 under the Securities Act (or any successor or similar provision adopted by the Commission then in effect) beginning on the effective date for such Registration Statement. Each Registration Statement shall contain substantially the “Plan of Distribution” and “Selling Shareholder” sections attached hereto as Annex A and Annex B, respectively; provided, however, that no Holder shall be required to be named as an “underwriter” without such Holder’s express prior written consent. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act, and to be supplemented and amended to the extent necessary to ensure that such Registration Statement is available or, if not available, that another Registration Statement is available, for the resale of all the Registrable Securities held by the Holders until the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders and any restrictive legend is removed to permit the delivery of the securities via the facilities of DTC (the “Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall promptly notify the Holders via facsimile or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d). When effective, a Registration Statement filed pursuant to this Section 2(a) (including the documents incorporated therein by reference) will comply as to form in all material respects with all applicable requirements of the Securities Act and the Exchange Act and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading.

(b) Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form F-3 or such other form available to register for resale the Registrable Securities as a secondary offering, and subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; provided, however, that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Securities Act Rules Compliance and Disclosure Interpretation Question 612.09.

-3-

(c) Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:

(i) First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities; and

(ii) Second, the Company shall reduce Registrable Securities represented by Shares, the Pre- Funded Warrants, the Pre-Funded Warrant Shares, the Common Warrants, the Common Warrant Shares, the Strategic Advisor Warrants and the Strategic Advisor Warrant Shares (applied, in the case that some Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares, Common Warrants, Common Warrant Shares, Strategic Advisor Warrants and/or Strategic Advisor Warrant Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares, Common Warrants, Common Warrant Shares, Strategic Advisor Warrants and/or Strategic Advisor Warrant Shares held by such Holders).

In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holder’s allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form F-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended.

(d) If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five (5) Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be “reviewed” or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale all of the Registrable Securities, subject to the cutback limitations set forth in Section 2(c) of this Agreement, is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration Statement, subject to the Company’s right under Section 3(k) of this Agreement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an “Event”, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as “Event Date”), then, in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to US$1,000 per day of such failure. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven (7) days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.

-4-

(e) [Reserved].

(f) Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate of a Holder as an Underwriter without the prior written consent of such Holder.

3. Registration Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

(a) Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review but not the express approval of such Holders other than as set forth in the remainder of this subsection as to inquiries and objections, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto, which objection will toll any applicable deadline required by this Agreement. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex C (a “Selling Shareholder Questionnaire”) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day following the date on which such Holder receives draft materials in accordance with this Section.

(b) (i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.

(c) If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of Ordinary Shares then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.

(d) Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; provided, however, that in no event shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries and the Company agrees that the Holders shall not have any duty of confidentiality to the Company or any of its Subsidiaries and shall not have any duty to the Company or any of its Subsidiaries not to trade on the basis of such information.

-5-

(e) Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

(f) Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.

(g) Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).

(h) The Company shall cooperate with any broker-dealer through which a Holder proposes to resell its Registrable Securities in effecting a filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by any such Holder, and the Company shall pay the filing fee required by such filing within two (2) Business Days of receipt of a request therefor.

(i) Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.

(j) If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates or book entry notification representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates or book entry notification shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may request.

-6-

(k) Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and its shareholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(k) to suspend the availability of a Registration Statement and Prospectus for a period not to exceed 30 consecutive calendar days or for a total of 60 calendar days (which need not be consecutive days) in any 12-month period, which suspension, for the avoidance of doubt, shall not require the Company to pay liquidated damages pursuant to Section 2(d) of this Agreement.

(l) Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.

(m) The Company shall use its reasonable best efforts to maintain eligibility for use of Form F-3 (or any successor form thereto) for the registration of the resale of the Registrable Securities.

(n) The Company may require each selling Holder to furnish to the Company a certified statement as to the number of Ordinary Shares beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information within five (5) Trading Days of the Company’s request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.

4. Registration Expenses. All fees and expenses incidental to the performance of or compliance with this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Ordinary Shares are then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), and (D) if not previously paid by the Company with respect to any filing that may be required to be made by any broker through which a Holder intends to make sales of Registrable Securities with FINRA pursuant to FINRA Rule 5110, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale, (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder.

-7-

Indemnification.

(a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call), advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, shareholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, and the Strategic Advisor and its affiliates, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees), expenses, judgments, fines, penalties, charges, and amounts paid in settlement (collectively, “Losses”), as incurred in investigating, preparing or defending against any litigation, commence or threatened, or any claim, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).

(b) Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information is contained in such Holder’s Selling Shareholder Questionnaire and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.

-8-

(c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.

An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that an actual conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.

Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.

(d) Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.

-9-

The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.

The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.

Miscellaneous.

(a) Remedies. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement (without the necessity of showing economic loss and without any bond or other security being required). Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

(b) Prohibition on Filing Other Registration Statements. Neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission; provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements.

(c) Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.

(d) Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any security); provided that, if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the prior written consent of such disproportionately impacted Holder (or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 6(e). No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.

-10-

(e) Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.

(f) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger, subject to any successor entity assuming in writing all of the obligations of the Company under this Agreement) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.

(g) No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in full.

(h) Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file or Docusign, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” or Docusign signature page were an original thereof.

(i) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement.

(j) Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.

(k) Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

(l) Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.

(m) Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.

(n) Further Acts. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

********************

[Signature Pages Follow]

-11-

IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

BRERA HOLDINGS PLC
By:
Name:
Title:

[SIGNATURE PAGES OF HOLDERS FOLLOWS]

[SIGNATURE PAGE OF COMPANY TO RRA]

[SIGNATURE PAGE OF HOLDERS TO RRA]

Name of Holder:
Signature of Authorized Signatory of Holder:
---
Name of Authorized Signatory:
---
Title of Authorized Signatory:
---

[SIGNATURE PAGES CONTINUE]

[SIGNATURE PAGE OF HOLDERS TO RRA]

Annex A

Plan of Distribution

[see attached]

PLAN OF DISTRIBUTION

Each Selling Shareholder (the “Selling Shareholders”) of the Securities and any of their pledgees, donees, transferees, assignees, and other successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the Securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Shareholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The Selling Shareholders reserve the right to accept and, together with their respective agents, to reject, any proposed purchase of securities to be made directly or through agents. The Selling Shareholders and any permitted transferees may sell their securities offered by this prospectus on any stock exchange, market or trading facility on which the securities are traded or in private transactions. A Selling Shareholder may use any one or more of the following methods when selling securities:

▪	through brokers or dealers (who may act as agent or principal and who may receive compensation in the form of discounts, concessions<br>or commissions from such Selling Shareholder, the purchaser or such other persons who may be effecting such sales, which discounts, concessions<br>or commissions as to any particular broker or dealer may be in excess of those customary to the types of transactions involved) for resale<br>to the public or to institutional investors at various times;
▪	through negotiated transactions, including, but not limited to, block trades in which the broker or dealer so engaged will attempt<br>to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
---	---
▪	through purchases by a broker or dealer as principal and resale by that broker or dealer for its account;
---	---
▪	on any national securities exchange or quotation service on which the shares may be listed or quoted at the time of sale at market<br>prices prevailing at the time of sale, at prices related to such prevailing market prices, or at negotiated prices;
---	---
▪	in privately negotiated transactions other than exchange or quotation service transactions;
---	---
▪	short sales, purchases or sales of put, call or other types of options, forward delivery contracts, swaps, offerings of structured<br>equity-linked securities or other derivative transactions or securities;
---	---
o	hedging transactions, including, but not limited to:
---	---
▪	transactions with a broker-dealer or its affiliate, whereby the broker-dealer or its affiliate will engage in short sales of shares<br>and may use shares held by such selling shareholder to close out its short position;
---	---
▪	options or other types of transactions that require the delivery of shares to a broker-dealer or an affiliate thereof, who will then<br>resell or transfer the shares; or
---	---
▪	loans or pledges of shares to a broker-dealer or an affiliate, who may sell the loaned shares or, in an event of default in the case<br>of a pledge, sell the pledged shares;
---	---
▪	through offerings of securities exercisable, convertible or exchangeable for shares, including, without limitation, securities issued<br>by trusts, investment companies or other entities;
---	---
▪	offerings directly to one or more purchasers, including institutional investors;
---	---
▪	through ordinary brokerage transactions and transactions in which a broker solicits purchasers;
---	---
▪	through distribution to the security holders of the Selling Shareholder;
---	---
▪	by pledge to secure debts and other obligations;
---	---
▪	through a combination of any such methods of sale; or
---	---
▪	through any other method permitted under applicable law.
---	---

The Selling Shareholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

There can be no assurance that any Selling Shareholder will sell any or all of the Ordinary Shares registered pursuant to the registration statement of which this prospectus forms a part.

In addition, a Selling Shareholder that is an entity may elect to make an in-kind distribution of securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the distributees to use the prospectus to resell the securities acquired in the distribution.

The Selling Shareholders also may transfer the securities in other circumstances, in which case the transferees, pledgees or other successors-in-interest will be the selling beneficial owners for purposes of this prospectus. Upon being notified by the Selling Shareholders that a donee, pledgee, transferee, other successor-in- interest intends to sell our securities, we will, to the extent required, promptly file a supplement to this prospectus to name specifically such person as a Selling Shareholder.

Broker-dealers engaged by the Selling Shareholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Shareholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

In connection with the sale of the securities or interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Shareholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Shareholders may also enter into option or other transactions with broker- dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The Selling Shareholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Shareholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

We are required to pay certain fees and expenses incurred by the Company incident to the registration of the Securities. The Company has agreed to indemnify the Selling Shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. The Company shall not be responsible for any of the Selling Shareholders’ selling costs incurred pursuant to any available method provided hereunder for selling securities.

We are obligated to maintain the effectiveness of this registration statement until all of the Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares, Common Warrants, Common Warrant Shares, Strategic Advisor Warrants, and Strategic Advisor Warrant Shares, registered pursuant to it (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the Ordinary Shares for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Shareholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Ordinary Shares by the Selling Shareholders or any other person. We will make copies of this prospectus available to the Selling Shareholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

Annex B

Selling Shareholders

Annex C

Selling Shareholder Notice and Questionnaire

BRERA HOLDINGS PLC

Selling Shareholder Notice and Questionnaire

The undersigned beneficial owner of Class B ordinary shares (the “Registrable Securities”) of Brera Holdings PLC, a public limited company incorporated in Ireland (the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration Rights Agreement”). A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

Certain legal consequences arise from being named as a selling shareholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling shareholder in the Registration Statement and the related prospectus.

NOTICE

The undersigned beneficial owner (the “Selling Shareholder”) of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement.

The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

QUESTIONNAIRE

1.	Name.

(a)	Full Legal Name of Selling Shareholder
(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
---	---
(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power<br>to vote or dispose of the securities covered by this Questionnaire):
---	---
2.	Address for Notices to Selling Shareholder:
---	---

Telephone:

E-Mail:

Contact Person:

3.	Broker-Dealer Status:

(a)	Are you a broker-dealer?

Yes ☐ No ☐

(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services<br>to the Company?

Yes ☐ No ☐

Note:	If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in<br>the Registration Statement.
(c)	Are you an affiliate of a broker-dealer?
---	---

Yes ☐ No ☐

(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities<br>in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements<br>or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

Yes ☐ No ☐

Note:	If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in<br>the Registration Statement.
4.	Beneficial Ownership of Securities of the Company Owned bythe Selling Shareholder.
---	---

Specify below the number of Registrable Securities beneficially owned by the Selling Shareholder that the Selling Shareholder wishes to include in the Registration Statement. Please note that registration does not obligate the Selling Shareholder to sell any or all of their securities:

Except as set forth below in this Item 4, the undersignedis not the beneficial or registered owner of any securities of the Company other than the Registrable Securities.

Type and Amount of other securities beneficially owned by the Selling Shareholder:

5. Relationships with the Company:

Except as set forth below, neitherthe undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securitiesof the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors oraffiliates) during the past three years.

State any exceptions here:

The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.

By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.

Date:	Beneficial Owner:
By:
---	---
	Name:
	Title:

PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED NOTICEAND QUESTIONNAIRE TO JEFFREY WOFFORD AT [email protected]

Exhibit 10.5

Execution Version

WARRANT PURCHASE AGREEMENT

This WARRANTPURCHASE AGREEMENT (the “Agreement”), dated as of September 23, 2025 (the “Effective Date”), is by and between Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the “Company”), and the investors identified on the signature pages hereto (including their successors and assigns, each an “Investor” and collectively the “Investors”, and together with the Company, the “Parties” and each a “Party”).

RECITALS

A. The Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”);

B. The Company has authorized the issuance to the Investors of warrants to acquire Class B ordinary shares, nominal value US$0.05 per share (the “Ordinary Shares”), substantially in the form attached hereto as ExhibitA (the “Warrants”) (the Ordinary Shares issuable upon exercise of the Warrants, collectively, the “WarrantShares”);

C. Subject to and conditioned upon, the closing of the transactions contemplated by that certain that certain Securities Purchase Agreement, dated as of the Effective Date, with the purchasers named therein, for the private placement of the Ordinary Shares (the “PIPE Transaction” and such agreement, the “PIPE SPA”), the Investors wish to purchase, and the Company wishes to sell, at the Closing (as defined below), upon the terms and conditions stated in this Agreement, the Warrants; and

D. The Warrants and the Warrant Shares are collectively referred to herein as the “Securities.”

AGREEMENT

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors, hereby agree as follows:

1.	PURCHASE AND SALE OF WARRANTS.

(a) Purchase of Warrants. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6(a) and 7(a) below, the Company shall issue and sell to each Investor, and each Investor, jointly and not severally, agrees to purchase from the Company on the Closing Date (as defined below) Warrants to initially acquire up to that aggregate number of Warrant Shares underlying the Warrants as set forth on each Investor’s signature page hereto (the “Closing”).

(b) Closing Date. The date and time of the Closing (the “Closing Date”) shall be the date and time of (or such time immediately following) the closing of the PIPE Transaction, so long as the Closing set forth in Sections 6(a) and 7(a) below are satisfied or waived (or such other date as is mutually agreed to by the Company and the Investors). As used herein “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in either The City of New York or Ireland are authorized or required by law to remain closed.

(c) Form of Payment. At the Closing, (i) each Investor, shall pay the amount for the Warrants as set forth on each Investor’s signature page hereto in U.S. dollars to the Company through the procedures communicated by the Company, and (ii) the Company shall deliver to each Investor Warrants to initially acquire up to that aggregate number of Warrant Shares underlying the Warrants, as set forth on each Investor’s signature page hereto. The Investors and the Company acknowledge that the amount paid at Closing shall include the nominal value of Warrant Shares which may be issued in accordance with paragraph 4(c) of the Warrants and that such amount shall be held by the Company to each Investor’s order pending exercise of the Warrants.

2.	INVESTORS REPRESENTATIONS AND WARRANTIES.

The Investors represent and warrant to the Company that, as of the date hereof and as of the Closing Date:

(a) Organization; Authority. Each Investor is either an individual or an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents (as defined below) (the “Transactions”) to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

(b) No Public Sale or Distribution. Each Investor (i) is acquiring the Warrants, and (ii) upon exercise of the Warrants will acquire the Warrant Shares issuable upon exercise thereof, in each case, for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act. The Investors do not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities in violation of applicable securities laws. For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any department or agency thereof.

(c) Reliance on Exemptions. Each Investor understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and each Investor’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of each Investor set forth herein in order to determine the availability of such exemptions and the eligibility of each Investor to acquire the Securities.

(d) Information. Each Investor and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities that have been requested by each Investor. Each Investor and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other due diligence investigations conducted by each Investor or its advisors, if any, or its representatives shall modify, amend or affect each Investor’s right to rely on the Company’s representations and warranties contained herein. Each Investor understands that its investment in the Securities involves a high degree of risk. Each Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.

(e) No Governmental Review. Each Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

(f) Transfer or Resale. Each Investor understands that: (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) Investors shall have delivered to the Company (if requested by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) Investors provide the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”); and (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) promulgated thereunder.

(g) Validity; Enforcement. This Agreement and the Transaction Documents to which each Investor is a party have been duly and validly authorized, executed and delivered on behalf of each Investor and shall constitute the legal, valid and binding obligations of each Investor enforceable against each Investor in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

(h) No Conflicts. The execution, delivery and performance by each Investor of this Agreement and the Transaction Documents to which each Investor is a party and the consummation by each Investor of the Transactions will not (i) result in a violation of the organizational documents of each Investor, or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which each Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to each Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of each Investor to perform its obligations hereunder.

(i) Foreign Person. If an Investor is not a United States person (as defined by Section 7701(a)(30) of the Code), the Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Securities or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Securities, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Securities. Each Investor’s subscription and payment for and continued beneficial ownership of the Securities will not violate any applicable securities or other laws of each Investor’s jurisdiction.

(j) Residence. The office or offices of each Investor in which it has its principal place of business is identified in the address or addresses of each Investor set forth on each Investor’s signature page or otherwise has been provided to the Company.

(k) No Other Representations or Warranties. Except for the representations and warranties contained in the Transaction Documents and in Section 3 of this Agreement, neither the Company, nor any Person on behalf of the Company, has made, and Investors have not relied on, any other representation and warranty, express or implied, relating to the Company, its Subsidiaries, the business of the Company or otherwise in connection with the Transactions or the results of operations or financial condition of the Company, including any representations or warranties as to the future sales, revenue, profitability or success of the business, or any representations or warranties arising from statute or otherwise, from a course of dealing or usage of trade.

3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

The Company represents and warrants to Investors that the following representations are true and correct as of the date hereof and as of the Closing Date. As used herein, the phrase “to the Company’s knowledge” shall mean the actual or constructive knowledge of any executive officer of the Company as of such time of determination, after due inquiry.

(a) Organization and Qualification. Each of the Company and each of its Subsidiaries are entities duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below). As used in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary, individually or taken as a whole, (ii) the Transactions or (iii) the authority or ability of the Company or any of its Subsidiaries to perform any of their respective obligations under any of the Transaction Documents. Other than SS Juve Stabia Srl and Brera Strumica FC, the Company has no significant Subsidiaries. “Subsidiaries” means any Person in which the Company, directly or indirectly, (I) owns any of the outstanding share capital or holds any equity or similar interest of such Person or (II) controls or operates all or any part of the business, operations or administration of such Person, and each of the foregoing, is individually referred to herein as a “Subsidiary.”

(b) Authorization; Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents by the Company, and the consummation by the Company of the Transactions (including, without limitation, the issuance of the Warrants and the reservation for issuance and issuance of the Warrant Shares issuable upon exercise of the Warrants as of the Closing Date) have been duly authorized by the Company’s board of directors and (other than the filing of a notice of listing of additional shares with Nasdaq Stock Market LLC (“Nasdaq”), and any filing(s) required by applicable state “blue sky” securities laws, rules and regulations (together the “Securities Filings”)) no further filing, consent or authorization is required by the Company, its board of directors or its shareholders. This Agreement has been duly executed and delivered by the Company, and constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law and except as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. “Transaction Documents” means, collectively, this Agreement, the Warrants, and each of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the Transactions, as may be amended from time to time.

(c) Issuance of Securities. The issuance of the Warrants at the Closing is duly authorized and upon issuance in accordance with the terms of the Transaction Documents shall be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances, security interests and other encumbrances (collectively “Liens”) with respect to the issuance thereof. Upon exercise in accordance with the Warrants, the Warrant Shares, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Ordinary Shares. Subject to the accuracy of the representations and warranties of Investors in this Agreement, the offer and issuance by the Company of the Securities is exempt from registration under the 1933 Act.

(d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the Transactions (including, without limitation, the issuance of the Warrants and the Warrant Shares) will not (i) result in a violation of the Company’s Constitution (as the same may be amended or restated from time to time, the “Constitution”) (including, without limitation, any certificate of designations, as the same may be amended or restated from time to time), or any share capital or other securities of the Company, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.

(e) Consents. Assuming the accuracy of the representations made by Investors in Section 2, the Company is not required to obtain any consent from, authorization or order of, or make any filing or registration with (other than the Securities Filings), any Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its respective obligations under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. “GovernmentalEntity” means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public international organization or any of the foregoing.

(f) No Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of shareholders of the Company for purposes of the 1933 Act or under any applicable shareholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation. None of the Company, its Subsidiaries, their affiliates nor any Person acting on their behalf have taken any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act or cause the offering of any of the Securities to be integrated with other offerings of securities of the Company.

(g) Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, interested shareholder, business combination, poison pill (including, without limitation, any distribution under a rights agreement), shareholder rights plan or other similar anti-takeover provision under the Constitution or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is or could become applicable to Investors as a result of the Transactions, including, without limitation, the Company’s issuance of the Securities and each Investor’s ownership of the Securities. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any shareholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Ordinary Shares or a change in control of the Company.

(h) Material Liabilities; Financial Information. The Company has no liabilities or obligations, absolute or contingent (individually or in the aggregate), except obligations under contracts made in the ordinary course of business that as of the date of this Agreement would not be required to be reflected in financial statements prepared in accordance with International Financial Reporting Standard as issued by the International Accounting Standards Board, consistently applied for the periods covered thereby (“IFRS”). The Financial Statements (as defined below) fairly present in all material respects the financial position of the Company at the respective dates thereof. The Company is not currently contemplating to amend or restate any of the Financial Statements, nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with IFRS. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.

(i) SEC Reports. Financial Statements. In the past twelve months, the Company has complied in all material respects with requirements to file all reports, schedules, forms, statements and other documents required to be filed by it under the 1933 Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d) thereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SECReports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the 1933 Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with IFRS, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by IFRS, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal year-end audit adjustments that are not expected to be material in the aggregate. The financial statements, including the notes thereto and supporting schedules included in the SEC Reports, fairly present in all material respects the financial position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with IFRS, consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by IFRS); and the supporting schedules included in the SEC Reports present fairly in all material respects the information required to be stated therein. Except as disclosed in the SEC Reports, (a) the Company has not incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its share capital, (c) there has not been any change in the share capital of the Company (other than (i) grants under any share compensation plan and (ii) Ordinary Shares issued upon exercise of option, warrants or convertible securities described in the SEC Reports), and (d) there has not been any Material Adverse Effect in the Company’s long-term or short-term debt.

(j) Accounting Controls. The Company maintains systems of “internal control over financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act regulations) that comply in all material respects with the requirements of the Exchange Act and have been designed by, or under the supervision of, its principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Based on a review conducted by executive officers of the Company, the Company’s internal control over financial reporting as of December 31, 2024, was not effective. Except as disclosed in the SEC Reports, the Company is not aware of any material weaknesses in its internal controls. The Company’s independent auditor and the audit committee of the board of directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses, if any, in the design or operation of internal controls over financial reporting which are known to the Company’s management and that have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, if any, known to the Company’s management, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

(k) Related Party Transactions. There are no business relationships or related party transactions involving the Company or any other person required to be described in the SEC Reports that have not been described as required.

(l) No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist based on events or circumstances that have occurred on or prior to the date hereof with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities, operations (including results thereof) or condition (financial or otherwise), that could reasonably be expected to have a Material Adverse Effect.

(m) Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in material violation of any term of or in default under its constitution, organizational charter, certificate of formation, memorandum of association, articles of association, or certificate of incorporation (including any certificate of designation) or bylaws or any other organizational documents or any of its material indebtedness, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for possible violations which would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries.

(n) [Reserved].

(o) Litigation. There is no action, suit, arbitration, proceeding, inquiry or investigation before or by any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to the Company’s knowledge, threatened in writing against or affecting the Company or any of its Subsidiaries, the Ordinary Shares or any of the Company’s or its Subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such. The Company is not aware of any fact which might result in or form the basis for any such action, suit, arbitration, investigation, inquiry or other proceeding. Neither the Company nor any of its Subsidiaries is subject to any order, writ, judgment, injunction, decree, determination or award of any Governmental Entity.

(p) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its filings under the Exchange Act and is not so disclosed or that otherwise would be reasonably likely to have a Material Adverse Effect.

(q) Foreign Corrupt Practices Act. Neither the Company nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or any other person acting on behalf of the Company, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any Governmental Entity or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) tha (i) might subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Effect or (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.

(r) Compliance with OFAC. Neither of the Company or its Subsidiaries nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or its Subsidiaries or any other person acting on behalf of the Company, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), and the Company and its Subsidiaries will not, directly or indirectly, use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

(s) Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(t) Sarbanes-Oxley Compliance.

(i) The Company and its Subsidiaries has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange Act regulations applicable to it, and except as disclosed in the SEC Reports, such controls and procedures are effective to ensure that all material information concerning the Company or its Subsidiaries will be made known on a timely basis to the individuals responsible for the preparation of the Company’s Exchange Act filings and other public disclosure documents.

(ii) The Company and its Subsidiaries are, and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”) applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company’s and its Subsidiaries future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.

4.	COVENANTS.

(a) Commercially Reasonable Efforts. The Company and Investors shall each use commercially reasonable efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in this Agreement.

(b) Books and Records. The Company will keep proper books of record and account, in which full and correct entries shall be made of all financial transactions and the asset and business of the Company in accordance with IFRS.

(c) Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no affiliate of the Company shall, sell, offer for sale, or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the 1933 Act of the sale of the Securities to Investors.

(d) Available Shares. The Company shall at all times keep authorized and available for issuance, free of preemptive rights, the minimum number of Warrant Shares issuable upon exercise in full of all Warrants at the exercise price in effect on such date.

(e) Securities Laws Disclosure; Publicity. The Company shall, within four (4) Trading Days following the date hereof, file a Current Report on Form 6-K report or other public disclosure disclosing the material terms of the Transactions and including this Agreement as an exhibit thereto. Investors will promptly provide any information reasonably requested by the Company or any of its affiliates for any regulatory application or filing made or to be made or approval sought in connection with the Transactions (including filings with the SEC).

(f) Exercise Procedures. The form of Exercise Notice (as defined in the Warrants) included in the Warrants set forth the totality of the procedures required of each Investor in order to exercise the Warrants.

The Company shall honor exercises of the Warrants and shall deliver the Warrant Shares in accordance with the terms, conditions and time periods set forth in the Warrants

(g) Listing of Shares. Within two (2) Business Days following the execution of this Agreement, the Company shall file with Nasdaq a listing of additional shares form reflecting the Transactions. The Company covenants to take all reasonable steps to be in compliance with all listing and maintenance requirements of Nasdaq.

5.	REGISTER; LEGENDS.

(a) Register. The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate by notice to each holder of Securities), a register for the Warrants in which the Company shall record the name and address of the Person in whose name the Warrants have been issued (including the name and address of each transferee), and the number of Warrant Shares issuable upon exercise of the Warrants held by such Person.

(b) Legends. Each Investor understands that the Securities have been issued (or will be issued in the case of the Warrant Shares) pursuant to an exemption from registration or qualification under the 1933 Act and applicable state securities laws, and except as set forth below, the Securities shall bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such share certificates):

[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [EXERCISABLE] HAVE BEEN] [THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

(c) Registration Rights. At the Closing, the Company on the one hand, and the Investors, on the other hand, shall enter into a registration rights agreement, in the form set forth as Exhibit B to this Agreement (the “RegistrationRights Agreement”), pursuant to which the Company shall grant the Investors certain registration rights with respect to the Warrant Shares. The execution and delivery of the Registration Rights Agreement by the Company and the Investors shall be a condition precedent to the obligations of the parties to consummate the Transactions.

6.	CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

The obligation of the Company hereunder to issue and sell the Warrants to Investors at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing Investors with prior written notice thereof:

(a) Investors shall have executed each of the other Transaction Documents to which it is a party and delivered the same to the Company.

(b) The representations and warranties of Investors shall be true and correct in all material respects as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date), and Investors shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by Investors at or prior to the Closing Date.

(c) No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the Transactions.

(d) The closing of the PIPE Transaction shall have occurred or shall occur concurrently.

7.	CONDITIONS TO INVESTORS’ OBLIGATION TO PURCHASE.

The obligation of Investors hereunder to purchase the Warrants at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for Investors’ sole benefit and may be waived by Investors at any time in its sole discretion by providing the Company with prior written notice thereof:

(a) The Company shall have duly executed and delivered to Investors each of the Transaction Documents to which it is a party and the Company shall have duly executed and delivered to Investors the Warrants (initially for such aggregate number of Warrant Shares as set forth on Investors’ signature page hereto), as being purchased by Investors at the Closing pursuant to this Agreement.

(b) The representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date), and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.

(d) The Company shall have obtained all governmental, regulatory or third-party consents and approvals, if any, necessary for the issuance and sale of the Securities, including without limitation, the approval of the Listing Application.

(e) Investors shall have received an opinion of Sichenzia Ross Ference Carmel LLP, the Company’s United States counsel, dated as of the Closing Date in form and substance acceptable to Investors to the effect that the Securities to be issued and sold, have been issued and sold pursuant to an exemption from registration.

(f) The closing of the PIPE Transaction shall have occurred or shall occur concurrently.

8.	TERMINATION.

This Agreement may be terminated and the Transactions may be abandoned, at any time prior to the Closing, as follows:

(a) by mutual written agreement of the Parties;

(b) by either the Investors or the Company, upon written notice, if for any reason the PIPE SPA terminates in accordance with its terms prior to the Closing;

(c) by either the Investors or the Company, if a court of competent jurisdiction or other governmental authority shall have issued a final and nonappealable order, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Transactions;

(d) by the Investors, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in Section 7(b) would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; or

(e) by the Investors if the Ordinary Shares have been suspended by the SEC or Nasdaq from trading on Nasdaq.

9.	MISCELLANEOUS.

(a) Governing Law; Jurisdiction; Jury Trial.

(i) This Agreement, and any claims or proceedings arising out of this Agreement or the subject matter hereof (whether at law or equity, in contract or in tort or otherwise), shall be governed by and construed in accordance with the laws of the State of Delaware without regard to the conflict of law principles thereof (or any other jurisdiction) to the extent that such principles would direct a matter to another jurisdiction.

(ii) This Agreement and all matters arising out of or relating to this Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction). Any legal suit, action, proceeding, or dispute arising out of or related to this Agreement or the Transactions may be instituted in the federal courts of the United States of America or the courts of the State of New York (the “Chosen Courts”), and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, proceeding, or dispute.

(iii) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY BE IN CONNECTION WITH, ARISE OUT OF OR OTHERWISE RELATE TO THIS AGREEMENT, ANY INSTRUMENT OR OTHER DOCUMENT DELIVERED PURSUANT TO THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY PROCEEDING DIRECTLY OR INDIRECTLY, IN CONNECTION WITH, ARISING OUT OF OR OTHERWISE RELATING TO THIS AGREEMENT, ANY INSTRUMENT OR OTHER DOCUMENT DELIVERED PURSUANT TO THIS AGREEMENT. EACH PARTY HEREBY ACKNOWLEDGES AND CERTIFIES (i) THAT NO REPRESENTATIVE OF THE OTHER PARTIES HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTIES WOULD NOT, IN THE EVENT OF ANY ACTION OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) IT MAKES THIS WAIVER VOLUNTARILY AND (iv) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS, ACKNOWLEDGMENTS AND CERTIFICATIONS CONTAINED IN THIS SECTION 9(a).

(b) Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

(c) Headings; Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

(d) Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Agreement will not in any way be affected or impaired thereby.

(e) Entire Agreement; Release.

(i) This Agreement (including the exhibits and annexes) and the Transaction Documents constitute the entire agreement among the Parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous agreements, negotiations, understandings, and representations and warranties, whether oral or written, with respect to such matters.

(ii) Each Party acknowledges and agrees that, except for the representations and warranties expressly set forth in Section 2 and Section 3, in the Transaction Documents or in any agreement, certificate, instrument or other document delivered pursuant to this Agreement or the Transaction Documents, (i) no Party has made or is making any representations, warranties or inducements, (ii) no Party has relied on or is relying on any representations, warranties, inducements, statements, materials or information (including as to the accuracy or completeness of any statements, materials or information) and (iii) each Party hereby disclaims reliance on any representations, warranties, inducements, statements, materials or information (whether oral or written, express or implied, or otherwise) or on the accuracy or completeness of any statements, materials or information, in each case of clauses (i) through (iii), relating to or in connection with the negotiation, execution or delivery of this Agreement or any Transaction Documents, the agreements, certificates, instruments or other documents delivered pursuant to this Agreement or the Transaction Documents, or the Transactions. Each Party hereby releases, discharges, ceases and waives any and all claims, demands, liabilities, obligations, debts, damages, losses, expenses, costs and proceedings (whether in contract or in tort, in law or in equity, or granted by statute) relating to the making (or alleged making) of any representations, warranties or inducements, the disclosure or making available of any statements, materials or information (or the accuracy or completeness thereof), or the reliance on (or alleged reliance on) any representations, warranties, inducements, statements, materials or information (including the accuracy or completeness of any statements, materials or information), except for such claims, demands, liabilities, obligations, debts, damages, losses, expenses, costs and proceedings arising from fraud with respect to the representations and warranties expressly set forth in Section 2 and Section 3, in the Transaction Documents or in any agreement, certificate, instrument or other document delivered pursuant to this Agreement or the Transaction Documents

(f) Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by electronic mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient’s email server that such e-mail could not be delivered to such recipient); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. The mailing addresses and e-mail addresses for such communications shall be:

If to the Company:

Brera Holdings PLC

Connaught House, 5th Floor

One Burlington Road

Dublin 4, D04 C5Y6

Republic of Ireland

Attention: Chief Executive Officer

With a copy (for informational purposes only) to:

mailto:Sichenzia Ross Ference Carmel LLP

1185 Avenue of Americas. 31^st^ Floor

New York, NY 10036 USA

Attention: Ross D. Carmel, Esq.

Email: [email protected]

If to Investors, to its mailing address and e-mail address set forth on each Investor’s signature page hereto, with copies to each Investor’s representatives as set forth on each Investor’s signature page hereto, or to such other mailing address and/or e-mail address and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s e-mail containing the time, date and recipient’s e-mail or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by e-mail or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

(g) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of the Warrants.

(h) No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

(i) Amendments and Modifications. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and each Investor which purchased at least majority in interest of the aggregate Warrant Shares issued or issuable pursuant to this Agreement (or, prior to the Closing, the Company and Investors) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts an Investor, the consent of that Investor also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any amendment effected in accordance with this Section 9(i) shall be binding upon Investors and the Company.

(j) Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the Transactions.

(k) Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents.

(l) Remedies. Each of the Parties acknowledges and agrees that the rights of each Party to consummate the Transactions are special, unique and of extraordinary character and that if for any reason any of the provisions of this Agreement are not performed or complied with in accordance with their terms or are otherwise breached, immediate and irreparable harm or damage would be caused for which money damages would not be an adequate remedy. Accordingly, each Party agrees that, in addition to any other available remedies a Party may have in equity or at law, each Party shall be entitled to equitable remedies against another Party for its breach or threatened breach of this Agreement, including to enforce specifically the terms and provisions of this Agreement or to obtain an injunction restraining any such breach or threatened breach of the provisions of this Agreement in the Chosen Courts, in each case, (i) without necessity of posting a bond or other form of security and (ii) without proving the inadequacy of money damages or another any remedy at law. In the event that a Party seeks equitable remedies in any proceeding (including to enforce the provisions of this Agreement or prevent breaches or threatened breaches of this Agreement), no Party shall raise any defense or objection, and each Party hereby waives any and all defenses and objections, to such equitable remedies on grounds that (x) money damages would be adequate or there is another adequate remedy at law or (y) the Party seeking equitable remedies must either post a bond or other form of security and prove the inadequacy of money damages or another any remedy at law.

(m) Expenses. Whether or not the Closing occurs, all costs and expenses incurred in connection with the preparation, negotiation, execution and performance of this Agreement, the Transaction Documents and the Transactions, including all fees and expenses of its Representatives, shall be paid by the Party incurring such expense.

[Signature page follows]

Execution Version

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first written above.

COMPANY:

Brera Holdings PLC

By:
	Name:
	Title:

[Signature Pagesto Warrant Purchase Agreement]

IN WITNESS WHEREOF, the undersigned has caused this Agreement to be duly executed by its respective authorized signatory as of the date first indicated above.

Funding Amount: $1,036,80

Warrant Shares Underlying Warrants: 103,680

Name of Investor: Guy Hirsch

Signature of Authorized Signatory of Investor: /s/ Guy Hirsch

Name of Authorized Signatory: Guy Hirsch

Title of Authorized Signatory: Investor

Address for Notice to Investor:

Email Address of Authorized Signatory:

Address for Delivery of Securities to Investor (if not same as address for notice):

EIN Number: ______________________________________

Address for a mandatory copy to counsel for Investor

(which shall not constitute notice):

[Signature Pages to WarrantPurchase Agreement]

IN WITNESS WHEREOF, the undersigned has caused this Agreement to be duly executed by its respective authorized signatory as of the date first indicated above.

Funding Amount: $1,036,80

Warrant Shares Underlying Warrants: 103,680

Name of Investor: Keren Kalima Maimon

Signature of Authorized Signatory of Investor: /s/ Keren Maimon

Name of Authorized Signatory: Keren Maimon

Title of Authorized Signatory: __________________

Address for Notice to Investor:

Email Address of Authorized Signatory:

Address for Delivery of Securities to Investor (if not same as address for notice):

EIN Number: _____________________________________

Address for a mandatory copy to counsel for Investor

(which shall not constitute notice):

[Signature Pages to WarrantPurchase Agreement]

IN WITNESS WHEREOF, the undersigned has caused this Agreement to be duly executed by its respective authorized signatory as of the date first indicated above.

Funding Amount: $1,036,80

Warrant Shares Underlying Warrants: 103,680

Name of Investor: Ron Sade

Signature of Authorized Signatory of Investor: /s/ Ron Sade

Name of Authorized Signatory: Ron Sade

Title of Authorized Signatory: Partner

Address for Notice to Investor:

Email Address of Authorized Signatory:

Address for Delivery of Securities to Investor (if not same as address for notice):

EIN Number: ____________________________________

Address for a mandatory copy to counsel for Investor

(which shall not constitute notice):

[Signature Pages to WarrantPurchase Agreement]

IN WITNESS WHEREOF, the undersigned has caused this Agreement to be duly executed by its respective authorized signatory as of the date first indicated above.

Funding Amount: $1,036,80

Warrant Shares Underlying Warrants: 103,680

Name of Investor: Alyazi Saeed Ahmed Alkhattal Almheiri

Signature of Authorized Signatory of Investor: /s/ Alyazi Saeed Ahmed Alkhattal Almheiri

Name of Authorized Signatory: Alyazi Saeed Ahmed Alkhattal Almheiri

Title of Authorized Signatory:

Address for Notice to Investor:

Email Address of Authorized Signatory:

Address for Delivery of Securities to Investor (if not same as address for notice):

EIN Number: ____________________________________

Address for a mandatory copy to counsel for Investor

(which shall not constitute notice):

[Signature Pages to WarrantPurchase Agreement]

IN WITNESS WHEREOF, the undersigned has caused this Agreement to be duly executed by its respective authorized signatory as of the date first indicated above.

Funding Amount: $2,073.60

Warrant Shares Underlying Warrants: 207,360

Name of Investor: Tariq Salem Ebraheem Alsaman Alnuaimi

Signature of Authorized Signatory of Investor: /s/ Tariq Salem Ebraheem Alsaman Alnuaimi

Name of Authorized Signatory: Tariq Salem Ebraheem Alsaman Alnuaimi

Title of Authorized Signatory:

Address for Notice to Investor:

Email Address of Authorized Signatory:

Address for Delivery of Securities to Investor (if not same as address for notice):

EIN Number: _____________________________________

Address for a mandatory copy to counsel for Investor

(which shall not constitute notice):

[Signature Pages to WarrantPurchase Agreement]

Exhibit A

Form of Warrant

[See attached]

Form of Warrant

NEITHER THIS WARRANT NOR THE SECURITIESINTO WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERREDOR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIESLAWS, OR AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OR APPLICABLESTATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT.

BRERA HOLDINGS PLC

CLASS B ORDINARY SHARE PURCHASE WARRANT

Warrant No. _______________	Original Issue Date: September [●], 2025
Initial Holder:	No. of Shares Subject to Warrant: ____________________
	Initial Exercise Price Per Share: $1.50 (subject to the adjustment pursuant to Section 9)
	Expiration Time: 5:00 p.m., Eastern time, on ______________, 2030

Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the “Company”), hereby certifies that, for value received, the Initial Holder shown above, or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to the number of Class B Ordinary Shares, $0.05 nominal value per share (the “Class B Ordinary Shares”), shown above (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at the exercise price shown above (as may be adjusted from time to time as provided herein, the “Exercise Price”), at any time and from time to time on or after the original issue date indicated above (the “Original Issue Date”) and through and including the expiration time shown above (the “Expiration Time”), and subject to the following terms and conditions:

This Warrant is being issued pursuant to a Warrant Purchase Agreement, dated September [•], 2025 (the “Warrant Purchase Agreement”), by and among the Company, the Initial Holder and the other parties thereto.

Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Warrant Purchase Agreement.
List of Warrant Holders. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the Initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned hereunder from time to time). The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

1
List of Transfers; Restrictions on Transfer. The Company shall register any transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto as Exhibit B duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a new Warrant to purchase Class B Ordinary Shares, in substantially the form of this Warrant (any such new Warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant.
Exercise and Duration of Warrant.

(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Section 4 at any time and from time to time on or after the Original Issue Date and through and including the Expiration Time. At the Expiration Time, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be terminated and shall no longer be outstanding.

(b) The Holder may exercise this Warrant by delivering to the Company: (i) an exercise notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), completed and duly signed, and (ii) if such Holder is not utilizing the cashless exercise provisions set forth in this Warrant, payment by wire transfer of immediately available funds to an account designated by the Company of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised. The date such items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

(c) Cashless Exercise. In lieu of exercising this Warrant by making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Exercise Price, the Holder may elect to receive the number of Class B Ordinary Shares equal to the value of this Warrant (or the portion thereof being exercised), by surrender of this Warrant to the Company, together with the exercise form attached hereto, in which event the Company will issue to the Holder the number of Class B Ordinary Shares in accordance with the following formula (a “Cashless Exercise”):

X	=	Y(A-B) A
Where,
X	=	The number of Class B Ordinary Shares to be issued to the Holder;
Y	=	The number of Class B Ordinary Shares for which the Warrant is being exercised;
A	=	The fair market value of one Class B Ordinary Share; and
B	=	The Exercise Price.

For purposes of Section 4(c), the fair market value means, for any date, the price determined by the first of the following clauses that applies: (a) if the Class B Ordinary Shares are then listed or quoted on an Eligible Market, the value shall be deemed to be the highest daily price on any trading day on such Eligible Market on which the Class B Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on New York City time) during the five trading days preceding the exercise, (b) if the OTCQB Venture Market (“OTCQB”) service or the OTCQX Best Market (“OTCQX”) service of OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices, the “OTC Markets Group”) is not an Eligible Market, the value shall be deemed to be the highest daily price on any trading day on the OTCQB or the OTCQX on which the Class B Ordinary Shares are then quoted as reported by Bloomberg L.P. (based on New York City time) during the five trading days preceding the exercise, as applicable, (c) if the Class B Ordinary Shares are not then listed or quoted for trading on the OTCQB or the OTCQX and if prices for the Class B Ordinary Shares are then quoted on the Pink Open Market service of OTC Markets (or a similar organization or agency succeeding to its functions of reporting prices) (the “Pink Sheets”), the value shall be deemed to be the highest daily price on any trading day on the Pink Sheets on which the Class B Ordinary Shares are then quoted as reported by OTC Markets Group (based on New York City time) during the five trading days preceding the exercise, or (d) in all other cases, the fair market value of a Class B Ordinary Share as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. “Eligible Market” means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, any Electronic Communication Network or any Alternative Trade Facility.

For purposes of Rule 144(d) promulgated under the Securities Act, as in effect on the date hereof, assuming the Holder is not an affiliate of the Company, it is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the closing date of the Offering pursuant to which the Company was obligated to issue this Warrant.

(d) The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant pursuant to the terms hereof.

Delivery of Warrant Shares.

(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than two (2) business days after the Exercise Date) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate, a certificate or book entry receipt for the Warrant Shares issuable upon such exercise, free of restrictive legends. The Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date. The Company shall, upon the written request of the Holder, use its best efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through the Depository Trust and Clearing Corporation or another established clearing corporation performing similar functions, if available; provided, that, the Company may, but will not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant Shares electronically through the Depository Trust and Clearing Corporation. If as of the time of exercise the Warrant Shares constitute restricted or control securities, the Holder, by exercising, agrees not to resell them except in compliance with all applicable securities laws.

(b) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates or book entry receipts representing Class B Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.

(c) If the Company fails to cause its transfer agent to transmit to the Holder a certificate(s) or book entry receipt(s) (either physical or electronic) representing the Warrant Shares pursuant to the terms hereof by applicable delivery date, then, the Holder will have the right to rescind such exercise.

Charges, Taxes and Expenses. Issuance and delivery of certificates or book entry receipts for Class B Ordinary Shares upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates or book entry receipts, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates or book entry receipts for Warrant Shares or the Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.
Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Class B Ordinary Shares, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.

4
Certain Adjustments to Exercise Price. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

(a) Adjustments for Share Splits and Combinations and Share Dividends. If the Company shall at any time or from time to time after the date hereof, effect a share split or combination of the outstanding Class B Ordinary Shares or pay a share dividend in Class B Ordinary Shares, then the Exercise Price shall be proportionately adjusted. Any adjustments under this Section 9(a) shall be effective at the close of business on the date the share split or combination becomes effective or the date of payment of the share dividend, as applicable.

(b) Merger Sale, Reclassification, etc. In case of any: (i) consolidation or merger (including a merger in which the Company is the surviving entity), (ii) sale or other disposition of all or substantially all of the Company’s assets or distribution of property to shareholders (other than distributions payable out of earnings or retained earnings), or reclassification, change or conversion of the outstanding securities of the Company or of any reorganization of the Company (or any other corporation the shares or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization on or after the date hereof (each, a “Fundamental Transaction”), then in each such case the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 9(b) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of share capital of such Successor Entity (or its parent entity) equivalent to the Class B Ordinary Shares acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such share capital (but taking into account the relative value of the Class B Ordinary Shares pursuant to such Fundamental Transaction and the value of such share capital, such number of share capital and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the Exercise Price.
Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be delivered in accordance with the procedures set forth in the Warrant Purchase Agreement.
Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

5
Miscellaneous.

(a) This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.

(b) All questions concerning the construction, validity, enforcement and interpretation of this Warrant and the Warrant Purchase Agreement shall be governed by and construed and enforced solely and exclusively in accordance with the laws of Ireland without reference to the principles thereof relating to the conflict of laws. The Company and Holder agree that courts of competent jurisdiction in Dublin, Ireland shall have jurisdiction with regard to any action arising out of any breach or alleged breach of this Agreement. The Company and Holder agree to submit to the personal jurisdiction of such courts and any other applicable court within Ireland. The Company and Holder further agree that the mailing of any process shall constitute valid and lawful process against each Party hereto. The Company and Holder waive any claim that any of the foregoing courts is an inconvenient forum. EACH PARTY HERETO (INCLUDING ITS AFFILIATES, AGENTS, OFFICERS, DIRECTORS AND EMPLOYEES) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

(c) The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

(d) In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

(e) Prior to exercise of this Warrant, the Holder hereof shall not, by reason of being a Holder, be entitled to any rights of a shareholder with respect to the Warrant Shares.

(f) No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Class B Ordinary Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

[Signature Page Follows]

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

BRERA HOLDINGS PLC
By:
Name:	Fabio Scacciavillani
Title:	Chief Executive Officer

EXHIBIT A

EXERCISE NOTICE

TO:	BRERA HOLDINGS PLC

(the “Company”)

(1) The undersigned hereby elects to purchase _______________Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

☐ in lawful money of the United States under Section 4(b); or

☐ if permitted Cashless Exercise in accordance with the formula under Section 4(c).

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_________________________________

[SIGNATURE OF HOLDER]

Name of Holder: _____________________________________________________________________

Signature of Authorized Signatory of Holder: _______________________________________________

Name of Authorized Signatory: ___________________________________________________________

Title of Authorized Signatory: ____________________________________________________________

Date: _______________________________________________________________________________

EXHIBIT B

FORM OF ASSIGNMENT

To be completed and signed only upon transfer of Warrant

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto_______________ the right represented by the within Warrant to purchase Class B Ordinary Shares to which the within Warrant relates and appoints any officer of the Company attorney to transfer said right on the books of the Company with full power of substitution in the premises.

Dated: __________________________	TRANSFEROR:
	Print name
	By:
	Title:
	TRANSFEREE:
	Print name
	By:
	Title:
WITNESS:	Address of Transferee:
Print name

Exhibit B

Form of Registration Rights Agreement

[See attached]

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is dated as of September 22, 2025, by Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the “Company”), and the Persons identified as “Investors” on the signature pages hereto (each an “Investor” and collectively, the “Investors”) (for each Investor, together with its respective successors and assigns).

WHEREAS, the Company has agreed to provide certain registration rights to the Investors in order to induce the Investors to enter into that certain Warrant Purchase Agreement by and among the Company and the Investors dated as of the date hereof (the “Warrant Purchase Agreement”).

Now, therefore, in consideration of the mutual promises and the covenants as set forth herein, the parties hereto hereby agree as follows:

Definitions. Unless the context otherwise requires, capitalized words and terms used herein without definition and defined in the Warrant Purchase Agreement are used herein as defined therein. Notwithstanding the foregoing, as used herein the capitalized words and terms defined in this Section 1 shall have the meanings herein specified for all purposes of this Agreement, applicable to both the singular and plural forms of any of the terms herein defined:

“Agreement” means this Registration Rights Agreement, as the same may be amended, modified, or supplemented in accordance with the terms hereof.

“Board” means the Board of Directors of the Company.

“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

“Company” has the meaning assigned to it in the introductory paragraph of this Agreement.

“Exchange Act” means the Securities Exchange Act of 1934 (or successor statute).

“Excluded Forms” means Registration Statements under the Securities Act on Forms S-4 and S-8 or any successors.

“Filing Date” has the meaning assigned to it in Section 3(a) of this Agreement.

“Investor(s)” has the meaning assigned to it in the introductory paragraph of this Agreement.

“Person” includes any natural person, corporation, trust, association, company, exempted company, partnership, joint venture, limited liability company and other entity and any government, governmental agency, instrumentality, or political subdivision.

“Proposed Registration” means any proposed Registration Statement to be filed pursuant to this Agreement.

The terms “register” “registered” and “registration” refer to a registration effected by preparing and filing a Registration Statement on other than any of the Excluded Forms in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such Registration Statement.

“Registration Statement” means any registration statement filed by the Company on behalf of the Investor that covers the resale of Registrable Securities under the provisions of this Agreement.

“Registrable Securities” means the Class B Ordinary Shares underlying the Warrants.

“Representatives” means all shareholders, officers, directors, members, managers, partners, employees and agents.

“Rule 144” has the meaning assigned to it in Section 7 of this Agreement.

“SEC” means the Securities and Exchange Commission or any other governmental body at the time administering the Securities Act.

“Securities Act” means the Securities Act of 1933 (or successor statute).

“Selling Expenses” means all selling commissions, underwriting discounts, other fees paid by the Investors to a broker-dealer, finder’s fees, and stock transfer taxes applicable to the Registrable Securities contained in a Registration Statement for the benefit of any Investor.

“Warrant Purchase Agreement” has the meaning assigned to it in the Recitals of this Agreement.

“Warrants” mean the Class B Ordinary Share Purchase Warrants purchased by the Investors pursuant to the Warrant Purchase Agreement.

RequiredRegistration. Within 30 days after the Closing, the Company shall file with the SEC a Registration Statement on Form F-3, or, if the Company is not then eligible to use Form F-3, on Form F-1, or any successor form covering the sale of all of the Registrable Securities.
Obligationsof the Company. If and whenever the Company is required by the provisions hereof to effect or cause the registration of any Registrable Securities under the Securities Act as provided herein, the Company shall:

(a) prepare and file with the SEC within the timeframe specified in Section 2, a Registration Statement with respect to such Registrable Securities (the “Filing Date”), and use its commercially reasonable efforts to cause such Registration Statement to become effective within 45 days after the Filing Date if the Staff of the SEC indicates to the Company that such Registration Statement will be subject to a “limited” review, or use its best efforts to cause such Registration Statement to become effective within 60 days after the Filing Date if the Staff of the SEC indicates to the Company that such Registration Statement will be subject to a “full” review, and to remain effective until the sale or other disposition of all Registrable Securities covered by such Registration Statement has occurred during such period in accordance with the intended methods of disposition by the Investors set forth in such Registration Statement (the “Effectiveness Period”), provided that before filing a Registration Statement or any amendment or supplement thereto, the Company will at least three Business Days prior to making any such filing furnish to each Investor a copy of the Registration Statement, as amended if applicable and any response letter or other correspondence to the Staff of the SEC proposed to be filed or submitted, and provide each Investor with a reasonable opportunity to review and provide comments or input on such Registration Statement and response letter or other correspondence, and address such comments or input so received from each Investor in good faith, prior to filing or submitting such documents. Notwithstanding anything to the contrary set forth herein, each Investor shall have the ability to approve, prior to filing or submission of any of the foregoing materials, any disclosure or communication with the SEC which directly relates to such Investor and the sale of Registrable Securities. Notwithstanding the above 45-day or 60-day periods, if the Staff of the SEC indicates to the Company that an applicable Registration Statement will not be reviewed, the Company shall promptly, but in no event later than two Business Days thereafter, cause such Registration Statement to become effective;

(b) subject to complying with Section 3(a), prepare and file with the SEC such amendments to any such Registration Statement (including post-effective amendments) and supplements to the prospectus included therein as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act during the Effectiveness Period;

(c) furnish to each Investor such number of copies of such Registration Statement and of each such amendment and supplement thereto (in each case including all exhibits), such number of copies of the prospectus included in such Registration Statement (including each preliminary prospectus), in conformity with the requirements of the Securities Act, and such other documents, as such Investor may reasonably request, in order to facilitate the public sale or other disposition of the Registrable Securities owned by such Investor;

(d) make such filings under the securities or blue sky laws of such states or commonwealths as an Investor may reasonably request to enable such Investor to consummate the sale;

(e) promptly notify each Investor at any time when a prospectus relating to their Registrable Securities is required to be delivered under the Securities Act, of the Company’s becoming aware that the prospectus included in the related Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and promptly prepare and furnish to such Investor a reasonable number of copies of a prospectus supplement or amendment so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus, as supplemented or amended, shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. In such event, the Company shall file a Form 6-K or amended prospectus or prospectus supplement within four Business Days in order to permit the Investor to be able to sell the Registrable Securities, which shall prior to filing first be provided to such Investor with a reasonable opportunity to review and provide comments and input;

(f) otherwise comply with all applicable rules and regulations of the SEC and to perform its obligations hereunder;

(g) cause the Registrable Securities to continue to be listed on the Principal Market;

(h) provide a transfer agent for all Registrable Securities and promptly pay all fees and costs of the transfer agent;

(i) notify the Investors of any stop order threatened or issued by the SEC and take all actions reasonably necessary to prevent the entry of such stop order or to remove it if entered; and

(j) promptly email the Investors copies of all comment letters, response letters and other communications from and with the Staff of the SEC, file an amendment to a Registration Statement within five Business Days, subject to extension upon consent of the Investors (which consent shall not be unreasonably withheld), after receipt of a comment letter or oral comments, and request acceleration of the effectiveness of the Registration Statement within two Business Days after the Company or its counsel has been advised that the Staff of the SEC will not review or has no further comments thereon, subject in each case to the Investors’ right to receive, and have a reasonable opportunity to review and provide comments and input on, such documents or communications prior to their respective filing or submission, as applicable.

(k) For purposes of this Agreement, any requirement on the part of the Company to provide, furnish copies of, notify and give an opportunity to provide comments or input regarding the Registration Statement, amendments, supplements, correspondence or other documents and communications to or with the SEC relating to the Registration Statement or otherwise contemplated by this Agreement to an “Investor” shall be deemed to include the Investor’s legal counsel, in addition to the Investor itself.

Subject to the Company’s ongoing compliance with Section 7, the Company’s obligations under this Section 3 with respect to any Registrable Securities proposed to be sold by an Investor shall not apply if, in the written opinion of counsel to the Company which has been issued to and accepted by the Transfer Agent with respect to such Registrable Securities and any other applicable third parties whose acceptance or approval thereof is necessary to effect a sale of such Registrable Securities by an Investor, all such Registrable Securities proposed to be sold by such Investor may then be sold unconditionally without registration in any ninety (90) day period pursuant to Rule 144 promulgated under the Securities Act without any limitations on volume. This paragraph shall cease to apply as to the Registrable Securities if and whenever such opinion of counsel has been withdrawn or rescinded or otherwise fails to comply with the conditions set forth in the preceding sentence, or if such conditions are otherwise not satisfied.

4. Other Procedures.

(a) Subject to the remaining provisions of this Section 4 and the Company’s general obligations under Section 3, the Company shall be required to maintain the effectiveness of a Registration Statement until the sale or other disposition of all Registrable Securities.

(b) In consideration of the Company’s obligations under this Agreement, each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(e) herein, such Investor shall forthwith discontinue its sale of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until the Investor’s receipt of the copies of the supplemented or amended prospectus contemplated by said Section 3(e).

(c) The Company’s obligation to file any Registration Statement or amendment including a post-effective amendment with respect to an Investor’s Registrable Securities, shall be subject to such Investor, as applicable, furnishing to the Company in writing such information and documents regarding the Investor and the distribution of such Investor’s Registrable Securities as may reasonably be required to be disclosed in the Registration Statement in question by the rules and regulations under the Securities Act or under any other applicable securities or blue sky laws of the jurisdiction referred to in Section 3(d) herein. The Company’s obligations are also subject to the Investor promptly executing any representation letter concerning compliance with Regulation M under the Exchange Act (or any successor rule or regulation). If an Investor fails to provide all of the information required by this Section 4(c), the Company shall have no obligation to include its Registrable Securities in a Registration Statement or it may withdraw such Investor’s Registrable Securities from the Registration Statement without incurring any penalty or otherwise incurring liability to such Investor.

(d) If any such registration or comparable statement refers to an Investor by name or otherwise as a shareholder of the Company, but such reference to such Investor by name or otherwise is not required by the Securities Act or the rules thereunder, then such Investor shall have the right to require the deletion of the reference to such Investor, as may be applicable.

(e) If as result of an SEC Staff policy, rule, or regulation or for any other reason, the Company is unable to register all Registrable Securities in one Registration Statement, then upon 30 days (or such earlier time as is permitted by the Staff of the SEC or any rule of the SEC) after any Registration Statement filed pursuant to this Agreement is declared effective by the SEC, the Company shall file another Registration Statement including all of the remaining Registrable Securities of the Investor, in which event the conditions of this Agreement shall apply; provided, however, in no event shall the Company delay the effective date of any Registration Statement for more than two Business Days after receipt of notice from the SEC Staff that it will either not review a Registration Statement or it has no further comments with respect to a Registration Statement.

5. RegistrationExpenses. In connection with any registration of Registrable Securities pursuant to Section 2, the Company shall, whether or not any such registration shall become effective, from time to time, pay all expenses (other than Selling Expenses) incident to its performance of or compliance, including, without limitation, all registration, and filing fees, fees and expenses of compliance with securities or blue sky laws, word processing, printing and copying expenses, messenger and delivery expenses, fees and disbursements of counsel for the Company and all independent public accountants and other Persons retained by the Company.

Indemnification.

(a) In the event of any registration of any shares of Common Stock under the Securities Act pursuant to this Agreement, the Company shall indemnify, defend and hold harmless each Investor, its Affiliates, and their respective Representatives, successors and assigns, from and against any losses, claims, damages or liabilities, joint or several, to which such Investor, its Affiliates, and its respective Representatives, successors and assigns may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Registration Statement under which such Registrable Securities were registered under the Securities Act, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereto, or any document incident to registration or qualification of any Registrable Securities pursuant to Section 3(d) herein, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or, with respect to any prospectus, necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, or any violation by the Company of the Securities Act, the Exchange Act, or state securities or blue sky laws or relating to action or inaction required of the Company in connection with such registration or qualification under the Securities Act or such state securities or blue sky laws. If the Company fails to defend an Investor, its Affiliates, and its respective Representatives, successors and assigns, as applicable, as required by Section 6(c) herein, it shall reimburse (after receipt of appropriate documentation) such Investor, its Affiliates, and its respective Representatives, successors and assigns for any legal or any other reasonable and documented out-of-pocket expenses incurred by any of them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company shall not be liable to such Investor, its Affiliates, or its respective Representatives, successors or assigns in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in said Registration Statement, said preliminary prospectus, said prospectus, or said amendment or supplement or any document incident to registration or qualification of any Registrable Securities pursuant to Section 3(d) hereof in reliance upon and in conformity with written information furnished to the Company by such Investor, its Affiliates, or its respective Representatives, successors or assigns specifically for use in the preparation thereof.

(b) In the event of any registration of any Registrable Securities under the Securities Act pursuant to this Agreement, the Investors shall, severally and not jointly, indemnify and hold harmless (in the same manner and to the same extent as set forth in Section 6(a)) the Company, each director of the Company, each officer of the Company who signs such Registration Statement, the Company’s attorneys and auditors and any Person who controls the Company within the meaning of the Securities Act, from and against any loss, claim, damage or liability that arises out of or is based upon any untrue statement or omission from such Registration Statement, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereto, if and to the extent that such untrue statement or omission was made in reliance upon and in conformity with written information furnished to the Company by an Investor specifically for use in the preparation of such Registration Statement, preliminary prospectus, final prospectus or amendment or supplement.

(c) Promptly after receipt by an indemnified party of notice of the commencement of any action involving a claim referred to in Section 6(a) or (b), such indemnified party shall, if a claim in respect thereof is made against an indemnifying party, give written notice to such indemnifying party of the commencement of such action. The indemnifying party shall be relieved of its obligations under this Section 6(c) if and to the extent that the indemnified party delays in giving notice and the indemnifying party is damaged or prejudiced by the delay. In case any such action is brought against an indemnified party, the indemnifying party shall be entitled to participate in and to assume the defense thereof, jointly with any other indemnifying party similarly notified to the extent that it may wish, with counsel reasonably satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election so as to assume the defense thereof, the indemnifying party shall be responsible for any legal or other expenses subsequently incurred by the indemnifying party in connection with the defense thereof, provided, however, that, if counsel for an indemnified party shall have reasonably concluded that there is an actual or potential conflict of interest between the indemnified party and the indemnifying party, the indemnifying party shall not have the right to assume the defense of such action on behalf of such indemnified party, and such indemnifying party shall reimburse such indemnified party for the reasonable and documented fees and expenses of counsel (including local counsel, if applicable) retained by the indemnified party which are reasonably related to the matters covered by the indemnity agreement provided in this Section 6. Provided, further, that in no event shall any indemnification by an Investor under this Section 6 exceed the net proceeds from the sale of Registrable Securities received by such Investor. No indemnified party shall make any settlement of any claims indemnified against hereunder without the written consent of the indemnifying party, which consent shall not be unreasonably withheld. In the event that any indemnifying party enters into any settlement without the written consent of the indemnified party, the indemnifying party shall not consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff of a release of such indemnified party from all liability in respect to such claim or litigation.

(d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which (i) any indemnified party makes a claim for indemnification pursuant to this Section 6, but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 6 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required in circumstances for which indemnification is provided under this Section 6; then, in each such case, the Company and each the Investor shall contribute to the aggregate losses, claims, damages or liabilities to which they may be subject as is appropriate to reflect the relative fault of the Company and such Investor in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, it being understood that the parties acknowledge that the overriding equitable consideration to be given effect in connection with this provision is the ability of one party or the other to correct the statement or omission (or avoid the conduct or take an act) which resulted in such losses, claims, damages or liabilities, and that it would not be just and equitable if contribution pursuant hereto were to be determined by pro-rata allocation or by any other method of allocation which does not take into consideration the foregoing equitable considerations. Notwithstanding the foregoing, (i) no Investor shall be required to contribute any amount in excess of the net proceeds to it of all Registrable Securities sold by it pursuant to such Registration Statement, and (ii) no Person who is guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person who is not guilty of such fraudulent misrepresentation.

Rule144. As long as an Investor holds Registrable Securities or Registrable Securities are underlying securities held by an Investor that are restricted securities (as that term is used in Rule 144), the Company covenants that it will (i) make and keep public information available, as those terms are understood and defined in Rule 144, at all times, (ii) file in a timely manner the reports and other documents required to be filed under the Securities Act or the Exchange Act and the rules and regulations adopted by the SEC thereunder, (iii) furnish to such Investor promptly upon request (x) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and the Exchange Act, (y) a copy of the most recent annual or quarterly report of the Company, and (z) such other information as such Investor may reasonably request, and (iv) cooperate with such Investor and respond as promptly as possible to any requests from the Investor in connection with Rule 144 transfers of restricted securities, in each case to enable such Investor to sell its Registrable Securities without registration under the Securities Act within the limitation of the exemption provided by (a) Rule 144 under the Securities Act, as such Rule may be amended from time to time, or (b) any similar rule or regulation hereafter adopted by the SEC (collectively, “Rule 144”); provided, however, nothing contained in this Section 7 or elsewhere in this Agreement shall prevent the Company from consummating a transaction in which another entity acquires it through a merger or similar transaction.
Severability. In the event any parts of this Agreement are found to be illegal, unenforceable or void, the remaining provisions of this Agreement shall nevertheless be binding with the same effect as though the illegal, unenforceable or void parts were deleted.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. The execution of this Agreement may be by actual, facsimile or “.pdf” signature.
Benefit. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their legal representatives, successors and assigns.
Noticesand Addresses. All notices, approvals, requests, demands and other communications hereunder shall be delivered or made in the manner set forth in, and shall be effective in accordance with the terms of, the Warrant Purchase Agreement.
Attorneys’Fees. In the event that there is any controversy or claim arising out of or relating to this Agreement, or to the interpretation, breach or enforcement thereof, and any action or proceeding relating to this Agreement is filed, the prevailing party shall be entitled to an award by the court of reasonable attorneys’ fees, costs and expenses.
EntireAgreement; Oral Evidence. This Agreement constitutes the entire Agreement between the parties and supersedes all prior oral and written agreements between the parties hereto with respect to the subject matter hereof. Neither this Agreement nor any provision hereof may be changed, waived, discharged or terminated orally, except by a statement in writing signed by the party or parties against which enforcement of the change, waiver discharge or termination is sought.

7
AdditionalDocuments. The parties hereto shall execute such additional instruments as may be reasonably required by their counsel in order to carry out the purpose and intent of this Agreement and to fulfill the obligations of the parties hereunder.
GoverningLaw. This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether relating to its execution, its validity, the obligations provided herein or performance shall be governed in accordance with the Warrant Purchase Agreement.
Modification. Any modifications to or waivers with respect to this Agreement shall be made in accordance with Section 10 of the Warrant Purchase Agreement.
Sectionor Paragraph Headings. Section headings herein have been inserted for reference only and shall not be deemed to limit or otherwise affect, in any matter, or be deemed to interpret in whole or in part any of the terms or provisions of this Agreement.

[Signature Page Follows]

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed personally or by a duly authorized representative thereof as of the day and year first above written.

Company:
BRERA HOLDINGS PLC
By:
Name:
Title:
Investors:
GUY HIRSCH
Address (for notice purposes):
TARIQ SALEM EBRAHEEM ALSAMAN ALNUAIMI
Address (for notice purposes):
KEREN KALIMA MAIMON
Address (for notice purposes):
RON SADE
Address (for notice purposes):
ALYAZI SAEED AHMED ALKHATTAL ALMHEIRI
Address (for notice purposes):

Exhibit 10.6

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is dated as of September 23, 2025, by Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the “Company”), and the Persons identified as “Investors” on the signature pages hereto (each an “Investor” and collectively, the “Investors”) (for each Investor, together with its respective successors and assigns).

Now, therefore, in consideration of the mutual promises and the covenants as set forth herein, the parties hereto hereby agree as follows:

Definitions. Unless the context otherwise requires, capitalized words and terms used herein without definition and defined in the Warrant Purchase Agreement are used herein as defined therein. Notwithstanding the foregoing, as used herein the capitalized words and terms defined in this Section 1 shall have the meanings herein specified for all purposes of this Agreement, applicable to both the singular and plural forms of any of the terms herein defined:

“Agreement” means this Registration Rights Agreement, as the same may be amended, modified, or supplemented in accordance with the terms hereof.

“Board” means the Board of Directors of the Company.

“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

“Company” has the meaning assigned to it in the introductory paragraph of this Agreement.

“Exchange Act” means the Securities Exchange Act of 1934 (or successor statute).

“Excluded Forms” means Registration Statements under the Securities Act on Forms S-4 and S-8 or any successors.

“Filing Date” has the meaning assigned to it in Section 3(a) of this Agreement.

“Investor(s)” has the meaning assigned to it in the introductory paragraph of this Agreement.

“Person” includes any natural person, corporation, trust, association, company, exempted company,

partnership, joint venture, limited liability company and other entity and any government, governmental agency, instrumentality, or political subdivision.